---
document_datetime: 2023-09-21 18:19:40
document_pages: 84
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/eliquis-h-c-2148-x-0004-g-epar-assessment-report-extension_en.pdf
document_name: eliquis-h-c-2148-x-0004-g-epar-assessment-report-extension_en.pdf
version: success
processing_time: 96.8856969
conversion_datetime: 2025-12-25 06:49:46.102264
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 September 2012 EMA/641505/2012

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Eliquis

apixaban

Procedure No.:

EMEA/H/C/002148/X/04/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

Facsimile

+44 (0)20 7523 7455

E-mail

info@ema.europa.eu Website www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................5                                     |                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................5          |                                                                                                          |
| 1.3. Steps taken for the assessment of the product.........................................................6                   |                                                                                                          |
| 2. Scientific discussion                                                                                                       | ................................................................................6                        |
| 2.1. Introduction.........................................................................................................6    |                                                                                                          |
| 2.2. Quality aspects                                                                                                           | ....................................................................................................8    |
| 2.2.1. Introduction......................................................................................................8     |                                                                                                          |
| 2.2.2. Active Substance...............................................................................................8        |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                              | ..................................................................................9                      |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................13                           |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                      | ......................13                                                                                 |
| 2.2.6. Recommendation(s) for future quality development.............................................13                         |                                                                                                          |
| 2.3. Non-clinical aspects                                                                                                      | ............................................................................................13           |
| 2.3.1. Pharmacology                                                                                                            | .................................................................................................13      |
| 2.3.2. Pharmacokinetics.............................................................................................14         |                                                                                                          |
| 2.3.3. Toxicology                                                                                                              | ......................................................................................................14 |
| 2.3.4. Environmental risk assessment                                                                                           | ........................................................................14                               |
| 2.3.5. Discussion on non-clinical aspects......................................................................15              |                                                                                                          |
| 2.3.6. Conclusion on the non-clinical aspects................................................................16                |                                                                                                          |
| 2.4. Clinical aspects                                                                                                          | ..................................................................................................16     |
| 2.4.1. Introduction....................................................................................................16      |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................21         |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................23            |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................24                |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology.................................................................24                 |                                                                                                          |
| 2.5. Clinical efficacy                                                                                                         | ..................................................................................................24     |
| 2.5.1. Dose response study(ies)                                                                                                | .................................................................................25                      |
| 2.5.2. Main studies                                                                                                            | ...................................................................................................26    |
| 2.5.3. Discussion on clinical efficacy............................................................................50           |                                                                                                          |
| 2.5.4. Conclusions on the clinical efficacy.....................................................................51             |                                                                                                          |
| 2.6. Clinical safety                                                                                                           | ....................................................................................................51   |
| 2.6.1. Discussion on clinical safety                                                                                           | ..............................................................................66                         |
| 2.6.2. Conclusions on the clinical safety.......................................................................71             |                                                                                                          |
| 2.7. Pharmacovigilance..............................................................................................72         |                                                                                                          |
| 2.8. User consultation                                                                                                         | ...............................................................................................76        |
| 3. Benefit-Risk Balance ...........................................................................77                          |                                                                                                          |
| Benefits...................................................................................................................77  |                                                                                                          |
| Risks.......................................................................................................................79 |                                                                                                          |
| Benefit-risk balance                                                                                                           | ..................................................................................................81     |
| 4. Recommendations...............................................................................83                            |                                                                                                          |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ACC

American College of Cardiology

ACS

acute coronary syndrome

ADR

adverse drug reaction

AE

adverse event

AF

atrial fibrillation

AHA

American Heart Association

ALP

alkaline phosphatase

ALS

amyotrophic lateral sclerosis

ALT

alanine aminotransferase

aPTT

activated partial thromboplastin time

ASA

acetylsalicylic acid (aspirin)

AUC

area under the concentration curve

AUC(INF)

area under the concentration-time curve to infinity

BID

twice daily

CAD

coronary artery disease

CDP

clinical development plan

CI

confidence interval

CLcr

creatinine clearance

CLT

total body clearance

CLT/F

apparent clearance

Cmax

maximum plasma concentration

CrCL

creatinine clearance

CNS

central nervous system

CRNM

clinically relevant non-major

CSR

Clinical Study Report

CT

computed tomography

CV

cardiovascular

CYP

cytochrome P450

DMC

Data Monitoring Committee

DAT

Dual antiplatelet therapy

DVT

deep vein thrombosis

EMA

European Medicines Agency

E-R

exposure-response

ESC

European Society of Cardiology

EU

European Union

FDA

Food and Drug Administration

FXa

factor Xa

GBS

Guillain-Barre syndrome

GI

gastrointestinal

GUSTO

Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries Trial

HR

hazard ratio

INR

International Normalized Ratio

ICH

International Conference on Harmonisation

ISTH

International Society on Thrombosis and Hemostasis

IV

intravenous(ly)

LFT

liver function test

LMWH

low molecular weight heparin

LTOLE

long-term open-label extension

LVEF

left ventricular ejection fraction

MHLW

Japan's Ministry of Health, Labor, and Welfare

MI

myocardial infarction

MRI

magnetic resonance image

NDA

New Drug Application

NHS

National Health Service

NI

non-inferiority

NNT

numbers needed to treat

NSAID

non-steroidal anti-inflammatory drug

PD

pharmacodynamic(s)

Eliquis

CHMP assessment report

<div style=\"page-break-after: always\"></div>

| PE    | pulmonary embolism                                         |
|-------|------------------------------------------------------------|
| PIP   | Pediatric Investigation Plan                               |
| PK    | pharmacokinetic(s)                                         |
| PO    | oral(ly)                                                   |
| POC   | point-of-care                                              |
| PPK   | population pharmacokinetics                                |
| PT    | prothrombin time                                           |
| QD    | once daily                                                 |
| RR    | risk reduction                                             |
| RRR   | relative risk reduction                                    |
| SA    | Scientific Advice                                          |
| SAE   | serious adverse event                                      |
| SAP   | statistical analysis plan                                  |
| SCE   | Summary of Clinical Efficacy                               |
| SCS   | Summary of Clinical Safety                                 |
| SE    | systemic embolism                                          |
| SPAF  | stroke prevention in atrial fibrillation                   |
| TBili | total bilirubin                                            |
| TIA   | transient ischemic attack                                  |
| TIMI  | Thrombolysis in Myocardial Infarction                      |
| THR   | total hip replacement                                      |
| TKR   | total knee replacement                                     |
| TTR   | time in therapeutic range                                  |
| ULN   | upper limit of normal                                      |
| UK    | United Kingdom                                             |
| US    | United States                                              |
| Vc/F  | apparent volume of distribution of the central compartment |
| VKA   | vitamin K antagonist                                       |
| VTE   | venous thromboembolism                                     |
| VTEp  | venous thromboembolism prevention                          |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

Pursuant to Article 7.2(b) of Commission Regulation (EC) No 1234/2008, Bristol-Myers Squibb/Pfizer EEIG submitted to the European Medicines Agency on 30 September 2011 an application for a group of variations  consisting  of  an  Extension  of  the  Marketing  Authorisation,  one  Type  II  variation  and  one Type IB variation.

The extension of the Marketing Authorisation for the above mentioned medicinal product concerns a new strength: 5 mg.

Within  Type  II  variation  the  MAH  has  also  applied  for  an  update  of  the  SmPC  to  include  a  new indication for the new strength (5 mg) and for previously approved 2.5 mg strength:

Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, including those unsuitable for vitamin K antagonists (VKA).

ELIQUIS also reduced the risk of major bleedings and death when compared to warfarin .'

The variations submitted in the group are the following:

| Variation(s) requested   | Variation(s) requested                      | Type   |
|--------------------------|---------------------------------------------|--------|
| B.II.e.5                 | Change in pack size of the finished product | IB     |

Addition of a new pack size for Eliquis 2.5mg film-coated tablets of 168 film coated tablets (12 blisters of 14 film-coated tablets each).

| Variation requested   |                                                                                                                      | Type   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------|--------|
| C.I.6.a               | Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | II     |

Update of the SmPC to include a new indication for the new strength (5 mg) and for 2.5 mg strength: Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, including those unsuitable for vitamin K antagonists (VKA).

ELIQUIS also reduced the risk of major bleedings and death when compared to warfarin .'

## Information on Paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/210/2011 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the P/210/2011 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

Not applicable.

## Additional Data/Market exclusivity

Not applicable.

<div style=\"page-break-after: always\"></div>

## Scientific Advice

The MAH received Scientific Advice from the CHMP on 15 December 2005 and 18 October 2006. The Scientific Advice pertained to clinical aspects of the dossier.

## Licensing status

Eliquis has been given a Marketing Authorisation in the EU on 18 May 2011.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Pieter de Graeff

Co-Rapporteur: Robert James Hemmings

- The application was received by the EMA on 30 September 2011.
- The procedure started on 19 October 2011.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 03 January 2012 .The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 04 January 2012.
- During the meeting on 16 February 2012, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 20 February 2012.
- During  the  meeting  on  15  March  2012,  the  CHMP  agreed  on  the  updated  consolidated  List  of Questions to be sent to the applicant. The final updated consolidated List of Questions was sent to the applicant on 16 March 2012.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 18 May 2012.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 29 June 2012.
- During the CHMP meeting on 19 July 2012 the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant.
- The applicant submitted the responses to the CHMP List of Outstanding Issues on 20 August 2012.
- During the meeting on 20 September 2012, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  an  extension associated with a grouped variation on 20 September 2012.

## 2. Scientific discussion

## 2.1. Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia, accounting for approximately one third of hospitalizations attributed to cardiac rhythm disturbances. During AF, electrical impulse propagation in  the  atria  is  disorganized  and  chaotic,  with  ineffective  mechanical  contraction.  This  results  in remodelling  of  atrial  anatomy,  stasis  of  blood  and  activation  of  prothrombotic  blood  constituents, leading to the formation of thrombus or clot. Fragments of clot can dislodge from such thrombi and

<div style=\"page-break-after: always\"></div>

embolize  to  the  brain  to  cause  a  stroke,  or  enter  the  systemic  circulation  and  occlude  the  arterial circulation of an organ or limb to produce a systolic embolism (SE). An estimated 2.6 million people in North America and 4.5 million people in Europe have AF, with increasing prevalence in older age.

Apart from the symptoms associated with AF, it is the strong association of AF with stroke that is a major  source  of  both  mortality  and  of  major  morbidity.  The  risk  of  stroke  is  increased  &gt;5-fold  in patients with AF; this risk increases with age. More than 15% of all strokes are due to AF and such strokes  are  more  severe  than  strokes  not  associated  with  AF.  Strokes  in  patients  with  AF  are associated with a 70% increase in mortality, a 20% increase in the length of hospital stay, and a 40% decrease in the rate of return to home because of more severe functional impairment. The outcome of such  cardioembolic  strokes  is  poor,  with  a  mortality  rate  of  25%  at  30  days  and  50%  at  1  year. Current guidelines recommend stroke prevention treatment for patients with either AF or atrial flutter, whether paroxysmal or chronic, who have at least one (CHADS2) 1  risk factor.  Bleeding is the major safety  concern  associated  with  current  therapies  for  stroke  prevention  in  AF.  When  considering appropriate  therapy,  clinicians  must  weigh  the  benefits  of  preventing  a  potentially  devastating outcome, such as stroke, with the risk of serious haemorrhage. Unfortunately, the risk of stroke and of haemorrhage  tends  to  rise  in  parallel,  so  that  those  patients  most  at  risk  for  stroke  are  also  at increased  risk  for  bleeding.    Because  of  the  concern  of  bleeding  associated  with  the  coumarin derivatives, acetylsalicylic acid (ASA) and other agents have been studied as alternatives. However a meta-analysis and review of these data by Hart and colleagues 2  concluded that anti-platelet therapies reduced  stroke  in  AF  patients  by  a  modest  20%,  and  were  associated  with  lower  rates  of  major bleeding  than  warfarin.  Nonetheless,  warfarin  reduced  stroke  by  ~40%  when  compared  with  antiplatelet  agents,  but  because  of  the  large  variability  of  stroke  risk  in  this  population,  there  is  still  a recognised unmet need for antithrombotic agents that are more efficacious than ASA and that are safer or more easily administered than adjusted-dose warfarin.

The ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation recommended that patients with a CHADS2 score of 2 or more be treated with warfarin (International Normalized Ratio [INR] 2.0 to 3.0). For those with a CHADS2 score of 1, recommended treatment was either ASA (81 to 325 mg daily) or warfarin (INR 2.0 to 3.0). The American College of Chest Physicians published practice guidelines in 2008 that were in substantial agreement with the ACC/AHA/ESC 2006 guidelines, but with a preference of warfarin over ASA for patients whose CHADS2 score was 1. The most recent ESC 'Guidelines for the management of AF' (2010) used a slightly different risk factor score (CHA2DS2-VASC) that includes female gender, vascular disease and age 65 to 74 as risk factors. Using this approach, they recommended oral anticoagulation with either warfarin/VKA or dabigatran for those whose score was 2 or greater. For those whose score was 1, ASA (75 to 325 mg daily) was acceptable,  but  oral  anticoagulation  (as  defined  above)  was  preferred.  The  recently  published  2011 ACCF/AHA/HRS Focused Update on the Management of Patients with Atrial Fibrillation (Updating the 2006 Guideline) added the recommendation that 'the addition of clopidogrel to ASA to reduce the risk of  major  vascular  events,  including  stroke,  might  be  considered  in  patients  with  AF  in  whom  oral anticoagulation  with  warfarin  is  considered  unsuitable  due  to  patient  preference  or  the  physician's assessment of the patient's ability to safely sustain anticoagulation'. In the 2012 focused update of the ESC Guidelines for the management of atrial fibrillation (published during the assessment), the use of

## «prodname»

CHMP assessment report

Rev04.12

1 CHADS2: cardiac failure, hypertension, age, diabetes, stroke (doubled)

2 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857- 867.

Page 7/84

<div style=\"page-break-after: always\"></div>

the CHA2DS2-VASc score was considered better at identifying 'truly low-risk' patients with AF and is as good as-and possibly better than-scores such as CHADS2 in identifying patients who develop stroke and thromboembolism. This guideline currently recommends in patients with a CHA2DS2-VASc score ≥2,  OAC  therapy  with  VKA  or  the  new  oral  anticoagulant  agents  [dabigatran  (anti-thrombin)  or rivoroxaban  (anti  Xa)],  unless  contraindicated.  In  patients  with  a  CHA2DS2-VASc  score  of  1,  OAC therapy  with  VKA  or  the  new  oral  anticoagulant  agents  should  be  considered  based  upon  an assessment of the risk of bleeding complications and patient preferences.

Eliquis  2.5  mg  film-coated  tablets  have  been  approved in the European Union for the prevention of venous  thromboembolic  events  (VTE)  in  adult  patients  who  have  undergone  elective  hip  or  knee replacement  surgery  through  centralised  procedure  on  18th  May  2011.  Currently  an  Extension Application is submitted for the addition of Eliquis 5 mg film-coated tablets in order to support a new proposed indication, grouped with a type II variation to add the newly proposed indication and a type IB variation to add a pack size of 168 tablets for Eliquis 2.5 mg film-coated tablets.

In the Extension Application the MAH cross reference to quality, non-clinical and pharmacokinetic data submitted previously for Eliquis 2.5 mg film-coated tablets. Therefore in this assessment report only the  newly  provided  quality,  non-clinical  and  pharmacokinetic  data  for  the  5  mg  strength  have  been discussed.

Apixaban (BMS-562247) is an orally active, direct, selective inhibitor of the coagulation factor Xa (FXa) that  reversibly  binds  directly  to  the  active  site  of  FXa,  and  exerts  anticoagulant  and  antithrombotic effects by diminishing the conversion of prothrombin to thrombin. As the common mediator of both extrinsic  and  intrinsic  activation  of  coagulation,  FXa  is  the  sole  physiological  mediator  of  thrombin formation. Thrombin, through its actions on fibrin formation and platelet activation, is a key mediator of thrombosis in both the venous and arterial circulation. Inhibition of thrombin generation, therefore, produces  antithrombotic  effects  under  a  variety  of  pathological  conditions.  Accordingly,  apixaban  is being developed for the prevention and treatment of a wide range of thrombotic diseases.

## 2.2. Quality aspects

## 2.2.1. Introduction

Eliquis 5 mg film-coated tablet contains 5 mg of apixaban active substance.  The tablet is a pink, oval shaped, biconvex film-coated tablets with '894' debossed on one side and '5' on the other side. It is presented in PVC/PVDC blisters of 14, 20, 56, 60, 100, 168 or 200 film-coated tablets in cartons.

The full list of ingredients is defined in section 6.1 of the SmPC.

## 2.2.2. Active Substance

The  active  substance  manufacturing  process,  controls  and  manufacturing  sites  have  already  been approved  in  conjunction  with  the  2.5  mg  tablets,  EU/1/11/691/001-005  and  no  new  information  is added.  Therefore  it  is  acceptable  that  no  further  assessment  or  discussion  concerning  the  drug substance has been provided in the context of the present line extension application.

It is noted that for the calculation of safe levels of impurities in this dossier a maximum daily dose 10 mg has been considered, covering both the recommended oral dose of 2.5 mg twice daily and also the maximum daily dose for Eliquis 5 mg for the new indication.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Finished Medicinal Product

## Pharmaceutical Development

It is noted that with the present Line Extension application quality information that is specific to 5 mg strength was provided including application of two NIR methods to perform on-line (pre-blending) and at-line  (tabletting)  testing  of  Eliquis  5  mg  uncoated  (core)  tablets  for  assay  (potency)  and  content uniformity in support of the RTRT at the two finished product manufacturing sites, Humacao, Puerto Rico,  USA  and  Mount  Vernon,  Indiana,  USA.  It  is  also  noted  that  with  the  recent  Type  II  variation EMEA/H/C/002148/II/003/G the initially proposed NIR method for releasing apixaban tablets 2.5 mg (real time release testing, RTRT) at both finished product manufacturing sites was registered. In view of the common granulate for both strengths, all principles also apply for the new 5 mg strength.

Eliquis  tablets  formulation  and  manufacturing  process  were  designed  to  produce  tablets  with  rapid disintegration and  dissolution characteristics ensuring consistent and  acceptable  bioavailability. Apixaban is non-ionisable; therefore, its aqueous solubility is not affected by changes in pH. It is highly soluble for doses up to 10 mg and is a low permeable compound, thus, it is classified as a Class III (high solubility/low permeability) compound as per the Biopharmaceutical Classification System (BCS).

Information on different strengths that were used in the early stages of the clinical development had already been presented at the time of the initial application form the 2.5 mg strength. The currently approved marketing application  for  apixaban  2.5  mg  tablet  included  all  the  relevant  information  on formulation and process development of apixaban 5 mg tablet as supporting information.

Of  all  the  strengths  initially  used,  the  2.5  mg  and  5  mg  were  selected  for  Phase  3  studies  and commercialisation. The 2.5 mg  tablet have been authorised for the prevention of venous thromboembolism (VTE). The 5 mg strength is intended for the new indication applied together with this  application.  Both  2.5  and  5  mg  tablets  are  manufactured  from  a  common  granulate  and proportional tablet weight (tablet core). The only difference is concerning the coating agent colour. The excipients  used  are  well  known.  The  concentrations  are  usual  for  an  immediate  release  tablet formulation and can be considered safe in the proposed concentrations.

Pharmaceutical development of the finished product contains QbD elements.

The formulation and manufacturing development have been evaluated through the use of design of experiments  and  risk  assessment  respectively  to  identify  the  critical  product  quality  attributes  and critical process parameters.

The  product  critical  quality  attributes  identified  were  appearance,  assay,  content  uniformity  and dissolution.  The  active  substance  particle  size  was  determined  as  CQA  as  well  in  view  of  the  low content of apixaban in the tablet.

Proven  acceptable  ranges  (PARs)  for  the  film  coated  tablet  composition  with  regards  to  the disintegrant,  surfactant  and  lubricant.  In  addition  PARs  have  been  established  for  the  pre-blending, roller compaction and compression steps of the manufacturing process.

The quality of the product is further assured by the comprehensive control strategy defined for the manufacture of Eliquis tablet including process analytical technology (PAT) NIR, as well as conventional tests, to control the in-process manufacture.

It was recognized that because of the targeted low dose for apixaban, content uniformity of the final product becomes an important product attribute. Since the drug substance is mixed with most of the excipients at the pre-blending, a quantitative on-line NIR method was developed to monitor the mixing profile  during  the  pre-blending  unit  operation  and  to  determine the  blending  endpoint. For this new

<div style=\"page-break-after: always\"></div>

strength  the  same  NIR  method  used  at  the  pre-blending  applies  since  the  5mg  tablets  are manufactured from an identical blend to that of the existing tablet strength.

Holding  times  have  been  established  and  the  results  generated  for  three  batches  demonstrate  that they did not negatively impact the product quality attributes.

No additional process development was conducted for the film-coating process step as typical coating procedures are followed.

An at-line NIR method, coupled with tablet weight monitoring throughout the compression run, is also applied on the tabletting step to control the content uniformity of the uncoated tablets. Tablets from various  batches  were  tested  in  order  to  demonstrate  the  use  of  the  at-line  FT-NIR  spectroscopy method for testing the 5 mg core tablets and the application of the large-N sample sizes. The results show a low %RSD with a very small number of units outside 85.0 - 115.5%. The comparison of the results  against  the  reference  method  (HPLC)  demonstrates  an  overall  good  correlation.  It  has  been observed that NIR method could show artificially inflated assay results due to the presence of localised concentrations of apixaban, suggesting agglomerates formation during pre-blending. To mitigate this risk,  a  screen  milling  step  was  added  to  the  commercial  manufacturing  process  to  further  ensure  a uniform blend. The application of the at-line NIR testing of the core tablets allows for more tablets to be tested compared  to the traditional methods  specified in the harmonised pharmacopoeial specification  for  uniformity  of  dosage  units.  The  proposed  alternative  approach  to  the  uniformity  of dosage units test (EP - 2.9.40) has been scientifically establish and set acceptance criteria for content uniformity  where  large-N  samples  are  tested.  The  proposed  test  is  based  on  a  one-tiered  counting system  and  applying  an  appropriate  quality  level  for  tablets  outside  the  set  Label  Claim  (LC).  The content  uniformity  (CU)  results  of  13  batches  of  2.5-mg  and  18  batches  of  5-mg  Eliquis  tablets, manufactured  at  commercial  scale  at  both  sites,  underline  that  the  applied  approach  including  NIR blend control and Large-N content uniformity testing on the tablet cores ensure manufacture of tablets showing a high content uniformity determined on tablets representative for the whole batch. NIR assay data  on  several  batches  of  the  2.5-mg  and  5-mg  tablets  manufactured  at  commercial  scale  are provided  to  demonstrate  the  suitability  of  the  NIR  methods  developed  for  both  strengths  and  thus there is no need for parallel testing.

The proposed control of content uniformity testing in both the blend as well the compression stage of manufacture is considered adequate and herewith acceptable.

The NIR models maintenance is a GMP issue. Nevertheless, it is expected that changes outside of the scope of the NIRS procedure will be submitted via an appropriate variation.

This grouped application that includes the line extension also includes a Type IB variation to add a new pack size of 168 film-coated tablets (12 blisters of 14 film-coated tablets each) for Eliquis 2.5 mg filmcoated tablets.

## Adventitious agents

Lactose  used  in  the  manufacture  of  tablets  is  of  animal  origin  (bovine  milk).  Statements  from  the suppliers and finished product manufacturer in relation to the quality of lactose confirm that all lactose used complies with EMEA/410/41/00/01 Rev.2 'Note for Guidance on Minimising Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products'.

<div style=\"page-break-after: always\"></div>

## Manufacture of the product

The manufacturing process was described in the original submission and comprises the following main steps: blending, granulation, blending, tabletting, film-coating and packaging. A flow-chart including in-process controls is provided.

The  validation  strategy  consisted  of  manufacture  of  three  consecutive  commercial  scale  batches  of Eliquis 5 mg coated tablets at the Humacao site. The in-process controls that were monitored during the  execution  of  the  validation  exercise  were:  pre-blend  active  substance  homogeneity,  roller compaction ribbon density and ribbon thickness, tablet core weight and hardness and coated tablet weight gain. In addition to the in-process controls, for the validation batches the final blend uniformity was  determined  by  NIR.  All  validation  results  were  in  accordance  with  the  set  acceptance  criteria. Finally, batch analysis results on the coated tablets according to the release specifications are listed for two coating loads sampled at each three locations. All results met the set requirements.

The process validation protocol for Eliquis 5 mg tablets at the new site (BMS Mount Vernon) at the proposed scale is also considered adequate.

It can be concluded that the validation is satisfactory, all the in-process control criteria were met, all the validation testing complied with the pre-established acceptance criteria, and the release testing of the batches were in compliance with the predetermined specifications and quality attributes.

Due to the use of  NIR  (as  PAT)  and  RTR  for  the  manufacturing  of  the  drug  product,  the  proposed finished product manufacturing site (Mount Vernon, USA) will be inspected post-approval in the scope of the planned re-inspection.

## Product specification

The same drug product specifications are applied for the 5 mg tablets as finalized in Type II variation procedure EMEA/H/C/00002148/II/0003/G for the 2.5 mg tablets.

The release and shelf-life specifications include tests and limits for appearance (visual), identification (Raman, IR, HPLC, at release only), assay (by approved Real Time Release testing (NIR and tablet weight)  or  HPLC  if  tested),  uniformity  of  dosage  units/  content  uniformity  (by  approved  Real  Time Release testing (NIR) or HPLC if tested, HPLC at release), disintegration (Ph. Eur., at release only), impurities/degradants (HPLC, stability only), dissolution (HPLC, stability only) and microbial limit test (Ph. Eur., not routinely).

A correlation between the particle size of the drug substance and dissolution rate of apixaban has been established. Based on this relationship, the specification for the particle size of the drug substance is proposed as a surrogate for dissolution testing and therefore the specification does not include a test for dissolution.

Based  on  the  evidence  of  stability  of  apixaban,  the  control  of  impurities  in  the  drug  substance  is considered sufficient to ensure the quality of the drug product at release because the impurity content of the drug product comes only from process-related impurities contained in the drug substance. Thus, the proposal not to test for impurities/degradants for batch release is considered justified.

Furthermore, due to microbial tests results of the long-term stability batches and low water activity of Eliquis film-coated tablets, the tablets are not susceptible to microbial growth. Batches are proposed to be  tested  on  a  skip-lot  basis  (one  lot  once  a  year  or  every  ten  batches,  whichever  is  sooner)  for microbial contamination.

<div style=\"page-break-after: always\"></div>

Batch analysis data for Eliquis  5  mg  tablets  were  available  from two  production  scale  batches  from Mount Vernon site and three production scale batches from BMS Humacao site. The tablets have been analysed according to both conventional finished product tests (HPLC assay, HPLC content uniformity) and RTRT tests (based on core tablets, NIR assay and NIR content uniformity). In addition results from a large number of batches from both strengths were also presented. Based on the comparative results it  has been demonstrated that the applied RTR tests could replace the conventional finished product tests based on HPLC.

All  results  on  other  parameters  like  disintegration,  dissolution  and  impurities  were  satisfactory  and meeting the set requirements. No differences between the two manufacturing sites could be observed.

The assay results obtained by HPLC (film-coated tablets) and by NIR (uncoated core tablets, large (N) - 150 to 160) are very similar.

The dissolution results are satisfactory and the levels found for the impurities are very low.

The batch analysis data demonstrate that the manufacturing process, both at the Humacao as well as the Mount Vernon site, is well under control.

## Stability of the product

Three  batches  of  active  substance  were  used  to  prepare  three  batches  of  Eliquis  5  mg  film-coated tablet.  All  batches  were  made  using  a  site  and  process  representative  of  the  proposed  commercial process. The stability protocol includes testing for all three batches packaged in PVC/PVDC blisters and HDPE  bottles.  The  PVC/PVDC  blister  represents  the  worst  case  for  water  and  oxygen  permeation. Therefore,  the  results  from  this  package  represent  the  worst  case  for  microbial  counts  and  are applicable  to  all  packages.  The  tablets  have  been  stored  for  36  months  under  three  long  term conditions (5°C, 25°C/60%RH and 30°C/75% RH) and for 6 months under accelerated 40°C/75%RH. Appearance,  HPLC  identification  (only  initially),  KF  water  content,  dissolution  +  HPLC/UV  detection, HPLC assay, HPLC impurity/degradants, microbial limit tests (including specified organisms), hardness and disintegration. During the 36 months studies in PVC/PVDC blisters or HDPE bottles at the 3 long term conditions and after 6 months accelerated study, no changes for appearance, assay, impurities, dissolution, hardness, disintegration, and microbial content have been seen. A slight increase in water content values was observed for the tablets packaged in PVC/PVDC blisters. However, there was no impact on any other attributes.

In  addition,  one  batch  was  packaged  in  an  in-process  bulk  container  and  tested  after  storage  at 30°C/65%RH through 6 months.

## Stress study

Stress  conditions  (50°C),  photostability,  freeze-thaw  cycling  and  bulk  stability  studies  have  been performed. One batch of apixaban tablets, for each package type, was exposed to the stress condition of  50°C.  One  batch  of  tablets  placed  in  a  single  layer  in  an  open  petri  dish  was  exposed  to 25°C/60%RH for 12 months or 40°C/75%RH for 6 months. One batch of tablets in the 60-count HDPE bottle was exposed to seven freeze-thaw cycles. Photostability studies were conducted as per ICH Q1B. In  addition,  one  batch  of  tablets  (equivalent  to  10%  of  the  anticipated  amount  packaged  for commercial  manufacturing)  placed  in  an  in-process  bulk  container  was  also  placed  on  stability  at 30°C/65%RH through 6 months.

The product when stored in PVC/PVDC blisters or HDPE bottles for 3 months at 50°C was stable with essentially  no  change  from  initial  observed  in  potency,  impurities,  hardness,  disintegration  time, appearance, or dissolution. The freeze/thaw cycling, open-dish, and high-temperature stress studies

<div style=\"page-break-after: always\"></div>

support shipping of the product through normal distribution channels. Based on the photostability data collected the product is considered not sensitive to light.

The overall stability results support the proposed shelf-life and storage conditions.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

The quality of Eliquis 5 mg film-coated tablets is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Information on development, manufacture and control of the drug substances has been presented in a satisfactory manner. The quality of the active substances is considered sufficiently described and adequately supported by data. Sufficient chemical and pharmaceutical documentation relating to development, manufacture and control of the drug product has been presented. Since the new 5 mg strength is manufactured from the same identical blend, the already  established  PARs  apply  also  for  5  mg  tablets.  The  same  PAT  tools  (NIR)  are  used  for  the monitoring of the pre-blending step for both strengths.

RTRT is proposed for the assay and content uniformity of the tablets. The NIR method together with tablet weight is used for this purpose has been approved for the 2.5 mg strength. The method has been satisfactorily validated for the new strength at both the proposed manufacturing sites. The results of  tests  carried  out  indicate  consistency  and  uniformity  of  important  product  quality  characteristics, and  these  in  turn  lead  to  the  conclusion  that  the  product  should  have  a  satisfactory  and  uniform performance in the clinic.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined  in  the  SmPC.  Physicochemical  and  biological  aspects  relevant  to  the  uniform  clinical performance of the product have been investigated and are controlled in a satisfactory way. The design space  is  considered  sufficiently  validated  for  the  proposed  batch  size  range  at  both  the  proposed manufacturing sites. The proposed RTRT for content uniformity and assay is accepted and has been sufficiently supported by data and validation studies.

Stability  tests  indicate  that  the  product  under  ICH  guidelines  conditions  is  chemically  stable  for  the proposed shelf life.

## 2.2.6. Recommendations for future quality development

Not applicable.

## 2.3. Non-clinical aspects

## 2.3.1. Pharmacology

No  new  pharmacology  studies  were  provided  within  current  application  to  support  the  extension  of indications.  Since  both  indications,  new  and  the  previously  approved  one,  are  based  on  the  same pharmacodynamic  mechanism,  the  CHMP  was  of  the  opinion  that  there  is  no  need  for  additional pharmacology  data.  Therefore,  the  reference  is  made  to  the  assessment  of  initial  marketing authorisation  application  (MAA)  for  Eliquis  2.5  mg  film-coated  tablets  and  only  new  information  is discussed in the current report.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

The  only  new  information  provided  consists  of  two  (non-GLP) in  vitro studies  showing  an  inhibiting effect  of  diltiazem  on  digoxin  efflux  in  Caco-  2  cells  and  in  porcine  kidney-derived  LLC-PK1  cell monolayers. Based on these data it can be concluded that diltiazem is an inhibitor of P-gp.

## 2.3.3. Toxicology

The final report was provided of the definitive juvenile rat toxicology study (GLP) which was ongoing at the time of the assessment of the initial MAA for Eliquis. In this study, cross-fostered rat pups were treated  from  postnatal  day  (PND)  4  to  PND  94.  Tested  doses  were  0,  10,  50  and  600  mg/kg/day. Subgroups  were  sacrificed on PND  10  (toxicokinetics), PND21  (coagulation  testing),  PND  94 (toxicokinetics),  on  PND  21  and  87  (organ  weights,  serum  chemistry,  hematology,  coagulation, urinalysis, necropsy, histopathology), or after a recovery period of 1 month (after production of an F2 generation, organ weights, coagulation, serum chemistry [males], testis histopathology). No apixabanrelated toxicity or changes of F1-generation fertility or mating indices were observed. Apixaban-related effects  were  limited  to  mild  prolongations  of  PT  and  aPTT  values  that  were  not  adverse  and  were recoverable. The no-observed-adverse-effect-level (NOAEL) was 600 mg/kg/day (AUC during PND 21 to  87  respectively  25  and  9  times  human  AUC  at  5  mg  BID)  changes.  Toxicokinetic  data  showed decreasing exposure from PND 10 to 87, presumably due to developmental changes (Tmax on PND 10 was about 2-3 times the Tmax on PND 21). Taking into account the additional information, the CHMP agreed not to consider the findings from this study as drug related for the following reasons: all other toxicity signs observed in the reproductive/developmental studies are related to apixaban's action on coagulation,  i.e.  its  pharmacodynamic  mechanism  of  action.  From  other  toxicity  studies  provided (repeated dose studies, fertility studies, juvenile toxicity studies) there was no evidence of any effects on parameters which could be related to female fertility. Based on the overall data set now available the observed slightly decreased mating and fertility indices in offspring of pre/post-natally treated rats is  unlikely  to  be  an  apixaban-related  effect.  Based  on  this  conclusion,  the  CHMP  agreed  on  the amendments of the SmPC text of sections 5.3 and 4.6.

## 2.3.4. Environmental risk assessment

A full ERA has already been presented and evaluated for Eliquis 2.5 mg tablets at the time of the initial MAA. At that time a complete dossier was submitted, meeting the requirements of the EMA guideline on ERA. The ERA concluded that no risk to the environment was anticipated following the use of Eliquis 2.5 mg tablets. In the current procedure the same, complete ERA dossier has been submitted. Due to the  added  indication,  the  environmental  exposure  is  expected  to  increase.  The  MAH  submitted  a revised ERA, which was evaluated with respect to the PEC calculations and the result of the revised risk quotients.

Apixaban (BMS-562247) is a selective, reversible inhibitor of the coagulation factor Xa (FXa). Its log K ow is 1.2 (shake flask), water solubility 38-60 mg/L at 25°C and its K oc 12.2 L/kg (HPLC method; log K oc = 1.09). Apixaban is not readily biodegradable. In a water/sediment simulation study (OECD 308), half life values of 31.5-41.7 d were found for the water phase and 100-182 d for the whole system, all determined  at  20±2°C.  The  toxicity  data  are  summarized  below.  Inhibition  of  activated  sludge respiration:  EC50 &gt; 1000 mg/L  and  hence  NOEC &gt; 1000  mg/L.  Aquatic  species:  green  alga P. subcapitata ,  3  d  NOEC 3.6 mg/L  (growth  rate);  crustacean D.  magna ,  21  d  NOEC  9.6  mg/L (reproduction); fish P. Promelas , 32 d NOEC ≥ 10 mg/L (E.L.S. test, hatching success, percentage of embryos producing live normal larvae at hatch, survival at test termination, and larval growth (total

<div style=\"page-break-after: always\"></div>

length  and  dry  weight)).  Sediment  dwelling  organism,  midge C.  riparius ,  28  d  NOEC 417 mg/kgdw (emergence and development rate; result normalised to 10% o.c.). Using a refined F pen of 0.01 (57% metabolism), PECsurface water was 0.0285 µg/L. No risk following the use of apixaban was anticipated for the  sewage  treatment  plant,  surface  water,  groundwater  and  sediment.  The  PBT  (Persistent, Bioaccumulative,  Toxic)  assessment  is  summarized  below.  Apixaban  does  not  meet  the  screening criterion for B, since log K ow is &lt; 4.5. Based on the OECD 308 study and the resulting whole system half life values of 100-182 at 20°C, the P criterion is met. Based on the aquatic toxicity data submitted, the substance is not T.

In  conclusion,  apixaban  was  considered  by  the  CHMP  not  PBT,  nor  vPvB  (very  persistent,  very bioaccumulative).

Table 1 ERA table of endpoints

| Substance (INN/Invented Name): apixaban                          | Substance (INN/Invented Name): apixaban         | Substance (INN/Invented Name): apixaban                                    | Substance (INN/Invented Name): apixaban         | Substance (INN/Invented Name): apixaban         |
|------------------------------------------------------------------|-------------------------------------------------|----------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| CAS-number (if available): 503612-47-3                           | CAS-number (if available): 503612-47-3          | CAS-number (if available): 503612-47-3                                     | CAS-number (if available): 503612-47-3          | CAS-number (if available): 503612-47-3          |
| PBT screening                                                    |                                                 | Result                                                                     |                                                 | Conclusion                                      |
| Bioaccumulation potential- log K ow                              | OECD107                                         | 1.2                                                                        |                                                 | not B                                           |
| PBT-assessment                                                   | PBT-assessment                                  | PBT-assessment                                                             | PBT-assessment                                  | PBT-assessment                                  |
| Parameter                                                        | Result relevant for conclusion                  |                                                                            |                                                 | Conclusion                                      |
| Bioaccumulation                                                  | log K ow BCF                                    | 1.2 not triggered                                                          |                                                 | not B                                           |
| Persistence                                                      | ready biodegradability                          | not readily                                                                | biodegradable                                   |                                                 |
|                                                                  | DT50 water                                      | 31.5-41.7 d at                                                             | 20°C                                            |                                                 |
|                                                                  | DT50 whole system                               | 100-182 d at 20°C                                                          |                                                 | P                                               |
| Toxicity                                                         | NOEC or CMR                                     | > 1 mg/L, not                                                              | CMR                                             | not T                                           |
| PBT-statement :                                                  | The compound is not considered not PBT nor vPvB | The compound is not considered not PBT nor vPvB                            | The compound is not considered not PBT nor vPvB | The compound is not considered not PBT nor vPvB |
| Phase I                                                          | Phase I                                         | Phase I                                                                    | Phase I                                         | Phase I                                         |
| Calculation                                                      | Value                                           | Unit                                                                       |                                                 | Conclusion                                      |
| PEC surface water                                                | 0.050                                           | µ g/L                                                                      |                                                 | > 0.01 threshold                                |
| Other concerns (e.g. chemical class)                             |                                                 |                                                                            |                                                 | N                                               |
| Phase II Physical-chemical properties and fate                   | Phase II Physical-chemical properties and fate  | Phase II Physical-chemical properties and fate                             | Phase II Physical-chemical properties and fate  | Phase II Physical-chemical properties and fate  |
| Study type                                                       | Test protocol                                   | Results                                                                    |                                                 | Remarks                                         |
| Adsorption-Desorption                                            | OECD 121                                        | K oc = 12.2                                                                | L/kg                                            |                                                 |
| Ready Biodegradability Test                                      | OECD 301                                        | not readily biodegradable                                                  |                                                 |                                                 |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems | OECD 308                                        | DT 50, water = 31.5-41.7 DT 50, whole system = % shifting to sediment 52.0 | d 100-182 d =40.2-                              | determined at 20±2°C                            |
| Phase IIa Effect studies                                         | Phase IIa Effect studies                        | Phase IIa Effect studies                                                   | Phase IIa Effect studies                        | Phase IIa Effect studies                        |
| Study type                                                       | Test protocol                                   | Endpoint                                                                   | value Unit                                      | Remarks                                         |
| Algae, Growth Inhibition Test/ Pseudokirchneriella subcapitata   | OECD 201                                        | NOEC 3.6                                                                   | x 10 3 µg/L                                     |                                                 |
| Daphnia sp . Reproduction Test                                   | OECD 211                                        | NOEC                                                                       | 9.6 x 10 3 µg/L                                 |                                                 |
| Fish, Early Life Stage Toxicity Test/ Pimephales promelas        | OECD 210                                        | NOEC ≥                                                                     | 10 x 10 3 µg/L                                  |                                                 |
| Activated Sludge, Respiration Inhibition Test                    | OECD 209                                        | NOEC EC50                                                                  | >1.0 x 10 6 >1.0 x 10 6 µg/L                    |                                                 |
| Phase IIb Studies                                                | Phase IIb Studies                               | Phase IIb Studies                                                          | Phase IIb Studies                               | Phase IIb Studies                               |
| Sediment dwelling organism / C. riparius                         | OECD 218                                        | NOEC                                                                       | ≥ 100 mg/kg                                     |                                                 |

## 2.3.5. Discussion on non-clinical aspects

The  MAH  submitted  supplemental  data  related  to:  (1)  potential  pharmacokinetic  interactions  with diltiazem and (2) the final report of an ongoing juvenile toxicity study. The evidence was provided that diltiazem inhibits P-gp.

No  evidence  of  juvenile  toxicity  was  found  at  systemic  exposure  of  9  -  25  times  human  exposure (based on data from adults). Since chronic use of apixaban was already assessed in the initial MAA of

<div style=\"page-break-after: always\"></div>

apixaban,  no  new  data  were  considered  necessary  by  the  CHMP  to  support  the  extension  of  the treatment duration that was approved within current application. The doses used in the non-clinical toxicity studies provided in the initial dossier resulted in sufficiently high exposure compared to clinical exposure. The MAH provided updated overview of exposure factors, based on the new clinical dose of 5 mg BID.

The CHMP agreed not to consider the findings from this study as drug related for the following reasons: all  other  toxicity  signs  observed in the reproductive/developmental studies are related to apixaban's action  on  coagulation,  i.e.  its  pharmacodynamic  mechanism  of  action.  From  other  toxicity  studies provided (repeated dose studies, fertility studies, juvenile toxicity studies) there was no evidence of any effects on parameters which could be related to female fertility. Based on the overall data provided the CHMP believed, that the observed slightly decreased mating and fertility indices in off-spring of pre/postnatally treated rats was unlikely to be an apixaban-related effect.  As a consequence, sections 4.6 and 5.3 of the SmPC were modified. In addition, the juvenile toxicity study was added to section 5.3 of the SmPC.

In addition, an updated ERA was provided within current line extension application in which the new indication was covered.

## 2.3.6. Conclusion on the non-clinical aspects

From  a  non-clinical  view,  Eliquis  5  mg  tablets  were  considered  approvable  by  the  CHMP.  Cross reference was made to the information in the assessment of the initial MAA for Eliquis 2.5 mg filmcoated  tablets.  Based  on  the  additional  juvenile  toxicity  data,  the  CHMP  proposed  amendments  to sections 4.6 and 5.3. of the SmPC.

## 2.4. Clinical aspects

## 2.4.1. Introduction

Apixaban is  a  novel,  orally  active,  selective,  direct,  reversible  inhibitor  of  the  coagulation  factor  Xa (FXa),  developed  as  an  anticoagulant.  Factor  Xa  plays  a  pivotal  role  in  the  coagulation  cascade because  it  sits  at  the  junction  of  the  intrinsic  and  extrinsic  pathways  of  the  coagulation  system. Inhibition  of  FXa  is  expected  to  exert  anticoagulant  and  antithrombotic  effects  by  decreasing  the conversion of prothrombin to active thrombin, thereby diminishing thrombin-mediated activation of the coagulation process, including fibrin formation and platelet activation.

## GCP

The clinical trials were performed in accordance with GCP as claimed by the applicant. The applicant has  provided  a  statement  to  the  effect  that  clinical  trials  conducted  outside  the  community  were carried out in accordance with the ethical standards of Directive 2001/20/EC.

A  request  for GCP  inspection  had  been  adopted  for  the  following  clinical  study  CV  185030 (ARISTOTLE). The outcome of this inspection was submitted and assessed. No critical findings were observed in three inspected sites. In conclusion the CHMP agreed with the inspectors that based on the inspections  conducted  in  three  different  sites  the  conduct  of  the  main  clinical  study  ARISTOTLE  is considered to be GCP compliant.

During  the  assessment  of  the  current  application  an  issue  was  raised  concerning  possible  errors  in medication dispensing. Analysis of a sample of labels (around 20% of dispensed labels) showed that these  occurred  within  values  that  could  be  expected  in  major  trials.  Sensitivity  analyses  further

<div style=\"page-break-after: always\"></div>

confirmed  the  robustness  of  the  data.  In  the  analysed  sample  of  labels,  illegible  labels  (after dispensing) were read using bar code readers. No medication errors were discovered in most of these labels. This further confirms the limited rate of medication errors previously calculated in ARISTOTLE (0.03%). There was also some concern whether monitoring activities were vigilant enough to detect the identified medication errors. The MAH submitted the monitoring plan implemented in ARISTOTLE, describing its frequency and the main  activities including source data verification and drug accountability.  The  submitted  analysis  shows  that  most  of  the  incorrect  medication  containers dispensed  (46/50)  were  detected  by  monitoring  visits  or  data  queries.  Also  corrective  actions  were taken.  Although  no  reference  standard  for  comparison  is  available,  the  submitted  analysis  and narratives are reassuring. In addition, the EMA inspections of three of the trial sites support that the study was GCP compliant.

Additional concerns were raised with regards to the integrity of the interactive voice response system (IVRS), which specified each container to be dispensed to the patient, and on discrepancies between the trial database and the data collected on the eCRF. In response, the MAH clearly explained that the identified discrepancies were isolated events and not part of systematic error. With regard to the IVRS, the MAH explained in sufficient detail the pre-defined procedures employed in case manual changes are implemented, the reason such changes were implemented, and the audit trail of such changes. The submitted data indicate that these changes were necessary, well documented and not interfering with the integrity of the data or the safety of the trial subjects. This response was considered acceptable by the CHMP.

- Tabular overview of clinical studies

Table 2 Tabular listing of clinical studies with apixaban submitted within current application

| Study Number      | Objectives                                                                                                                                                                                                      | Study Design                                                               | Type of Subjects   | Dosage, Route                                                                                                         | Duration of Treatment                                                            | Number of Treated Subjects   | Study Status, Type of Report   |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|------------------------------|--------------------------------|
| Completed Studies | Completed Studies                                                                                                                                                                                               | Completed Studies                                                          | Completed Studies  | Completed Studies                                                                                                     | Completed Studies                                                                | Completed Studies            | Completed Studies              |
| CV185029          | To assess the oral bioavailability of apixaban solution formulation (Treatment B, 10 mg as 25 mL x 0.4 mg/mL) relative to apixaban Phase 3 tablets (Treatment A, 10 mg as 2 x 5 mg tablets) in healthy subjects | Phase 1, Open- label, randomized, 2- period, 2- treatment, crossover study | Healthy            | Treatment A: apixaban 10 mg (2 x 5mg tablets) / Oral; Treatment B: apixaban 10 mg (25 mL x 0.4 mg/mL) / Oral Solution | Apixaban tablets - single dose; Apixaban OS - single dose (4 day washout period) | 14                           | Completed, Full CSR            |

<div style=\"page-break-after: always\"></div>

Table 2 Tabular listing of clinical studies with apixaban submitted within current application

| Study Number   | Objectives                                                                                                                                                                                                                                                                                                                              | Study Design                                                              | Type of Subjects   | Dosage, Route                                                                                        | Duration of Treatment              |   Number of Treated Subjects | Study Status, Type of Report   |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------------|------------------------------------------------------------------------------------------------------|------------------------------------|------------------------------|--------------------------------|
| CV185074       | To assess the multiple-dose pharmacokinetics (PK) of apixaban and rivaroxaban following oral administration in healthy subjects and to compare plasma concentration peak to trough ratio (Cmax/Cmin) of rivaroxaban to apixaban following oral administration in                                                                        | Phase 1 Open-label, randomized, 2- period, 2- treatment, crossover study  | Healthy            | Treatment A: Rivaroxaban 10 mg QD Treatment B: Apixaban 2.5 mg Q12h                                  | Trt A: 4 days Trt B: 4 days        |                           14 | Completed, Full CSR            |
| CV185104       | healthy subjects The primary objective was to assess the effect of activated charcoal on the pharmacokinetics of apixaban, when administered 2 hours or 6 hours following the dose of apixaban in healthy subjects. The secondary objective was to assess the safety of apixaban when administered with and without activated charcoal. | Phase 1, Open-label, 3- treatment, 3- period, randomized, crossover study | Healthy            | Apixaban 20 mg (4 x 5 mg tablets) with 50 g activated charcoal and 96 g sorbitol, single dose / Oral | Single dose (4 day washout period) |                           18 | Completed Full CSR             |

<div style=\"page-break-after: always\"></div>

Table 2 Tabular listing of clinical studies with apixaban submitted within current application

| Study Number        | Objectives                                                                                                                                                                                  | Study Design                                                                    | Type of Subjects                             | Dosage, Route                                                                                       | Duration of Treatment                  | Number of Treated Subjects                 | Study Status, Type of Report   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------|-----------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------------------------|--------------------------------|
| CV185066            | To characterize the in vitro PD activity of apixaban in blood obtained from pediatric subjects (neonates through adolescents) and cord blood as compared to blood obtained from             | Non- therapeutic, in vitro study                                                | Healthy                                      | Not applicable, non- therapeutic study                                                              | Not applicable, non- therapeutic study | Not applicable, non- therapeutic study     | Completed, Full CSR            |
| CV185067 (B0661003) | To assess (safety endpoint) the effect of 2 doses of apixaban (2.5 mg BID and 5.0 mg BID) versus warfarin on the composite endpoint of major and CRNM bleeding during the Treatment Period. | Phase 2b, randomized, double-blind (apixaban), open-label comparator (warfarin) | non- valvular atrial fibrillation (in Japan) | Oral apixaban: 2.5 mg bid 5.0 mg bid Warfarin given per label requirements as per standard of care. | 12 weeks                               | 2.5 mg BID: 72 5.0 mg BID: 71 warfarin: 75 | Completed, Full CSR            |

<div style=\"page-break-after: always\"></div>

Table 2 Tabular listing of clinical studies with apixaban submitted within current application

| Study Number   | Objectives                                                                                                                                                                                                                                                                       | Study Design                                                                                                                       | Type of Subjects                  | Dosage, Route                                                                                                                            | Duration of Treatment   | Number of Treated Subjects   | Study Status, Type of Report                                        |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------------------|---------------------------------------------------------------------|
| CV185030       | To determine if apixaban is noninferior to warfarin (INR target range 2.0 3.0) in the combined endpoint of stroke (ischemic or hemorrhagic) and systemic embolism, in subjects with AF and at least one additional risk                                                          | Phase 3, active (warfarin)- controlled, randomized, multi-national, multi-center, double-blind, double-dummy, parallel group study | Non- valvular atrial fibrillation | 5 mg (2.5 mg for select subjects with a higher risk of bleeding) BID apixaban/ Oral Warfarin with INR therapeutic range 2.0 to 3.0/ Oral | 2.1 years average a     | 18,140                       | Completed, Full CSR                                                 |
| CV185048       | factor for stroke To determine if apixaban is superior to aspirin for preventing the composite outcome of stroke or systemic embolism in patients with AF and at least one additional risk factor for stroke who have failed or are unsuitable for vitamin K antagonist therapy. | Phase 3 randomized, multi-national, multi-center, double-blind, double-dummy, parallel-arm                                         | Non- valvular atrial fibrillation | 5 mg (2.5 mg for select subjects with a higher risk of bleeding) BID apixaban/ Oral Aspirin 81 to 324 mg QD / Oral                       | 1.6 years average a     | 5578                         | Double- Blind Phase: Completed, Full CSR; Open-Label Phase: Ongoing |

<div style=\"page-break-after: always\"></div>

Table 2 Tabular listing of clinical studies with apixaban submitted within current application

| Study Number   | Objectives                                                                                                                                                                                                | Study Design                                                   | Type of Subjects                                                                | Dosage, Route                                                             | Duration of Treatment              | Number of Treated Subjects   | Study Status, Type of Report   |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------|------------------------------------|------------------------------|--------------------------------|
| CV185068       | To determine if apixaban is superior to placebo for preventing the composite of cardiovascular death, myocardial infarction, or ischemic stroke, in subjects with a recent acute coronary syndrome (ACS). | Phase 3, randomized, placebo- controlled, parallel group study | Recent ACS and at least 2 additional risk factors for recurrent ischemic events | Oral apixaban 2.5 (for patients with CrCl< 40 mL/min) or 5 mg BID placebo | Apixaban 27 weeks Placebo 28 weeks | Apixaban 3672 Placebo 1508   | Completed, Full CSR            |

ACS  =  Acute  Coronary  Syndrome;  AF  =  atrial  fibrillation;  BID  =  twice  daily;  CrCl  =  creatinine clearance; CRNM = clinically relevant non-major; CSR = clinical study report; DR = dry granulation; DVT  =  deep  vein  thrombosis;  GI  =  gastrointestinal;  INR  =  international  normalized  ratio;  IV  = intravenous;  LMWH  =  low  molecular  weight  heparin;  PD  =  pharmacodynamic;  PE  =  pulmonary embolism;  PK  =  pharmacokinetic;  PO  =  by  mouth;  QD  =  once  daily;  SC  =  subcutaneous;  TIA  = transient ischemia attack; VKA = vitamin k antagonist; VTE = venous thromboembolism

## 2.4.2. Pharmacokinetics

The pharmacokinetic data submitted within initial MAA were considered sufficient for the authorisation of  the  5  mg  tablet,  as  the  pharmacokinetics  of  both  tablets  were  intensively  investigated  in  the submitted phase I-III studies. All studies in the initial MAA were relevant for both strengths, and the 2.5  and  5  mg  tablets  showed  dose  proportionality.  Therefore,  reference  is  made  to  the  information assessed within the initial MAA of Eliquis 2.5 mg film-coated tablets and only new information will be discussed.

For the current application the MAH submitted 2 additional PK studies (study CV185029 and CV185074) and updated the (pop-pk) pharmacokinetic analysis with data of newly performed phase 2/3 studies which employed sparse sampling.

## Newly submitted pharmacokinetic studies

The following pharmacology studies including population pharmacokinetics are new in this application compared to the initial application of the 2.5 mg strength.

Study CV185029 was designed to evaluate the relative bioavailability (BA) of the apixaban Phase 3 tablet (2.5 mg) and an oral solution formulation. This study provides additional data showing that the extent of absorption of apixaban from the tablet and solution formulation is comparable.

<div style=\"page-break-after: always\"></div>

The results of this study did not contribute specifically for the application of the 5mg tablet, but merely confirmed the observations already made with regard to the absorption profile of apixaban tablets, as Study CV185029 showed that absorption seems not to be dissolution-rate dependent.

Study CV185074 provided  an  additional  assessment  of  apixaban  multiple  dose  PK  following administration  of  2.5  mg  BID  in  healthy  subjects.  This  study  also  allowed  a  relative  assessment  of apixaban  PK  and  rivaroxaban  PK  within  the  same  individual.  The  results  of  the  study  are  used  to update  figure  PK16  (assessment  report)  and  in  the  tables  below,  however  they  are  not  separately discussed. The results are completely in line with previous pk results for multiple dose administration of 2.5 mg BD apixaban in healthy subjects.

The tables below (Table 3 and 4) are updated with data from studies CV185029 and CV185074 . The single- and multiple dose pharmacokinetics parameters estimates of apixaban are not changed after including these studies.

Table 3 Apixaban Oral Single-Dose PK Parameter Values Following Administration of 2.5-, 5- and 10-mg Apixaban Doses

| Dose (n)                | Cmax (ng/mL) Geom. Mean (%CV)   | Tmax (h) Median (min, max)   | AUC(INF) a (ng*h/mL) Geom. Mean (%CV)   | T-HALF (h) Mean (SD)   | CLR (mL/min) Mean (SD)   | F (%) Geom. Mean %CV)   |
|-------------------------|---------------------------------|------------------------------|-----------------------------------------|------------------------|--------------------------|-------------------------|
| Solution 10 mg (n = 13) | 287 (30)                        | 2.0 (1.0, 4.0)               | 2855 (21)                               | 13.8 (6.1)             | -                        | -                       |
| Tablet,10 mg (n = 214)  | 185 (39)                        | 3.0 (0.5, 8.0)               | 1924 b (32)                             | 12.4 b (5.6)           | 15.1 c (6.0)             | 49 d (24)               |

AUC(0-T) is not listed since it accounted for &gt;93% of AUC(INF) across the dose full range n= 212,

n= 20

n= 80

Table 4  Apixaban Oral Steady-State PK Parameters Following Administration of 2.5-, 5, and 10-mg BID Apixaban Doses

| Dose BID (n)   | Cmax (ng/mL) Geom. Mean (%CV)   | Cmin (ng/mL) Geom. Mean (%CV)   | Tmax (h) Median (min, max)   | AUC(TAU) (ng*h/mL) Geom. Mean (%CV)   | T-HALF (h) Mean (SD)   | CLR (mL/min) Mean (SD)   | AI Mean (SD)   |
|----------------|---------------------------------|---------------------------------|------------------------------|---------------------------------------|------------------------|--------------------------|----------------|
| 2.5 mg (n= 25) | 77.2 (25)                       | 18.5 (20)                       | 2.0 (1.0, 9.0)               | 527.9 (23.5)                          | 8.48 (2.2)             | 15.7 (5.6)               | 1.53 (0.31)    |
| 5 mg (n= 12)   | 162.3 (27)                      | 55.9 (19)                       | 4.0 (2.0, 4.0)               | 1276.4 (23)                           | 10.9 (3.8)             | 17.8 b (4.7)             | 1.83 (0.36)    |
| 10 mg (n= 24)  | 341.2 (28)                      | 105.7 (39)                      | 4.0 (2.0, 4.0)               | 2647.9 (28)                           | 10.1 (3.9)             | 18.4 (6.2)               | 1.76 (0.38)    |

AUC(TAU) represents AUC for the dosing interval, 0-12 h post dose, following the morning dose.

n = 6

n=11

n=18

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependencies

The  summary  of  clinical  pharmacology  data  submitted  to  support  the  registration  of  for  venous thromboembolism prevention (VTEp) indication remains largely unchanged, even with the additional new data from the CV185029 study. As such, the interpretation of these findings remains consistent with  that  presented  in  the  Clinical  pharmacology  Summary  (CPS)  for  VTEp  indication.  Loss  of proportionality at doses ≥ 25 mg has little, if any, clinical impact for this indication.

## POP-PK update and update intrinsic factors

The  MAH used sparse sampling in several  newly  submitted  phase  2  and  3  trials  (study  CV185030, CV185067, CV185070, and CV185023). A POP-PK analysis was conducted with this new data. Results of  this  analysis  indicated  that,  in  general,  the  effect  of  intrinsic  factors  (age,  gender,  body  weight, renal function) characterized in Phase 1 clinical pharmacology studies accounted for the differences in exposure observed between the healthy Phase 1 subjects and patients with AF.  In addition, patient status accounted for a small, 14% reduction in apixaban CL/F.

Higher apixaban exposures, up to approximately 30%, were observed for intrinsic factors such as age, gender, race, or low body weight ( ≤ 50 kg). Subjects with AF who are at a potentially greater risk of bleeding (defined as those who meet at least 2 of the following 3 criteria: age ≥ 80 yrs, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL) may require a lower dose of apixaban (i.e., 2.5 mg BID). It was shown in phase 3 trials that exposures in the subjects who met the dose reduction criteria and received 2.5 mg BID was slightly lower (~25%) than that of AF subjects treated with apixaban 5 mg BID (daily median AUCss values of 2703 ng*hr/mL versus 3603 ng*hr/mL, respectively). Therefore, this advice of dose reduction is incorporated in section 4.2 of the SmPC.

## Other important PK updates

Additionally  the  MAH  included  in  the  clinical  overview  information  with  regard  to  possible  genetic polymorphism.  The  MAH  confirmed  and  the  CHMP  agreed  that  genetic  polymorphism  resulting  in clinical significant differences in metabolic clearance of apixaban is not likely.

## 2.4.3. Pharmacodynamics

Pharmacodynamic data presented during the original application to  support the  VTEp  indication  are also applicable to the current indication.

## Mechanism of action

Apixaban is an orally active, direct, selective inhibitor of coagulation factor Xa (FXa) that reversibly binds  directly  to  the  active  site  of  FXa,  and  exerts  anticoagulant  and  antithrombotic  effects  by diminishing the conversion of prothrombin to thrombin. As the common mediator of both extrinsic and intrinsic  activation  of  coagulation  FXa  is  the  sole  physiological  mediator  of  thrombin  formation. Thrombin,  through  its  actions  on  fibrin  formation  and  platelet  activation,  is  a  key  mediator  of thrombosis in both the  venous and arterial circulation.  Inhibition  of  thrombin  generation,  therefore, produces  antithrombotic  effects  under  a  variety  of  pathological  conditions.  PD  effects  of  apixaban include inhibitory effects on FXa activity and ex vivo thrombin generation as well as the prolongation of clotting tests such as PT/INR, aPTT, and mPT.

<div style=\"page-break-after: always\"></div>

## Primary pharmacology

For this application, the MAH included one new pharmacodynamic Study CV185066 which provided an assessment  of  apixaban  PD  in  paediatric  and  adult  plasma  utilizing  2  different  anti-Xa  assays. Presented data show that the Rotachrom chromogenic (RCC) anti-Xa (AXA) assay is not affected by intrinsic  factor  X  levels.  Although  apixaban  does  not  require  routine  monitoring  of  exposure,  the Rotachrom anti-Xa assay may be useful in situations where knowledge of apixaban exposure may help to  inform  clinicians  when  taking  decisions.  However  its  use  was  not  implemented  in  the  clinical program limiting any recommendation regarding its applicability.

Based on PKK and exposure-response ER modelling from the pivotal study CV185030 (ARISTOTLE), AXA activity and apixaban plasma concentration are shown to be highly correlated within and above concentrations achieved following administration of apixaban 2.5 mg and 5 mg BID in AF patients. This is in line with data provided in the original MAA for subjects receiving 2.5 mg BID for VTEp indication. The model predicts a tight correlation between higher exposure and bleeding, but a lesser correlation between higher exposure and efficacy, in the form of prevention of stroke.

## Secondary pharmacology

No new data since initial MAA were provided.

## 2.4.4. Discussion on clinical pharmacology

Pharmacokinetic  and  pharmacodynamic  data  presented  during  the  original  application  for  the  VTEp indication  are  also  relevant  for  the  current  application.  New  data  further  support  the  utility  of Rotachrom anti-Xa assay, however, there was limited utilization of this assay in the phase 3 studies.

## 2.4.5. Conclusions on clinical pharmacology

The initial MAA included sufficient pharmacokinetic data to support the marketing authorisation of the 5 mg tablet. The PD properties of apixaban are adequately characterized and are in line with those of a direct  FXa  inhibitor.  The  Rotachrom  anti-Xa  assay  was  not  used  for  decision-making  in  the  clinical program limiting any recommendation regarding its applicability.

## 2.5. Clinical efficacy

Overview of the two new phase 3 studies to support the proposed indication are included in table E1. The phase 2 study CV185067 is discussed under Safety.

Table E1 Overview of phase 3 clinical studies in AF

<div style=\"page-break-after: always\"></div>

| Study No. Study Phase #of sites Regions                                                                                         | Subject Population Study Design                                                                                                                                                                                                                            | Study Start Enrollment Status Target Randomized                                                            | Number Randomized Duration                                                                                                                                                                                                                                                         | Gender M/F (%) Age Mean (min, max)                              | Primary and Other Key Endpoints / Objectives and Testing Strategy                                                                                                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CV185030 Phase 3 1053 sites enrolled subjects 1034 sites randomized subjects North America, Europe, Latin America, Asia/Pacific | Subjects (both warfarin- naive and warfarin- experienced) with AF and at least one additional risk factor for stroke Randomized, acrive- controlled, double- blind, double-dummy, parallel-group study                                                     | 19-Dec-2006 Complete Randomized Target: 18,000 subjects (9,000 in each group)                              | Apixaban: 9,120 Warfarin: 9,081 Event driven: The Double- blind Treatment Period was to be completed after approximately 448 subjects had a primary efficacy endpoint. The mean extent of exposure to double-blind study drug was 1.7 years for subjects in both treatment groups. | Apixaban: 64.5/35.5 69.1 (21, 95) Warfarin: 65/35 69.0 (19, 97) | Primary: stroke (hemorrhagic, ischemic or of unspecified type) or SE. Key Secondary: ISTH major bleeding; all-cause death Objectives and Testing: NI for stroke/SE followed by superiority for stroke/SE, followed bysuperiority for ISTH major bleeding. followed by superiority for all-cause death           |
| CV185048 Phase 3 526 North America, Europe, Latin America, Asia/Pacific                                                         | Subjects with AF and at least one additional risk factor for stroke, who failed (Demonstrated VKA unsuitable) or were expected to be unsuitable for VKA treatment (Expected VKA unsuitable) Randomized, double- blind, double-dummy, parallel-group study. | 31-Aug-2007 Double-blind Complete Randomized Target: 5600 subjects (2800 in each group) Open-label Ongoing | Apixaban: 2807 ASA:2791 Event driven: The Double- blind Treatment Period was to be completed after at least 226 subjects had a primary efficacy endpoint. The mean extent of exposure to double-blind study drug was 1.1 years for subjects in both treatment groups.              | Apixaban: 59.1/40.9 69.7 (48, 95) ASA: 57.9/42.1 70.0 (49, 100) | Primary: stroke (hemorrhagic, ischemic or of unspecified type) or SE Key Secondary: major vascular events (stroke, SE, MI or vascular death; all-cause death. Objectives and Testing: Superiority for stroke/SE, followed by superiority for major vascular events,followed by superiority for all- cause death |

## 2.5.1. Dose response study

No new dose response studies were provided by the MAH to support this appllication. In the phase 3 studies, 5 mg BID was the selected dose. For certain patients deemed to be at higher risk of bleeding with study drug (e.g., the elderly, small stature, renal impairment), a lower dose of apixaban (2.5 mg BID) was used.

Selection of the 5 mg BID dose of apixaban was based primarily on the Phase 2 dose-ranging study in VTEp (CV185010), the Phase 2 study in deep vein thrombosis (DVT) treatment (CV185017; 3 months treatment duration), and experiences from other anticoagulants studies in this patient population. In the Scientific Advice provided by the EMEA in 2005, it was agreed that dose selection for apixaban in AF studies could be derived from Phase II studies in prophylaxis and treatment of VTE and that there was no need in repeating dose-finding in patients with AF.

Study  CV185010 (assessed within  the  original  MAA)  showed  that  all  selected  doses  had  favourable efficacy, but the rate of bleeding with the higher doses (10 and 20 mg/day) was similar or higher than with enoxaparin/warfarin (Fig E1).

<div style=\"page-break-after: always\"></div>

Figure E1: Apixaban Phase 2 VTEp after Knee Replacement (CV185010)

<!-- image -->

A  dose  of  2.5  mg  BID  was  selected  for  the  VTEp  indication.  In  AF,  where  stroke  is  the  primary endpoint, a failure of efficacy would result in substantial morbidity and mortality and is thus a much greater  concern.  This  favoured  the  selection  of  5  mg  BID  dose  as  it  appeared  to  have  increased efficacy compared to the 2.5 mg BID dose without a substantial increase in bleeding risk.

Modified dose: Results of PK/PD studies indicate that factors such as renal function, age, and body weight individually have limited effect on apixaban's exposure, however, combinations of these factors could result in clinically significant higher exposures. Accordingly, the Phase 3 program implemented a dose  modification  strategy  (2.5  mg  BID)  in  patients  who  fulfilled  any  2  of  the  following  criteria  at baseline: Age ≥80 years; body weight ≤60 kg and serum creatinine ≥1.5 mg/dL (133 μmol/L).

## 2.5.2. Main studies

The two Phase 3 studies were both active-controlled, randomized, multi-national, multi-centre, doubleblind, parallel-group studies with independent, blinded adjudication of efficacy and safety endpoints by an external Events Adjudication Committee. The treatment period of each study was to be completed after a pre-specified number of subjects (448 subjects in CV185030 and 226 subjects in CV185048) had  a  primary  efficacy  endpoint.  Study  CV185048  also  included  an  optional  Long-Term  Open-label Treatment Extension (LTOLE).

## Study CV185030 (ARISTOTLE)

## Methods

This is a Phase 3 study designed to evaluate the efficacy and safety of apixaban versus warfarin (INR target  range  2.0  -  3.0)  in  subjects  with  non-valvular  AF  and  at  least  one  additional  risk  factor  for stroke.  The  comparator  warfarin  was  well  chosen  since  the  European  Society  of  Cardiology  (ESC) clinical practice guidelines for the management of AF recommend VKA in AF patients with ≥1 stroke risk  factor(s)  provided  there  are  no  contraindications.  For  a  valid  comparison  between  a  new  anticoagulant versus VKA, it is important to ensure that patients on VKA spend a relevant time (more than 60% of the time) in therapeutic range of INR 2-3. Challenges in maintaining an adequate INR level in a global trial  are  acknowledged. Control of INR for warfarin subjects was determined by using central monitoring  of  INR  measurements.  Methods  described  by  the  MAH  appear  adequate  to  maintain

<div style=\"page-break-after: always\"></div>

therapeutic VKA levels, though only the results can confirm their adequacy. Rosendaal's method 3  to measure  individual  TTR  (time  in  therapeutic  range)  was  also  employed  in  the  RELY  study  and  is acceptable.

## Study Participants

The ARISTOTLE study included subjects with AF who were eligible for warfarin treatment (VKA naïve or experienced subjects). Main inclusion criteria were subjects ≥18 years of age with documented AF or atrial flutter, and presenting with at least 1 additional risk factor for stroke. Risk factors included the following:  age  ≥  75  years;  prior  stroke,  transient  ischemic  attack  (TIA)  or  SE;  either  symptomatic congestive heart failure within 3 months or left ventricular (LV) dysfunction with an LV ejection fraction (LVEF)  ≤40%;  diabetes  mellitus;  hypertension  requiring  pharmacological  treatment.  Main  exclusion criteria included: clinically significant (moderate or severe) mitral stenosis and increased bleeding risk that was believed to be a contraindication to oral anticoagulation. The inclusion and exclusion criteria used in the study are deemed adequate for AF patients who might benefit from this treatment.

## Treatments

The dose of apixaban assigned at randomization (5 mg BID or 2.5 mg BID in special populations) was to be maintained throughout the study, even in case criteria changed during the study. Study dosage of warfarin treatment was based on INR measurements (INR target range 2.0 to 3.0). According to the MAH,  a  major  effort  to  train,  track  and  assure  the  quality  of  the  INR  control  in  the  study  was undertaken. INRs were measured and collected into a central database in a blinded fashion with pointof-care (POC) devices. The protocol specified the collection of INRs on all treated subjects by Day 4 after initiation of study drug, with increased frequency during titration of warfarin (or warfarin/placebo), and monthly after that. The POC devices would deliver true INR readings for VKA patients,  but  would  sham  the  INR  results  for  those  on  apixaban.    INR  control  was  assessed  by  the method of Rosendaal and divided into terciles (TTR &lt;2.0, 2.0 - 3.0 and &gt;3.0) and was carried out on the  country  level.  Rosendaal's  method  provides  each  subject  with  an  INR  measurement  every  day, either actual or by estimation through linear interpolation.

The  study included  3  periods:  (1)  the  screening  period  of  up  to  14  days,  (2)  the  treatment  period lasted until the earlier of a subject's treatment discontinuation or the attainment of approximately 448 primary efficacy events and (3) the follow-up period lasted until the latter of 30 days after treatment discontinuation or the attainment of 448 primary efficacy events.

## Objectives

The primary objective was to determine if apixaban was non-inferior (NI) to warfarin for the combined endpoint of stroke (haemorrhagic, ischemic or of unspecified type) or SE, in subjects with AF and at least one additional risk factor for stroke. The key secondary objectives were to determine if apixaban was superior to warfarin for: the combined endpoint of stroke or SE; major  bleeding (International Society on Thrombosis and Hemostasis [ISTH] criteria); and all-cause death.

«prodname»

CHMP assessment report Rev04.12

Page 27/84

3  Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-9

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

The primary efficacy endpoint was the time from randomisation to first occurrence of confirmed stroke or SE, regardless of whether the subject was receiving treatment at the time of the event during the Intended Treatment Period.

Diagnosis of stroke required non-traumatic, focal neurological deficit lasting at least 24 hours. A retinal ischemic event (embolism, infarction) was considered as a stroke and transient ischemic attack (TIA) was  defined  as  a  non-traumatic  abrupt  onset  of  focal  neurological  symptoms  lasting  less  than  24 hours.  The  study  protocol  recommended  that  a  cerebral  imaging  study  such  as  a  computed tomography  (CT)  scan  or  magnetic  resonance  imaging  (MRI)  would  be  performed  for  all  suspected strokes. Systemic embolism was judged to occur where there was a clinical history consistent with an acute  loss  of  blood  flow  to  a  peripheral  artery  (or  arteries),  which  was  supported  by  evidence  of embolism from surgical specimens, autopsy, angiography, or other objective testing.

All  suspected  efficacy  events  were  adjudicated  by  an  independent,  expert  panel  of  physicians experienced in adjudication of these types of clinical study endpoints.

The  endpoints/outcome  of  the  study  was  adequately  chosen,  discussed  and  agreed  on  during  the scientific  advise  given    by  the  CHMP.  The  chosen  primary  endpoint  of  stroke/SE  is  also  in  line  with recently assessed clinical trials. Since imaging studies were not consistently performed to verify stroke or  sub-classify  ischemic  stroke,  the  results  might  be  influenced  by  the  judgment  of  the  study investigator. However, considering the double-blind design, the influence on study outcome would be limited.

## Randomisation and blinding (masking)

Eligible subjects were randomized in a 1:1 ratio to either apixaban or warfarin. All subjects received matching placebo (double-dummy design).

## Statistical methods and sample size

## Populations for Statistical Analyses .

Randomized Population : includes all subjects who signed informed consent and were randomized. In this population, subjects are categorized to the group to which they were assigned by the automated voice response system (As Randomized).

Evaluable Population : subset of Randomized Population, excluding full (if deviation occurred prior to randomization) or partial data (if deviation occurred after randomization) from subjects with protocol deviations expected to affect the primary efficacy endpoint. If a deviation occurred after randomization, then the data up to the time of the deviation was included in the Evaluable data set. In this population subjects are categorized according to the As Randomized group. This population is used for sensitivity analyses associated with NI assessments in the CV185030 study.

Choice of NI margin. The following two analyses were performed; NI of apixaban relative to warfarin was demonstrated:

1. If the upper bound of the two-sided 95% confidence interval (CI) for risk reduction (RR) was less than 1.38.
2. If the upper bound of the two-sided 99% CI for RR was less than 1.44.

The 4 key objectives of the study were tested following a pre-specified hierarchical testing strategy at a significance level adjusted for the formal interim test for superiority. The adjustment was small and

<div style=\"page-break-after: always\"></div>

did  not  impact  the  results.  Overall  type  I  error  was  preserved  at  ≤5%.  NI  for  the  primary  efficacy endpoint was assessed first (at NI margin=1.38 and one-sided α= 0.025; and at NI margin=1.44 and one-sided α= 0.005).

The following tests in the sequence were performed at the one-sided α= 0.025:

-  If  NI  for  the  primary  efficacy  endpoint  (using  a  NI  margin  of  1.38)  was  demonstrated,  then superiority for the primary efficacy endpoint was tested.

· If superiority for the primary efficacy endpoint was demonstrated, then superiority for ISTH major bleeding was tested.

• If superiority for major bleeding was demonstrated, then superiority for all-cause death was tested.

The study size was calculated to meet the NI margin of 1.44. With 448 subjects with confirmed strokes or SE, the study would have at least 90% power. Based on a sample size of 18,000 subjects allocated in a 1:1 ratio to the apixaban or warfarin group, assuming a primary efficacy endpoint rate of 1.20 per hundred subject-years, an average follow-up of ~2.1 years was estimated to be required to accrue the target  number  of  primary  efficacy  events.  These  calculations  assumed  an  incidence  of  1%  loss  to follow-up.

Primary  efficacy  analysis :  An  intention-to-treat  analysis  was  performed  on  the  Randomized Population  based  on  adjudicated  primary  efficacy  endpoint  events  occurring  during  the  Intended Treatment Period (starts on day of randomisation and ends at the efficacy  cut-off date: 448 had a primary efficacy endpoint.).

Per-protocol  analyses were  sensitivity  analyses  used  for  NI  assessments  and  included  events occurring  from  first  dose  through  x  days  after  last  dose  of  blinded  study  drug  for  the  Evaluable Population (x=2, 7, or 30 days in each of the sensitivity assessments).

In the scientific advise (EMEA/CHMP/SAWP/411449/2005) the non-inferiority margin of 1.44 based on the  relative  risk  of  apixaban  compared  to  warfarin  was  discussed  and  considered  appropriately justified.

The rationale of the sample size calculations is plausible. The statistical methods used are acceptable. Superiority of apixaban was tested following a pre-specified hierarchical testing strategy, after NI for apixaban (primary outcome) was shown. The sequence of the tests used in the study is acceptable.

In general the design of ARISTOTLE study was considered by the CHMP as adequate and in line with recently conducted studies with dabigatran and rivaroxaban supporting the same indication, i.e. RELY and ROCKET-AF studies, respectively.

## Results

## Participant flow

A  total  of  20,998  subjects  were  enrolled  in  study  CV185030.  Of  these  subjects,  18,201  were randomised to receive study treatment. Around 25% of the patients discontinued the study, which is in line with the experience in similar studies. Main reasons for discontinuation were subject request to discontinue  treatment  (around  10  %  in  each  treatment  group),  adverse  events  (7.4%  and  8.1%, respectively) and deaths (3.6% and 3.8%, respectively). Stroke and SE are both listed as reasons for discontinuation which can lead to misinterpretation of the results, as they are primary endpoints. The incidence of SE (0.2% and &lt; 0.1%, respectively) and MI (0.3% and 0.2%, respectively) leading to study discontinuation in the apixaban group are slightly higher than the VKA group, which is not in line with the efficacy results shown below. This discrepancy occurred as one calculation was based on the investigator's  assessment,  the  other  was  based  on  the  blinded  adjudication  by  an  independent

<div style=\"page-break-after: always\"></div>

committee.  When  the  same  events  were  assessed  by  the  latter  committee,  the  results  of  both apixaban and warfarin were comparable.

## Recruitment

The study was conducted globally across 40 countries and 1053 sites and included subjects from EU, NA,  Asia/Pacific  and  Latin  America  (table  E2).  Subject's  disposition  was  comparable  between  the treatment  groups.  About  40%  of  the  patients  were  classified  as  in  Europe.  It  is  noted  that  Russia (~10%), Israel (2%) and South Africa (0.5%) were also included under Europe. Actual representation from the EU region was 2032 and 2026 patients randomized to apixaban and VKA groups, respectively (~22%). This latter population allows a better comparison considering the expected difference in INR control per region.

Table E2  Summary of Enrolment by Region - Randomized Subjects- CV185030

|               | CV185030            | CV185030            | CV185030          |
|---------------|---------------------|---------------------|-------------------|
|               | Apixaban (N = 9120) | Warfarin (N = 9081) | Total (N = 18201) |
| Europe        | 3672 (40.3)         | 3671 (40.4)         | 7343 (40.3)       |
| North America | 2249 (24.7)         | 2225 (24.5)         | 4474 (24.6)       |
| LatinAmerica  | 1743 (19.1)         | 1725 (19.0)         | 3468 (19.1)       |
| Asia/Pacific  | 1456 (16.0)         | 1460 (16.1)         | 2916 (16.0)       |

'Europe' included: Russia, Israel and South Africa

## Baseline data

The treatment groups were well balanced for the baseline disease characteristics, including risk factors, with no clinically relevant differences noted between the apixaban and warfarin groups (Table E3). The study population adequately reflects the target population for the intended indication. The mean age was 69.1 years, with adequate representation of patients ≥ 75 years. Mean CHADS2 risk score was 2.1 in  each  treatment  group;  the  majority  of  subjects  (66.9%)  in  both  treatment  groups  had  ≥2  risk factors at baseline. Treated hypertension was the most common risk factor (87.4%) followed by CHF (35.4%),  and  age  ≥75  years  (31.2%).  Overall,  19.4%  of  subjects  had  a  prior  stroke,  TIA,  or  SE. Although the studies included subjects with AF and at least one additional risk factor for stroke, a small percentage (n=12) of subjects in both treatment groups had a CHADS2 score of 0. The MAH explained that  the  CHADS2  score  criteria  are  more  restrictive  than  the  study  inclusion  criteria  based  on  risk factors,  which  explains  inclusion  patients  with  CHADS2  score=0.  These  patients  were  considered protocol deviations. Comparing participants in ARISTOTLE to those of recently published studies in the same  indication  shows  that  ARTISTOLE  and  RELY  (dabigatran)  recruited  patients  with  comparable CHADS2 scores (around 2). In ROCKET-AF (rivaroxaban) the mean CHADS2 score was higher (3.47), making  further  comparisons  among  these  agents  difficult.  Co-administered  medications  reflect  the associated  co-morbidities  (anti-arrhythmics,  anti-hypertensions  and  anti-platelets).  ASA  was  coadministered  in  around  30%  of  the  patients  allowing  adequate  conclusions  on  the  safety  of  this combination. Both VKA naïve and experienced patients are properly presented in the study (~42% and ~57%, respectively).

## Table E3 Baseline characteristic of the randomized subjects in CV185030

<div style=\"page-break-after: always\"></div>

|                                                                   | Apixaban N = 9120                   | Warfarin N= 9081                              | Total N = 18201                               |
|-------------------------------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| AGE (YRS)                                                         |                                     |                                               |                                               |
| N                                                                 | 9120                                | 9081 69.0 70.0                                | 18201                                         |
| MEAN                                                              | 69.1                                |                                               | 69.1                                          |
| MEDIAN                                                            | 70.0                                |                                               | 70.0                                          |
| MIN ， MAX                                                         | 21,95                               | 19,97 63.0, 76.0                              | 19, 97                                        |
| 887 8                                                             | 63.0, 76.0                          | 9.74                                          | 63.0, 76.0                                    |
| STANDARD DEVIATION                                                | 9.61                                |                                               | 9.68                                          |
| AGE CATEGORY (%)                                                  |                                     |                                               |                                               |
| <65                                                               | 2731 ( 29.9)                        | 2740 (30.2)                                   | 5471 (30.1)                                   |
| 65-<75                                                            | 3539 38.8)                          | 3513 38.7)                                    | 7052 ( 38.7)                                  |
| >=75                                                              | 2850 ( 31.3)                        | 2828 ( 31.1)                                  | 5678 (31.2)                                   |
| NOT REPORTED                                                      | 0                                   | 0                                             | 0                                             |
| GENDER (°%)                                                       |                                     |                                               |                                               |
| MALE                                                              | 5886 ( 64.5)                        | 5899 ( 65.0)                                  | 11785 ( 64.7)                                 |
| FEMALE                                                            | 3234 ( 35.5)                        | 3182 ( 35.0)                                  | 6416 ( 35.3)                                  |
| NOT REFORTED                                                      | 0                                   | 0                                             | 0                                             |
| FEMALE AGE CATEGORY (%)                                           |                                     |                                               |                                               |
| <=50                                                              | 81 0.9)                             | 88 1.0)                                       | 169 0.9)                                      |
| >50                                                               | 3153 34.6)                          | 3094 34.1)                                    | 6247 (34.3)                                   |
| NOT APPLICABLE (MALE)                                             | 5886 ( 64.5)                        | 5899 ( 65.0)                                  | 11785 ( 64.7)                                 |
| NOT REPORTED                                                      | 0                                   | 0                                             | 0                                             |
|                                                                   | Apixaban                            | Warfarin                                      | Total                                         |
| Level of Renal Impainment (CrCL)                                  | N=9120                              | N=9081                                        | N=18201                                       |
| SEVERE (<=30ML/MIN) (%)                                           | 137 (.1.5) 1365 15.0)               | 133 1.5) 1382 15.2)                           | 270 1.5) 2747 15.1)                           |
| MODERATE (>30 -<=50 ML/MIN) (%) (%)                               |                                     | 3770 41.5)                                    | 7587 (41.7)                                   |
| MILD (>50 - <=80 ML/MIN)                                          | 3817 (41.9)                         |                                               |                                               |
| NORMAL_ (> 80 ML/MIN)(%)                                          | 3761 ( 41.2)                        | 3757 (41.4)                                   | 7518 (41.3)                                   |
| NOT REPORTED (%)                                                  | 40 (0.4)                            | 39 (0.4)                                      | 79 0.4)                                       |
| APIXABAN OR MATCHING PLACEBO DOSE AT RANDOMIZATION (?) 2.5 MG BID | 428(4.7)                            | 403 (4.4)                                     | 831 (4.6)                                     |
|                                                                   | 8692 ( 95.3)                        |                                               |                                               |
| 5.0 MG BID                                                        |                                     | 8678 ( 95.6)                                  | 17370 ( 95.4)                                 |
| TYPEOFRISKFACTORAT ENROLIMENT(%)                                  |                                     |                                               |                                               |
| AGE >= 75 YEARS                                                   | 2850 ( 31.3) 19.2)                  | 2828 ( 31.1)                                  | 5678 ( 31.2)                                  |
| PRIOR STROKE，TIA,OR SYSTEMIC EMBOLISM                             | 1748                                | 1790 19.7)                                    | 3538 19.4)                                    |
| PRIOR STROKE                                                      | 1045 11.5)                          | 1082 11.9)                                    | 2127 11.7)                                    |
|                                                                   | 6.6)                                |                                               | 1257 6.9)                                     |
| PRIOR TIA                                                         | 603                                 | 654 7.2)                                      |                                               |
| PRIOR SYSTEMIC EMBOLISM                                           | 142 1.6)                            | 129 1.4)                                      | 271 1.5)                                      |
| SYMPTOMATICCHFWITHIN3MONTHSORLVEF<=40%                            | 3235 35.5) 30.5)                    | 3216 35.4)                                    | 6451 35.4) 5541 30.4)                         |
| SYMPTOMATICCHF                                                    | 2784 14.5)                          | 2757 30.4) 1301 14.3)                         | 2625 14.4)                                    |
| LVEF <=40% DIABETES MELLITUS                                      | 1324 2284                           | 2263 24.9)                                    | 4547 25.0)                                    |
| HYPERTENSIONWITHPHARMACOLOGICALTREATMENT                          | 25.0) 7962 (87.3)                   | 7954                                          |                                               |
|                                                                   |                                     | (87.6)                                        | 15916 5(87.4)                                 |
| NUMBER OF RISKFACTORSAT ENROLIMENT()                              |                                     |                                               |                                               |
| NOT REPORTED                                                      | 0                                   |                                               |                                               |
| <←=1 Y2                                                           | 3025 5( 33.2)                       |                                               | 6025 (33.1)                                   |
| CHADS-2 SCORE AT ENROLIMENT(°)                                    | 6095 ( 66.8) 0                      | 3000 33.0) 6081 67.0) 0                       | 12176 66.9) 0                                 |
| NOT REPORTED ←=1 MEAN (SD)                                        | 3100 (34.0) 3262 35.8) 2758 ( 30.2) | 3083 34.0) 3254 35.8) 2744 ( 30.2) 2.1 (1.11) | 6183 34.0) 6516 35.8) 5502 ( 30.2) 2.1 (1.10) |
|                                                                   | 2.1 (1.10)                          |                                               | (0.0, 6.0)                                    |
| MIN, MAX                                                          | (0.0, 6.0)                          | (0.0, 6.0)                                    |                                               |

Source: Source: Tables S.3.2C1 and S.3.3A1 of CV185030 CSR

## Conduct of the study

Importantly,  the  level  of  INR  control  is  highlighted,  with  several  analyses  submitted  showing  that generally the INR was controlled within the therapeutic range (2-3) for a median of 60%; and 66% after exclusion of the first 7 days and periods of VKA interruptions, in line with results of other recent studies (table E4).

<div style=\"page-break-after: always\"></div>

Table E4 Median TTR for Recent Stroke Prevention in AF Studies

| Study     | TTR (median)   |
|-----------|----------------|
| ACTIVE-W  | 65%            |
| RE-LY     | 67.3%          |
| ROCKET-AF | 57.8%          |
| CV185030  | 66.0%          |

This TTR allows a fair comparison versus apixaban. As expected VKA naïve patients had slightly lower levels of TTR (52.15%) vs 60.7% in the VKA experienced.

## Numbers analysed

Table E5 Analysis Population Summary

|                        |   Apixaban | Apixaban   |   Warfarin | Warfarin   |   Total | Total   |
|------------------------|------------|------------|------------|------------|---------|---------|
| RANDOMIZED SUBJECTS, N |       9120 |            |       9081 |            |   18201 |         |
| TREATED SUBJECTS,N     |       9088 |            |       9052 |            |   18140 |         |
| EVALUABLESUBJECTS (%)  |       8518 | (93.4)     |       8475 | (93.3)     |   16993 | (93.4)  |

## Outcomes and estimation

The non-inferiority NI of apixaban versus warfarin for the primary efficacy endpoint was demonstrated, followed  by  demonstration  of  superiority.  The  Kaplan-Meier  Plot  for  stroke/SE  during  the  Intended Treatment  Period  is  presented  in  Figure  E2.  The  NI  assessment  was  also  performed  based  on  PP analyses. Three separate sets of PP analyses were performed including events from first dose through 2, 7, and 30 days after the last dose. The observed HR and p-values for NI and superiority tests were lower than those for intent-to-treat (ITT) analyses supporting the conclusion of superiority of apixaban relative to warfarin for the primary efficacy endpoint.

Figure  E2  Kaplan-Meier  Plot  for  Stroke/SE  during  the  intended  treatment  period  randomised subjects CV185030

<!-- image -->

Eliquis

CHMP assessment report

<div style=\"page-break-after: always\"></div>

This superiority is mainly driven by the lower incidence of hemorrhagic stroke in the apixaban group (0.42%)  compared  to  0.84%  in  the  VKA  group  and  to  a  lesser  extent  ischemic  stroke  (1.74%  vs 1.91% respectively), with comparable effect on SE (0.16% vs 0.18% respectively). The results point that  apixaban  is  probably  a  safer  alternative  in  terms  of  bleeding  rather  than  a  more  effective  one (See: Summary of efficacy tables, Table E24 and E25).

Apixaban  showed  a  reduction  in  all-cause  death,  a  secondary  endpoint  in  the  hierarchical  testing strategy, results are on the border of statistical significance [HR=0.89; 95%CI= 0.80; 1.00, two-sided p-value=0.0465]. Both cardiovascular deaths [HR=0.89; 95%CI =0.76-1.04] and non-cardiovascular deaths  [HR=0.93;  95%CI=0.77-1.13]  were  just  numerically  lower  in  the  apixaban  group,  without showing robust superiority in either subgroup.

Of note, apixaban treatment was associated with a lower incidence of MI (0.53%/yr) compared to VKA (0.61%), HR =0.88 (95% CI:0.66-1.17). These results compare favourably with dabigatran which was associated with a slightly higher incidence of MI compared to VKA (overall rate in RELY: 0.82, 0.81, and 0.64 % / year for dabigatran 110 mg BID and 150 mg BID and VKA respectively).

Since  warfarin  effectiveness  depends  heavily  on  the  degree  of  INR  control,  TTR  of  INR  therapeutic levels (2-3) was taken into account. Most of presented analyses show a favourable effect of apixaban over VKA using different methods of calculating TTR, however superiority was not consistently shown except  with study  sites with INR  below  the  median  quartile  of  INR  control (TTR  individual 65.99%)(HR=0.78; 95% CI: 0.62-0.98) but lost in sites with INR ≥ median INR (HR=0.81; 95% CI: 0.61-1.08).  Using  TTR,  presented  by  centres 4 TTRc,  apixaban  shows  favourable  results,  with  HR consistently below 1 (0.77-0.81) but no superiority compared to VKA; 95% CI varying from 0.57-1.07 to  0.52-1.26  (table  E6).  Conclusions  are  also  applicable  to  all  cause  death,  but  importantly,  in  the highest TTRc quartile (&gt; 72.2%), HR was 1.04 (95%CI: 0.82-1.33). Thus, although the overall results support the superiority of apixaban over VKA, this superiority was not shown in patients well controlled on VKA.

«prodname»

CHMP assessment report

Rev04.12

4 Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376(9745): 975-83.

Page 33/84

<div style=\"page-break-after: always\"></div>

Table E6: Comparison of Apixaban and VKA Efficacy Outcome Events (Stroke/SE, All Cause Mortality) by TTRc Quartile

|                 | N        | N        | Events   | Events   | Rate/100 person yrs   | Rate/100 person yrs   | HR   |            | Adjusted Interaction P-value   |
|-----------------|----------|----------|----------|----------|-----------------------|-----------------------|------|------------|--------------------------------|
| Center TTRc     | Apixaban | Warfarin | Apixaban | Warfarin | Apixaban              | Warfarin              |      |            |                                |
| Sroke/SE        |          |          |          |          |                       |                       |      |            | 0.2842                         |
| ≤ 58.1          | 2280     | 2263     | 71       | 88       | 1.78                  | 2.28                  | 8L0  | 0.57, 1.07 |                                |
| 58.1 -<65.7     | 2253     | 2277     | 53       | 68       | 1.28                  | 1.61                  | 0.79 | 0.55, 1.13 |                                |
| 65.7 -<72.2     | 2260     | 2273     | 51       | 65       | 1.21                  | 1.55                  | 0.79 | 0.54. 1.13 |                                |
| ≥ 72.2          | 2277     | 2261     | 36       | 44       | 8'0                   | 1.02                  | 0.81 | 0.52, 1.26 |                                |
| All eaute death |          |          |          |          |                       |                       |      |            | 0.4093                         |
| ≤ 58.1          | 2280     | 2263     | 162      | 195      |                       | 58'                   | 0.81 | 0.66, 1.00 |                                |
| 38.1 -~63.7     | 2233     | 2277     | 139      | 173      |                       | 4.00                  | 0.93 | 0.73, 1.16 |                                |
| 65.7 -<72.2     | 2260     | 2273     | 147      | PLI      | 3.44                  | 4.07                  | 0.84 | 0.68, 1.05 |                                |
| ≥ 72.2          | 2277     | 2261     | 133      | 127      | 3.03                  | 2.91                  | 1.04 | 0.82, 1.33 |                                |

Efficacy  results  presented  in  different  subgroups  were  generally  consistent with  the  primary  efficacy results for the study (Figure E3). Importantly, for the subgroup of patients receiving the reduced dose of  apixaban  (2.5  mg  BID),  event  rates  favoured  apixaban  over  warfarin  (1.43%/yr  vs  7.23%/yr, HR=0.19, 95% CI: 0.04, 0.91), suggesting effective exposure in this reduced dose group (Figure E3). In patients  &lt;  65  years ,  incidence  of  stroke/SE  was  slightly  higher  in  the  apixaban  group  than  VKA group resulting in a HR=1.16 (95% CI: 0.77- 1.73), although results of patients above 75 years were in line with the general favourable results. The MAH explored three parameters which could have led to worse  results  in  patients  &lt;65  years,  mainly:  patient's  characteristics,  VKA  control  and  apixaban exposure in the ARISTOTLE study. Submitted analyses show that none of these parameters could have significantly  affected  the  results.  This  is  further  supported  by  data  from  the  AVERROES  study presented below. It can be concluded that the trend for worse efficacy results in patients &lt;65 years is probably a chance finding.

Figure  E3  Forest  Plot  for  Stroke/SE  during  the  Intended  Treatment  Period  -  Randomised Subjects (CV185030)

<!-- image -->

| Subgroup                  |                       | Apixaban n (x/yr)     | Warforin n (xz/yr)   | Hozard Rotio (95t C1)   | dnoubqns            |                       |                       | Apixobon n (x/yr)Warforin n (x/yr)   | Hozord Rotio (95t CI)   |
|---------------------------|-----------------------|-----------------------|----------------------|-------------------------|---------------------|-----------------------|-----------------------|--------------------------------------|-------------------------|
| BMI                       |                       |                       |                      |                         | PRIOR STROKE OR TIA |                       |                       |                                      |                         |
| <= 28 KG/M2               |                       | 115 ( 1.55)           | 148 ( 1.97)          | 0.79 ( 0.62, 1.00)      | YES                 |                       | 73 ( 2.46)            | 98 ( 3.24)                           | 0.76 ( 0.56, 1.03)      |
| > 28 T0 33 KG/M2          |                       | 62 ( 1.15)            | 72 ( 1.43)           | 0.81 ( 0.57, 1.13)      | NO                  | H+                    | 139 ( 1.01)           | 167 ( 1.23)                          | 0.82 ( 0.65, 1.03)      |
| > 33 KG/M2                |                       | 34 ( 0.88)            | 44 ( 1.11)           | 0.79 ( 0.51, 1.24)      | AGE >=75 YEARS      |                       |                       |                                      |                         |
| LEVEL OF RENAL IMPAIRMENT |                       |                       |                      |                         | YES                 | H                     | 79 ( 1.56)            | 109 ( 2.19)                          | 0.71( 0.53, 0.95)       |
| SEVERE OR MODERATE        |                       | 54 (2.11)             | 69 ( 2.67)           | 0.79 ( 0.56, 1.13)      | NO                  |                       | 133 ( 1.14)           | 156 ( 1.35)                          | 0.85 ( 0.67, 1.07)      |
| MILD                      |                       | 87 ( 1.24)            | 116 ( 1.69)          | 0.74 ( 0.56, 0.97)      | DIABETES            |                       |                       |                                      |                         |
| NORMAL                    |                       | 70 (0.99)             | 79 ( 1.12)           | 0.88 ( 0.64, 1.21)      | YES                 |                       | 57 ( 1.39)            | 75 ( 1.86)                           | 0.75 ( 0.53, 1.05)      |
| NUMBER OF RISK FACTORS    |                       |                       |                      |                         | NO                  |                       | 155 ( 1.23)           | 190 ( 1.51)                          | 0.81 ( 0.65, 1.00)      |
| <=1                       |                       | 44 (0.76)             | 51 ( 0.89)           | 0.85 ( 0.57, 1.27)      | HYPERTENSION        |                       |                       |                                      |                         |
| >=2                       |                       | 168 ( 1.54)           | 214 ( 1.97)          | 0.78 ( 0.64, 0.95)      | YES                 | 王                     | 191 ( 1.31)           | 231 ( 1.59)                          | 0.82 ( 0.68, 1.00)      |
| CHADS2                    |                       |                       |                      |                         | NO                  |                       | 21 ( 0.99)            | 34 ( 1.87)                           | 0.59 ( 0.34, 1.01)      |
| <=1                       |                       | 44 (0.74)             | 51 ( 0.87)           | 0.85 ( 0.57, 1.27)      | HEART FAILURE       |                       |                       |                                      |                         |
| =2                        |                       | 74 ( 1.24)            | 82 ( 1.37)           | 0.90 ( 0.66, 1.23)      | YES                 |                       | 70 ( 1.40)            | 79 ( 1.61)                           | 0.86 ( 0.63, 1.19)      |
| >=3                       |                       | 94 ( 1.95)            | 132 ( 2.80)          | 0.70 ( 0.54, 0.91)      | NO                  | H                     | 142 ( 1.21)           | 186 ( 1.59)                          | 0.76 ( 0.61, 0.94)      |
|                           |                       |                       |                      |                         |                     | 1                     |                       |                                      |                         |
|                           | Hazord Ratio (95x CI) | Hazord Ratio (95x CI) |                      |                         |                     | Hazard Ratio (95x CI) | Hazard Ratio (95x CI) |                                      |                         |

<div style=\"page-break-after: always\"></div>

Reduced efficacy is shown in patients randomized in the EU: HR for stroke/SE= 0.92; (95% CI = 0.56; 1.52), HR for all cause death= 0.89 (95% CI = 0.68; 1.18). This could probably be attributed to a better INR control (median 68.93%). Patients with severe renal impairment were poorly represented in ARISTOTLE  (n=270,  apixaban  group  =  137).  Generally  lower  events  rates  were  reported  in  the apixaban group compared to the warfarin group; with more favourable results in patients administered the  lower  dose  (n=89)  (1.43%/yr  vs  7.23%/yr,  HR=0.19,  95%  CI:  0.04-0.91),  than  patients administered the full dose (n=48) (HR and upper bound of the associated 95% CI were ≥1; 95% CI was wide (0.43-34.72). Further analysis of the data showed that patients with exclusive severe renal impairment  have  a  more  favourable  benefit  risk  profile  when  administered  the  reduced  dose  (see: Clinical Safety section of the CHMP AR).

During the period from the end of Intended Treatment Period up to 30 days after the last dose of study medication, a total of 27 stroke/SE events in the apixaban group versus only 10 events occurred in the warfarin  group.  A  similar  observation  was  seen  in  the  ROCKET-AF  (31  cases  of  stroke/SE  in  the rivaroxaban group compared to 12 cases warfarin group between day 2 and day 7 after discontinuation of randomized treatment). According to the MAH, this excess number of events in the apixaban group is  unlikely  to  represent  a  lack  of  efficacy  nor  is  it  a  'rebound'  phenomenon  as  most  of  the  events occurred more than 2 weeks after discontinuation of study drug. The MAH believed that the 'rebound' phenomenon  is  more  observed  in  inhibitors  of  thrombin.  Direct  FXa  inhibitor,  such  as  apixaban  or rivaroxaban or an indirect FXa inhibitor, such as fondaparinux, are not expected to impact thrombin or activated protein C levels. Cessation of rivaroxaban following orthopedic surgery was not followed by rebound 5 .  It  can  be  agreed  that  since  subjects  were  still  on  apixaban  treatment  in  only  four  cases versus three cases still on warfarin therapy, a direct relation with apixaban was not shown. Of note, the PP sensitivity analysis still showed superiority of apixaban over warfarin in an analysis inclusive of events  till  30  days  from  last  study  drug  intake.  Further  analyses  shows  that  the  highest  risk  of stroke/SE is seen in patients not used to VKA (either VKA naïve, or on apixaban) switching to VKA. Most of the events in these switchers occurred 2 weeks after the switch. These findings support that this higher incidence events is probably due to the difficulties associated with establishing an adequate INR in VKA naïve patients. The late onset of events precludes a rebound hypercoagulability problem. These conclusions can also explain the slight imbalance of mortality (apixaban=53; VKA=48) following discontinuation of these anticoagulants.

To  minimise  the  risk  of  stroke/SE  when  switching  from  apixaban  to  VKA,  the  MAH  proposed  some SmPC changes in section 4.2. These recommendations were generally acceptable by the CHMP.

## Study CV185048 (AVERROES)

To  support  the  indication  of  administration  of  apixaban  in  patients  unsuitable  for  VKA,  the  MAH submitted the AVERROES study.

«prodname»

CHMP assessment report Rev04.12

Page 35/84

5 Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786.

<div style=\"page-break-after: always\"></div>

## Methods

Recruitment to AVERROES study was limited to subjects with AF and at least one additional risk factor for stroke, who were not receiving VKA therapy at study entry and included both those subjects who had previously used but discontinued VKA (Demonstrated VKA Unsuitable) and those subjects who had not previously used VKA but were considered unsuitable candidates by the investigator (Expected VKA Unsuitable). This study was initiated after ARISTOTLE, but was terminated earlier due to the shown efficacy (an interim analysis showed clinically relevant efficacy of apixaban over ASA). Subjects who discontinued VKA therapy (demonstrated unsuitable) were patients in whom laboratory monitoring was unsuccessful (e.g., unable to obtain or maintain INR measurements at requested intervals, unable or refused to adhere to dose or INR monitoring instructions); patients who experienced adverse events; and patients who refused further treatment with VKA. Expected VKA unsuitable group included patients who were considered unlikely to comply with dosing or monitoring requirements; patients considered unlikely to adhere to restrictions on alcohol, diet or non-prescription medications, or were unwilling to take  VKA  and  patients  in  whom  the  risk  of  VKA  therapy  was  considered  to  outweigh  the  potential benefits for preventing stroke or SE.

The  chosen  criteria  to  indicate  patient's  unsuitability  to  VKA  is  quite  subjective.  It  depends  on  the perception  of  both  the  investigator  and  the  patient,  and  also  based  on  medical  as  well  as  social preferences. It can be agreed that in real life such decisions are also not entirely objective. However, in a  clinical  study  and  in  order  to  allow  proper  extrapolation  of  the  results,  more  objective  measures should have been chosen for recruitment, in particular previous discontinuation of VKA due to bleeding. As shown below, this subgroup is very limitedly represented.

## Study Participants

The main inclusion criteria were subjects ≥50 years of age, with documented permanent, paroxysmal or persistent AF, presenting with at least one risk factor for stroke, and not currently receiving VKA therapy. Main study exclusion criteria included: AF due to reversible causes, valvular disease requiring surgery and planned AF ablation procedure to be performed within 3 months. The study population adequately reflected the target population for the intended indication.

## Treatments

Subjects were randomised in a 1:1 ratio to either apixaban or ASA. Apixaban posology followed the same algorithm used in ARISTOTLE Study. The ASA dose (81, 162, 243, or 324 mg QD) was at the discretion  of  the  investigator.  The  ASA  dose  initially  assigned  to  the  subject  was  to  be  maintained throughout  the  study  unless  a  change  in  dose  within  the  range  was  clinically  indicated.  Additional open-label ASA was permitted for subjects who had a clear clinical indication for anti-platelet therapy, but was not to exceed 100 mg QD.

The study consisted of a Screening period of 0 to 28 days; followed by the Double-blind Treatment Period  lasting  until  the  earlier  of  a  subject's  discontinuation  of  double-blind  study  drug  or  the attainment of approximately 226 primary efficacy events. The 30-day Follow-up Period started after the  last  dose  of  double-blind  study  drug  for  subjects  who  did  not  enter  the  Optional  Open-label Treatment  Period  (LTOLE).  Subjects  who  discontinued  study  treatment  were  followed  for  outcome events until the double-blind phase of the study end date.

The  choice  of  ASA  as  the  active  comparator  deserves  some  discussion  as  it  impacts  on  the interpretation of the results. According to the ESC clinical practice guideline for the management of AF (2010) , the combination of ASA and clopidogrel could be used in patients intolerant to VKA, for reasons

<div style=\"page-break-after: always\"></div>

other than an increased risk of bleeding. This could apply in particular to patients with a relatively high risk of thrombosis. However, this combination was not approved at the time AVERROES was started. The efficacy of ASA in the updated focused ESC guideline (2012) is considered weak, with a potential for harm, since the risk of major bleeding (and ICH) with aspirin is not significantly different to that of OAC, especially in the elderly. However, based on the available guidance at the time of conducting the trials, ASA appeared to be the only available choice for patients intolerant to VKA due to an increased risk of bleeding. The suitability of using ASA as the active comparator could only be determined by the actual representation of each of the different sub-groups, in particular patients who discontinued VKA due to bleeding. This subgroup is also important as it is expected to be the main group to support the claim that patients who had a higher bleeding risk with VKA are being better managed with apixaban. Most of the patients in the ASA group were administered doses of 81 or 162 mg, which is a bit higher than currently advised by the ESC clinical practice guideline (75-100 mg), but no strict recommendations are given.

## Objectives

Primary  objective  was  to  determine  if  apixaban  is  superior  to  ASA  for  preventing  the  composite outcome of stroke or SE in subjects with AF and at least one additional risk factor for stroke who have failed  or  are  unsuitable  for  VKA  therapy.  Secondary  objectives  were  to  determine,  in  the  same subjects, if apixaban is superior to ASA for prevention of the composite outcome of stroke, SE, MI, or vascular death (major vascular events).

## Outcomes/endpoints

The primary efficacy endpoint was the time from randomisation to first occurrence of un-refuted stroke (any type including ischemic, hemorrhagic or of uncertain type) or SE during the Intended Treatment Period.

## Statistical methods and sample size

The testing strategy was as follows:

- Superiority of apixaban relative to ASA for stroke/SE (primary efficacy endpoint) was tested first.
- If superiority for stroke/SE was demonstrated, then superiority was tested for major vascular events (stroke/SE/MI/vascular death) at the one-sided α= 0.00003. (The small significance level resulted from meeting the early stopping criterion for the primary endpoint).
- If superiority for major vascular events was demonstrated, then superiority was tested for all-cause death at the one-sided α= 0.00003.

Sample size : Assuming an average 1.6 years follow-up and a stroke rate of 3.3 per hundred subject years in ASA-treated subjects, the study would have at least 90% power to detect a 35% relative risk reduction (RRR) of apixaban versus ASA at the one-sided α = 0.025 if there were 226 subjects with un-refuted strokes or systemic emboli. It was calculated that 5600 subjects need to be randomised and  allocated  in  a  1:1  ratio  to  the  apixaban  or  ASA  group  to  achieve  the  desired  power.  These calculations  assumed  an  incidence  of  1%  loss  to  follow  up.  Event  rates  and  between  group assumptions for this study were based on intent-to-treat analyses of previous outcome studies.

The study included 2 planned interim analyses for efficacy:

1.  The  first  analysis  was  targeted  to  occur  when  approximately  50%  of  the  total  226  subjects  with primary  events  un-refuted  by  adjudication  had  accrued.  In  this  interim  look,  the  primary  endpoint

<div style=\"page-break-after: always\"></div>

would be monitored using a modified Haybittle- Peto boundary of 4 standard deviations (two-sided pvalue &lt;0.00006). The boundary refers to a treatment difference that is greater than the prescribed number of standard errors and that favours apixaban.

2. The second analysis was targeted to occur when approximately 75% of the total 226 subjects with primary  events  un-refuted  by  adjudication  had  accrued.  In  this  interim  look,  the  primary  endpoint would  be  monitored  using  a  modified  Haybittle-  Peto  of  3  standard  deviations  (two-sided  p-value &lt;0.0026).

## Results

## Participant flow

A total of 6,421 subjects were enrolled in study CV185048; of these subjects, 5,598 were randomised to  receive  study  treatment.  Discontinuation  rates  were  558  (19.9%)  subjects  in  the  apixaban treatment group, versus 649 (23.3%) patients in the ASA treatment group. Importantly, discontinuations due to bleeding are more frequently reported in the apixaban group (n=35, 1.2%) compared to ASA (n=20, 0.7%).

## Recruitment

The trial was conducted across 36 countries and 526 sites (Table E15). The countries with the greater proportion  of  randomized  subjects  (≥5%  of  the  total)  were  Russia  (12.5%),  USA  (9.5%),  Brazil (7.4%), Mexico (6.2%), and Germany (5.8%).

Table E15 Summary of Enrolment by Region and Country - Randomized Subjects

| Region 1 (%)   |   Apixaban N=2807 | Apixaban N=2807   |   ASA N=2791 | ASA N=2791   |   Total N=5598 | Total N=5598   |
|----------------|-------------------|-------------------|--------------|--------------|----------------|----------------|
| NORTH AMERICA  |               408 | (14.5)            |          396 | (14.2)       |            804 | (14.4)         |
| LATINAMERICA   |               589 | (21.0)            |          596 | (21.4)       |           1185 | (21.2)         |
| EUROPE         |              1263 | (45.0)            |         1244 | (44.6)       |           2507 | (44.8)         |
| ASIA/PACIFIC   |               547 | (19.5)            |          555 | (19.9)       |           1102 | (19.7)         |

Europe included Turkey, Russia, South Africa and Israel.

The treatment groups were balanced at End of Treatment subject disposition with no clinically relevant differences in these data, except for events related to the primary efficacy endpoint (Table E16).

<div style=\"page-break-after: always\"></div>

Table E16 End of Treatment Period Subject Status Summary - Randomised Subjects (CV185048)

|                                           | Apixaban   | Apixaban   | ASA   | ASA     |
|-------------------------------------------|------------|------------|-------|---------|
| NUMBER. OF RANDOMIZED SUBJECTS, n         | 2807       |            | 2791  |         |
| NUMBER. OF SUBJECTS DISCONTINUED, n (%)   | 558        | (19.9)     | 649   | 9(23.3) |
| REASON FOR DISCONTINUATION, n (%)         |            |            |       |         |
| DEATH                                     | 31         | (1.1)      | 56    | (2.0)   |
| ADVERSE EVENT                             | 174        | 6.2)       | 260   | (9.3)   |
| STROKE                                    | 18         | (0.6)      | 73    | (2.6)   |
| SYSTEMIC EMBOLISM                         | 0          |            | 12    | (0.4)   |
| MYOCARDIALINFARCTION                      | 10         | 0.4)       | 6     | (0.2)   |
| BLEEDING                                  | 35         | 1.2)       | 20    | (0.7)   |
| OTHER.                                    | 112        | 4.0)       | 149   | (5.3)   |
| SUBJECTREQUESTTODISCONTINUESTUDYTREATMENT | 156        | 5.6)       | 171   | (6.1)   |
| SUBJECT WITHLREW CONSENT                  | 92         | (3.3)      | 98    | (3.5)   |
| LOSTTOFOLLOW-UP                           | 26         | (0.9)      | 29    | (1.0)   |
| POOR/NON-COMPLIANCE                       | 17         | 0.6)       | 22    | 0.8)    |
| PREGNANCY                                 | 0          |            | 0     |         |
| SUBJECT NO LONGER MEETS STUDY CRITERIA    | 18         | (0.6)      | 18    | ( 0.6)  |
| AIMINISTRATTVE REASON BY SPONSOR          | 1          | (<0.1)     | 0     |         |
| OTHER                                     |            | 131 ( 4.7) | 102   | (3.7)   |

Approximately one-third of the subjects in CV185048 (31.6% in the apixaban group and 33.4% in the ASA group) did not enter the optional Open-label Extension (LTOLE) and completed the planned 30day Follow-up Period. At the time of database lock for the double-blind phase of the study, 40.4% of subjects in the apixaban group and 38.2% in the ASA group had entered the LTOLE (i.e., had received at least one dose of open-label apixaban).

## Baseline data

Treatment groups were well balanced for baseline demographic characteristics and physical measurements  with  no  clinically  relevant  differences  noted  in  these  characteristics  for  randomised subjects (Table E17). The mean age of randomised subjects was 69.9 years; 33.8% of subjects were ≥75 years of age and 35.5% of subjects were ≥65 but &lt;75 years of age. Most subjects were white (78.6%) and male (58.5%). Approximately 84% were &gt;60 kg in weight and approximately 47% had a BMI of &gt;28 kg/m 2 .

Table E17 Baseline Characteristics of Randomised Subject (CV185048)

|                    | Apixaban N=2807   | ASA N=2791   | ASA N=2791   | Total N=5598   | Total N=5598   |
|--------------------|-------------------|--------------|--------------|----------------|----------------|
| AGE (yrs)          |                   |              |              |                |                |
| N                  | 2807              | 2791         |              | 5598           |                |
| MEAN               | 69.7              | 70.0         |              | 69.9           |                |
| AGE CATEGORY(%)    |                   |              |              |                |                |
| <65                | 855 (30.5)        |              | 865 (31.0)   | 1720 (30.7)    |                |
| > 65 BUT<75        | 1049 (37.4)       |              | 938 (33.6)   | 1987 (35.5)    |                |
| >= 75              | 903 (32.2)        | 988          | (35.4)       | 1891 (33.8)    |                |
| NOTREPORTED        | 0                 | 0            |              | 0              |                |
| GENDER (%)         |                   |              |              |                |                |
| MALE               | 1660 (59.1)       |              | 1617 (57.9)  | 3277 (58.5)    |                |
| FEMALE             | 1147 (40.9)       |              | 1174 (42.1)  | 2321 (41.5)    |                |
| NOTREPORTED        | 0                 | 0            |              | 0              |                |
| ETHNICITY (%)      |                   |              |              |                |                |
| HISPANIC/LATINO    | 557 (19.8)        |              | 559 (20.0)   | 1116 (19.9)    |                |
| NOTHISPANIC/LATINO | 2224 (79.2)       |              | 2196 (78.7)  | 4420 (79.0)    |                |
| NOTREPORTED        | 26 ( 0.9)         |              | 36 (1.3)     | 62 (1.1)       |                |

The mean CHADS2 score was 2.0 in each treatment group. Overall, 38.3% of randomised subjects had a CHADS2 score of 1, 35.2% had a score of 2 and 26.5% had a score ≥3. The most common risk factors were hypertension with pharmacological treatment (86.4%).

<div style=\"page-break-after: always\"></div>

## Conduct of the study

Study  CV185048  was  stopped  early  because  a  planned  interim  analysis  by  an  independent  DMC demonstrated  evidence  of  a  clinically  important  reduction  in  stroke  and  SE  in  subjects  in  this  AF population  who  had  received  apixaban  in  comparison  with  ASA;  in  addition  to  reduction  of  major vascular  events  and  all  cause  deaths.  These  impressive  results  should  be  treated  with  caution considering the above concerns about the choice of ASA as a comparator in the first place.

## Numbers analysed

Table E21 Analysis Population Summary

|                        | Apixaban    | ASA         | Total      |
|------------------------|-------------|-------------|------------|
| RANLOMIZED SUBJECTS, n | 2807        | 2791        | 5598       |
| TREATED SUBJELIS,n     | 2798        | 2780        | 5578       |
| EVALUABLE SUBJECTS ()  | 2714 (96.7) | 2695 (96.6) | 5409(96.6) |

## Outcomes and estimation

Due to the premature termination of the study, the original target number of efficacy events was not achieved prior to ending the Double-blind Treatment Period of Study CV185048.

Primary  Efficacy  Endpoint .  Apixaban  was  superior  to  ASA  [HR=0.45;  (95%CI;  0.32;  0.62);  twosided p-value &lt;0.00001] for the prevention of stroke/SE (see table E22). The majority of the primary outcome events were ischemic or unspecified strokes with 43 (1.53%) events in the apixaban group, versus  95  (3.4%)  events  in  the  ASA  group    [HR  =  0.44  (95%  CI  =0.31,  0.63)].  Apixaban  [n=2 (0.07%)] was also associated with lower numbers in SE relative to ASA [n=11 (0.39%)].

Overall,  2237  of  5598  (40%)  randomized  subjects  had  previously  used  VKA  (demonstrated  VKA unsuitable) and 60% were expected VKA unsuitable. Among prior VKA users, 48.4% had difficulty with INR  control  and  23.9%  experienced  bleeding  on  VKA  (4.3%  major  bleeds)  (Table  E22).  The  actual representation  of  patients  who  had  discontinued  VKA  due  to  bleeding  was  very  small  (11.9%);  the most  common  reasons  provided  for  discontinuations  were  physician's  decision  (20.4%),  patient's decision (19.7%), and difficulty to control INR (19.1%).

<div style=\"page-break-after: always\"></div>

Table E22 Summary of Prior VKA Experience - Randomized Subjects Who Previously Used VKA

|                                                     | Apixaban N = 1121   | Apixaban N = 1121   |            | Total N = 2237   | Total N = 2237   |
|-----------------------------------------------------|---------------------|---------------------|------------|------------------|------------------|
| DIFFICULTY WITH INR CONIROL (%)                     |                     |                     |            |                  |                  |
| NO                                                  |                     | 280 (25.0)          | 308 (27.6) |                  | 588 (26.3)       |
| YES                                                 |                     | 539 (48.1)          | 544(48.7)  |                  | 1083 (48.4)      |
| UNKNONN                                             | 289(                | (25.8)              | 257 (23.0) |                  | 546 (24.4)       |
| ESTIMATEDOFINRVALUES OUTSIDERANGE OF2.O-3.0(%)      |                     |                     |            |                  |                  |
| <= 25% OF TIME                                      |                     | 256 (22.8)          | 284 (25.4) |                  | 540 (24.1)       |
| >25%-40%OFTIME                                      | 134                 | (12.0)              | 127 (11.4) | 261              | (11.7)           |
| >40%-50%OFTIME                                      | 102                 | (9.1)               | 94 (.8.4)  | 196              | (8.8)            |
| > 50°OF TIME                                        | 255                 | (22.7)              | 270 (24.2) | 525              | (23.5)           |
| NOT REPORTED                                        | 374                 | (33.4)              | 341 (30.6) | 715              | (32.0)           |
| BLEEDING WHILE ON VKA (%)                           |                     |                     |            |                  |                  |
| NO                                                  |                     | 839 (74.8)          | 845 (75.7) |                  | 1684 (75.3)      |
| YES                                                 |                     | 269 (24.0)          | 265 (23.7) |                  | 534 (23.9)       |
| MAJOR BLEED                                         | 48                  | 8 (4.3)             | 48 (.4.3)  | 96               | (4.3)            |
| MINOR BLEED                                         | 221                 | (19.7)              | 217 (19.4) | 438              | (19.6)           |
| NOT REPORTED                                        |                     | 13 ( 1.2)           | 6 (0.5)    | 19               | ( 0.8)           |
| REASONS FOR DISCONTINUING VKA BEFORE SCREENING (°%) |                     |                     |            |                  |                  |
| BLEEDING                                            |                     | 127 (11.3)          | 139 (12.5) |                  | 266 (11.9)       |
| DIFFICULTTOCONTROLINR                               | 212                 | (18.9)              | 216 (19.4) | 428              | (19.1)           |
| INDICATIONRESOLVEDOR TREATEDADEQUATELY              | 56                  | (5.0)               | 48 ( 4.3)  | 104              | (4.6)            |
| OTHERCOMPLICATIONS                                  | 30                  | (2.7)               | 48 (.4.3)  | 78               | (3.5)            |
| PARTICIPANTDECISION                                 | 231                 | (20.6)              | 209 (18.7) | 440              | (19.7)           |
| PHYSICIAN DECISION                                  | 210                 | (18.7)              | 247 (22.1) | 457              | (20.4)           |
| UNKNONN                                             | 10                  | (0.9)               | 13 ( 1.2)  |                  | 23 (1.0)         |

Based on the investigator's judgement, more than  half of the randomised patients were considered unsuitable  for  VKA  due  to  reasons  related  to  bleeding  (Table  E23).  Still  this  population  is  not considered  to  reflect  VKA  unsuitable  patients  compared  to  patients  who  actually  had  bleeding  or discontinued VKA due to bleeding. Also, the majority of patients who had a history of bleeding on VKA, reported mainly minor bleeds on VKA with only few major bleedings. This specifically questions the ability of AVERROES to address VKA unsuitable patients, and whether apixaban offers to these patients a safer and equally effective alternative to VKA. The question of the comparability of apixaban to VKA in general is addressed in ARISTOTLE.

<div style=\"page-break-after: always\"></div>

Table  E23  Summary  of  Reasons  that  Vitamin  K  Antagonist  (VKA)  Therapy  is  Unsuitable  Randomized Subjects

|                                                                                   |              | ASA N=2791   | ASA N=2791   |                |
|-----------------------------------------------------------------------------------|--------------|--------------|--------------|----------------|
| NOTCURRENTLYRECEIVINGVKATHERAPYATSCREENING                                        | 2807 (100.0) |              | 2791 (100.0) | 5598 (100.0)   |
| VKADEMONSTRATEDTOBEUNSUITABLE                                                     | 1108  (39.5) |              | 1107 (39.7)  | 2215 (39.6)    |
| VKA EXPECTED TOBE UNSUITABLE                                                      | 1699 (60.5)  |              | 1684 (60.3)  | 3383 (60.4)    |
| NOT REFORTED                                                                      | 0            | 0            |              | 0              |
| REASONS VKA IS UNSUITABLE(PRIOR OR NO PRIOR USE)                                  |              |              |              |                |
| UNABLE/UNLIKELY TO OBTAININRSATREQUESTEDINTERVALS                                 | 1196 (42.6)  |              | 1191 (42.7)  | 2387 (42.6)    |
| DIFFICULTY/EXPECTEDDIFFICULTYIN CONTACTINGPARTICIPANTIN CASEOF URGENTDOSECHANGE   | 322 (11.5)   | 331          | (11.9)       | 653 (11.7)     |
| PARTICIPANTCANNOTBERELIEDONTOADHERETOVKAMEDICATION INSTRUCTIONS                   | 437( (15.6)  | 405          | (14.5)       | 842 (15.0)     |
| NEEDFORMEDICATIONSWHICHMAYALTERTHEANTICOAGULANTACTIVITYOF VKA                     | 50  (1.8)    | 53           | (1.9)        | 103 (1.8)      |
|                                                                                   | 35 (1.2)     | 46           | 1.6)         | 81 (1.4) 275   |
| UNABIE/UNLIKELYTOADHERETOVKA-RELATEDRESTRICTIONS                                  | 134 4.8)     | 141          | 5.1)         | 4.9)           |
| HEPATICDISEASE                                                                    | 13 (0.5)     | 9            | 0.3)         | 22 0.4)        |
| MILDCOGNITIVEIMPAIRMENT                                                           | 85 （ 3.0)    | 86           | 3.1)         | 171 (3.1)      |
| HEARTFAILURE/CARDIOMYOPATHY                                                       | 179 6.4)     | 188          | 6.7)         | 367 6.6)       |
| OTHER FACTORS WHICH MAY BE ASSOCIATEDWITHINCREASEDRISK OFVKA USE                  | 96 (3.4)     | 123          | (4.4)        | 219 ( 3.9)     |
|                                                                                   | 590 (21.0)   | 605          | (21.7)       | 1195 (21.3) 95 |
| OTHERCHARACTERISTICSWHICHINDICATETHATSTROKERISKISTOOIOWTO WARRANTTREATMENTWITHVKA | 55 (2.0)     | 40           | (1.4)        | (1.7)          |
| PARTICIPANTREFUSES TREATMENTWITHVKA                                               | 1053 (37.5)  | 1039         | (37.2)       | 2092 (37.4)    |
| OTHER                                                                             | 184 ( 6.6)   | 189          | (6.8)        | 373 ( 6.7)     |
| REASONSVKA IS UNSUITABLE(PRIORUSE)                                                |              |              |              |                |
|                                                                                   | 465 5 (16.6) | 468          | (16.8)       | 933 (16.7)     |
| AESRELATEDTOVKATHERAPY                                                            | 86 (3.1)     | 94           | (3.4)        | 180 (3.2)      |
| SIGNFICIANT BLEEDING WHILE ON COUMADIN                                            | 92 (3.3)     | 82           | (2.9)        | 174 (3.1)      |
| INR < 3.0                                                                         | 41 (1.5)     | 45           | (1.6)        | 86  (1.5)      |
| INR >= 3.0                                                                        | 40 (1.4)     | 34           | (1.2)        | 74 ( 1.3)      |
| VKATHERAPYUNSUITABLESTATUS                                                        |              |              |              |                |
| SUBJECTREFUSEDTREAIMENTWITHVKA(ONLYREASON)                                        | 421 (15.0)   |              | 394 (14.1)   | 815 (14.6)     |
| CHADS-2 SCORE =1 AND PHYSICIAN DOESNOT RECOMMEND VKA(ONLY REASON)                 | 294 (10.5)   | 318          | (11.4)       | 612 (10.9)     |
| ALL OTHER REASONS                                                                 | 2091 (74.5)  |              | 2079 (74.5)  | 4170 (74.5)    |
| NOT REFORTED                                                                      | 1 (<0.1)     | 0            |              | 1 (<0.1)       |

Overall results within each subgroup were consistent with the primary efficacy endpoint. Importantly, results  of  patients  with  demonstrated  VKA  intolerance  (apixaban:  1.73%  vs.  ASA:  4.2%;  HR=0.33; 95% CI: 0.19-0.56) were comparable to those expected to be intolerant (apixaban: 1.79% vs. ASA: 3.25%; HR=0.55; 95% CI: 0.36-0.84) (Figure E4). The subgroup of patients with CHADS2 =1 and physician did not recommend VKA was the only subgroup with conflicting results (HR= 2.18; 95% CI; 0.040- 11.91).

Figure E4 Forest Plot for Stroke or SE during the Intended Treatment Period - Randomised Subjects (Study CV185048)

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Subgroup                  | Apixaban n（x/yr)   | ASA n（x/yr)   | Hazard Ratio （95%C1)   |
|---------------------------|--------------------|---------------|------------------------|
| Ethnicity                 |                    |               |                        |
| Hispanic/latino           | 6 (1.02)           | 30 (5.21)     | 0.20(0.08,0.47)        |
| Not hispanic/latino       | 45 (1.78)          | 82 (3.29)     | 0.54(0.38,0.78)        |
| Weight                    |                    |               |                        |
| Weight <= 60 kg           | 18 (3.88)          | 20 (4.61)     | 0.84(0.44,1.58)        |
| Weight>60 kg              | 33 (1.23)          | 93(3.48)      | 0.36(0.24.0.53)        |
| BMI                       |                    |               |                        |
| BMI <= 28 kg/m2           | 34 (2.20)          | 56 (3.49)     | 0.63(0.41,0.97)        |
| BMl > 28 to 33 kg/m2      | 14.(1.42)          | 40 (4.30)     | 0.33(0.18,0.61)        |
| BMI > 33 kg/m2            | 3 (0.50)           | 17 (2.99)     | 0.17(0.05,0.57)        |
| Level of Renal lmpairment |                    |               |                        |
| Severe/Moderate           | 13 (2.25)          | 32 (5.61)     | 0.40(0.21,0.76)        |
| Mild                      | 22 (1.83)          | 58 (4.95)     | 0.37(0.23,0.61)        |
| Normal                    | 12 (1.09)          | 16 (1.48)     | 0.74(0.35,1.57)        |
| CHADS2 Score              |                    |               |                        |
| <= 1                      | 12 (1.00)          | 19 (1.58)     | 0.63(0.31,1.30)        |
| 2                         | 23 （1.95)          | 43(4.04)      | 0.49(0.29,0.81)        |
| =3                        | 16 (2.09)          | 51 (6.04)     | 0.35(0.20,0.61)        |
| Prior Stroke or TIA       |                    |               |                        |
| No                        | 41 (1.50)          | 80 (2.95)     | 0.51(0.35,0.74)        |
| Yes                       | 10 (2.45)          | 33 (8.29)     | 0.29(0.14,0.60)        |
| Diabetes Mellitus         |                    |               |                        |
| No                        | 37 (1.44)          | 91 (3.66)     | 0.40(0.27,0.58)        |
| Yes                       | 14 (2.40)          | 22 (3.54)     | 0.67(0.34,1.31)        |

## Summary of main studies

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment.

<div style=\"page-break-after: always\"></div>

## Table E24 Summary of Efficacy for trial ARISTOTLE (CV185030)

| Title: A Phase 3, Active (Warfarin)-Controlled, Randomized, Double-blind, Parallel Arm Study to Evaluate Efflcacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism (SE) in   | Title: A Phase 3, Active (Warfarin)-Controlled, Randomized, Double-blind, Parallel Arm Study to Evaluate Efflcacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism (SE) in   | Title: A Phase 3, Active (Warfarin)-Controlled, Randomized, Double-blind, Parallel Arm Study to Evaluate Efflcacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism (SE) in   | Title: A Phase 3, Active (Warfarin)-Controlled, Randomized, Double-blind, Parallel Arm Study to Evaluate Efflcacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism (SE) in                                                                                                                                                                                                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                              | Subjects with Nonvavular Atrial Fibrillation (AF) Study code: CV185030                                                                                                                        | Subjects with Nonvavular Atrial Fibrillation (AF) Study code: CV185030                                                                                                                        | Subjects with Nonvavular Atrial Fibrillation (AF) Study code: CV185030                                                                                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                        | Design: randomized, double-blind, multi-national, double-dummy, parallel- arm study                                                                                                           | Design: randomized, double-blind, multi-national, double-dummy, parallel- arm study                                                                                                           | Design: randomized, double-blind, multi-national, double-dummy, parallel- arm study                                                                                                                                                                                                                                                                                                                                                           |
| Design                                                                                                                                                                                        | Duration of main phase: Follow-up phase:                                                                                                                                                      | Duration of main phase: Follow-up phase:                                                                                                                                                      | Double-blind Treatment Perlod lasting until the earlier of a subject's discontinuation of double-blind study drug or the attainment of the target number of primary efficacy events 30-day Follow-up Period starting after the latter of 30 days after treatment discontinuation or the attainment of 448 primary efficacy events                                                                                                             |
| Hypothesis                                                                                                                                                                                    | Apixaban is non-inferior to warfarin for the primary efficacy endpoint.                                                                                                                       | Apixaban is non-inferior to warfarin for the primary efficacy endpoint.                                                                                                                       | Apixaban is non-inferior to warfarin for the primary efficacy endpoint.                                                                                                                                                                                                                                                                                                                                                                       |
| Treatments groups                                                                                                                                                                             | Apixaban                                                                                                                                                                                      | Apixaban                                                                                                                                                                                      | Apixaban (or matching apixaban-placebo) 5.0 mg BID or 2.5 mg BID for subjects deemed to be at increased risk of bleeding. Subjects randomized to the 2.5 mg BID dose of aplxaban (or matching placebo) continued on this dose throughout the study. Scheduled study vlslts occurred quarterly during the treatment period (Months 3, 6, 9, 15, 18, 21, 27,30,33, 39,42,45,51,54, 57) until completion of the double-blind phase of the study. |
| Treatments groups                                                                                                                                                                             | Warfarin                                                                                                                                                                                      | Warfarin                                                                                                                                                                                      | Warfarin sodium 2 mg titrated to INR 2.0-3.0. INR testing frequency occurred at least every month during the treatment period, more frequently during titration and, if clinically indicated.                                                                                                                                                                                                                                                 |
| Endpoints and definitions                                                                                                                                                                     | Primary endpoint                                                                                                                                                                              | Primary endpoint                                                                                                                                                                              | Time to flrst occurrence of confirmed stroke (ischemic, hemorrhagic, or of unspecified type) or SE, during the Intended Treatment Period                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                     | Secondary endpoint                                                                                                                                                                            | Key Secondary endpoint                                                                                                                                                                        | Time to first occurrence of all-cause death during the Intended Treatment Period                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                                     | Secondary endpoint                                                                                                                                                                            | Other Secondary endpoint                                                                                                                                                                      | Time to first occurrence of the individual efficacy endpoints, including the components of the primary efficacy endpoint (ischemic stroke, stroke of unspecified type, hemorrhagic stroke, SE) and Ml, during the Intended Treatment Period.                                                                                                                                                                                                  |
| Database lock                                                                                                                                                                                 | 10-Jun-2011                                                                                                                                                                                   | 10-Jun-2011                                                                                                                                                                                   | 10-Jun-2011                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Results and Analysis                           | Results and Analysis                                                                                                                                           | Results and Analysis                                                                                                                                           | Results and Analysis                                                                                                                                           | Results and Analysis                                                                                                                                           | Results and Analysis                                                                                                                                           |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                           | PrimaryAnalysis                                                                                                                                                | PrimaryAnalysis                                                                                                                                                | PrimaryAnalysis                                                                                                                                                | PrimaryAnalysis                                                                                                                                                | PrimaryAnalysis                                                                                                                                                |
| Analysis population and time point description | This analysis was performed on the Randomized Population based on adjudicated primary efficacy endpoint events occurring during the Intended Treatment Period. | This analysis was performed on the Randomized Population based on adjudicated primary efficacy endpoint events occurring during the Intended Treatment Period. | This analysis was performed on the Randomized Population based on adjudicated primary efficacy endpoint events occurring during the Intended Treatment Period. | This analysis was performed on the Randomized Population based on adjudicated primary efficacy endpoint events occurring during the Intended Treatment Period. | This analysis was performed on the Randomized Population based on adjudicated primary efficacy endpoint events occurring during the Intended Treatment Period. |
| Descriptive statistics                         | Treatment group                                                                                                                                                | Apixaban                                                                                                                                                       | Warfarin                                                                                                                                                       | Warfarin                                                                                                                                                       |                                                                                                                                                                |
| Descriptive statistics                         | Number of                                                                                                                                                      | 9120                                                                                                                                                           | 9081                                                                                                                                                           | 9081                                                                                                                                                           |                                                                                                                                                                |
| Descriptive statistics                         | subjects Primary endpoint (rate)                                                                                                                               | 1.27                                                                                                                                                           | 1.60                                                                                                                                                           | 1.60                                                                                                                                                           |                                                                                                                                                                |
| Effect estimate per comparison                 | Primary endpoint                                                                                                                                               | Comparison groups                                                                                                                                              | Comparison groups                                                                                                                                              | Apixaban vs. Warfarin                                                                                                                                          | Apixaban vs. Warfarin                                                                                                                                          |
| Effect estimate per comparison                 | Primary endpoint                                                                                                                                               | Hazard Ratio                                                                                                                                                   | Hazard Ratio                                                                                                                                                   | 0.79                                                                                                                                                           | 0.79                                                                                                                                                           |
| Effect estimate per comparison                 | Primary endpoint                                                                                                                                               | 95% CI                                                                                                                                                         | 95% CI                                                                                                                                                         | (0.66, 0.95)                                                                                                                                                   | (0.66, 0.95)                                                                                                                                                   |
| Effect estimate per comparison                 | Primary endpoint                                                                                                                                               | P-value*                                                                                                                                                       | P-value*                                                                                                                                                       | <0.0001                                                                                                                                                        | <0.0001                                                                                                                                                        |
| Effect estimate per comparison                 | Primary endpoint                                                                                                                                               | P-value**                                                                                                                                                      | P-value**                                                                                                                                                      | <0.0001                                                                                                                                                        | <0.0001                                                                                                                                                        |
| Effect estimate per comparison                 |                                                                                                                                                                | P-value***                                                                                                                                                     | P-value***                                                                                                                                                     | 0.0114                                                                                                                                                         | 0.0114                                                                                                                                                         |
| Notes                                          | * denotes 1-sided p-value for NI test (NI margin = 1.38)                                                                                                       | * denotes 1-sided p-value for NI test (NI margin = 1.38)                                                                                                       | * denotes 1-sided p-value for NI test (NI margin = 1.38)                                                                                                       | * denotes 1-sided p-value for NI test (NI margin = 1.38)                                                                                                       | * denotes 1-sided p-value for NI test (NI margin = 1.38)                                                                                                       |
| Notes                                          | ** denotes 1-sided p-value for NI test (NI margin = 1.44)                                                                                                      | ** denotes 1-sided p-value for NI test (NI margin = 1.44)                                                                                                      | ** denotes 1-sided p-value for NI test (NI margin = 1.44)                                                                                                      | ** denotes 1-sided p-value for NI test (NI margin = 1.44)                                                                                                      | ** denotes 1-sided p-value for NI test (NI margin = 1.44)                                                                                                      |
| Notes                                          | *** denotes 2-sided p-value for superiority test                                                                                                               | *** denotes 2-sided p-value for superiority test                                                                                                               | *** denotes 2-sided p-value for superiority test                                                                                                               | *** denotes 2-sided p-value for superiority test                                                                                                               | *** denotes 2-sided p-value for superiority test                                                                                                               |
| Analysisdescription                            | Secondary analysis - All-cause Death                                                                                                                           | Secondary analysis - All-cause Death                                                                                                                           | Secondary analysis - All-cause Death                                                                                                                           | Secondary analysis - All-cause Death                                                                                                                           | Secondary analysis - All-cause Death                                                                                                                           |
| Analysis population and time point description | All analyses of secondary efficacy endpoints were performed on the Randomized Population.                                                                      | All analyses of secondary efficacy endpoints were performed on the Randomized Population.                                                                      | All analyses of secondary efficacy endpoints were performed on the Randomized Population.                                                                      | All analyses of secondary efficacy endpoints were performed on the Randomized Population.                                                                      | All analyses of secondary efficacy endpoints were performed on the Randomized Population.                                                                      |
| Descriptive statistics                         | Treatment group                                                                                                                                                | Apixaban                                                                                                                                                       | Warfarin                                                                                                                                                       | Warfarin                                                                                                                                                       |                                                                                                                                                                |
| Descriptive statistics                         | Number of subjects                                                                                                                                             | 9120                                                                                                                                                           | 9081                                                                                                                                                           | 9081                                                                                                                                                           |                                                                                                                                                                |
| Descriptive statistics                         | All-cause death (rate)                                                                                                                                         | 3.52                                                                                                                                                           | 3.94                                                                                                                                                           | 3.94                                                                                                                                                           |                                                                                                                                                                |
| Effect estimate per comparison                 | All-cause death                                                                                                                                                | Comparison groups                                                                                                                                              | Comparison groups                                                                                                                                              | Apixaban vs. Warfarin                                                                                                                                          | Apixaban vs. Warfarin                                                                                                                                          |
| Effect estimate per comparison                 | All-cause death                                                                                                                                                | Hazard Ratio                                                                                                                                                   | Hazard Ratio                                                                                                                                                   | 0.89                                                                                                                                                           | 0.89                                                                                                                                                           |
| Effect estimate per comparison                 | All-cause death                                                                                                                                                | 95% CI                                                                                                                                                         | 95% CI                                                                                                                                                         | (0.80, 1.0)                                                                                                                                                    | (0.80, 1.0)                                                                                                                                                    |
| Effect estimate per comparison                 | All-cause death                                                                                                                                                | P-value                                                                                                                                                        | P-value                                                                                                                                                        | 0.0465                                                                                                                                                         | 0.0465                                                                                                                                                         |
| Analysisdescription                            | Ischemic or Unspecified Stroke                                                                                                                                 | Ischemic or Unspecified Stroke                                                                                                                                 | Ischemic or Unspecified Stroke                                                                                                                                 | Ischemic or Unspecified Stroke                                                                                                                                 | Ischemic or Unspecified Stroke                                                                                                                                 |
| Descriptive statistics                         | Treatment group                                                                                                                                                | Apixaban                                                                                                                                                       | Apixaban                                                                                                                                                       | Warfarin                                                                                                                                                       | Warfarin                                                                                                                                                       |
| Descriptive statistics                         | Number of subjects                                                                                                                                             | 9120                                                                                                                                                           | 9120                                                                                                                                                           | 9081                                                                                                                                                           | 9081                                                                                                                                                           |
| Descriptive statistics                         | Ischemic or Unspecified Stroke (rate)                                                                                                                          | 0.97                                                                                                                                                           | 0.97                                                                                                                                                           | 1.05                                                                                                                                                           | 1.05                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Effect estimate per comparison   | Ischemic or Unspecified Stroke   | Comparison groups   | Apixaban vs. Warfarin   |
|----------------------------------|----------------------------------|---------------------|-------------------------|
| Effect estimate per comparison   | Ischemic or Unspecified Stroke   | Hazard Ratio        | 0.92                    |
| Effect estimate per comparison   | Ischemic or Unspecified Stroke   | 95% CI              | (0.74, 1.13)            |
| Effect estimate per comparison   | Ischemic or Unspecified Stroke   | P-value             | 0.4220                  |
| Analysis description             | Hemorrhagic Stroke               | Hemorrhagic Stroke  | Hemorrhagic Stroke      |
| Descriptive statistics           | Treatment group                  | Apixaban            | Warfarin                |
| Descriptive statistics           | Number of subjects               | 9120                | 9081                    |
| Descriptive statistics           | Hemorrhagic Stroke (rate)        | 0.24                | 0.47                    |
| Effect estimate per comparison   | Hemorrhagic Stroke               | Comparison groups   | Apixaban vs. Warfarin   |
| Effect estimate per comparison   | Hemorrhagic Stroke               | Hazard Ratio        | 0.51                    |
| Effect estimate per comparison   | Hemorrhagic Stroke               | 95% CI              | (0.35, 0.75)            |
| Effect estimate per comparison   | Hemorrhagic Stroke               | P-value             | 0.0006                  |
| Analysisdescription              | Systemic Embolism                | Systemic Embolism   | Systemic Embolism       |
| Descriptive statistics           | Treatment group                  | Apixaban            | Warfarin                |
| Descriptive statistics           | Number of subjects               | 9120                | 9081                    |
| Descriptive statistics           | Systemic Embolism (rate)         | 0.09                | 0.10                    |
| Effect estimate per comparison   | Systemic Embolism                | Comparison groups   | Apixaban vs. Warfarin   |
| Effect estimate per comparison   | Systemic Embolism                | Hazard Ratio        | 0.87                    |
| Effect estimate per comparison   | Systemic Embolism                | 95% CI              | (0.44, 1.75)            |
| Effect estimate per comparison   | Systemic Embolism                | P-value             | 0.7020                  |
| Analysis description             | MI                               | MI                  | MI                      |
| Descriptive statistics           | Treatment group                  | Apixaban            | Warfarin                |
| Descriptive statistics           | Number of subjects               | 9120                | 9081                    |
| Descriptive statistics           | MI (rate)                        | 0.53                | 0.61                    |
| Effect estimate per comparison   | MI                               | Comparison groups   | Apixaban vs. Warfarin   |
| Effect estimate per comparison   | MI                               | Hazard Ratio        | 0.88                    |
| Effect estimate per comparison   | MI                               | 95% CI              | (0.66, 1.17)            |
| Effect estimate per comparison   | MI                               | P-value             | 0.3720                  |

<div style=\"page-break-after: always\"></div>

## Table E25 Summary of Efficacy for trial AVERROES (CV185048)

<!-- image -->

| Title: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-Blind Trial   | Title: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-Blind Trial   | Title: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-Blind Trial   | Title: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-Blind Trial                                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                            | Study code: CV185048                                                                                                                                                                                        | Study code: CV185048                                                                                                                                                                                        | Study code: CV185048                                                                                                                                                                                                                                                                                                                                                                          |
| Design                                                                                                                                                                                                      | Design: randomized, multi-national, multi-center, double-blind, double- dummy, parallel-group                                                                                                               | Design: randomized, multi-national, multi-center, double-blind, double- dummy, parallel-group                                                                                                               | Design: randomized, multi-national, multi-center, double-blind, double- dummy, parallel-group                                                                                                                                                                                                                                                                                                 |
| Design                                                                                                                                                                                                      | Duration of main phase:                                                                                                                                                                                     | Duration of main phase:                                                                                                                                                                                     | Double-blind Treatment Period lasting until the earlier of a subject's discontinuation of double-blind study drug or the attainment of the target number of primary efficacy events                                                                                                                                                                                                           |
| Design                                                                                                                                                                                                      | Follow-up phase:                                                                                                                                                                                            | Follow-up phase:                                                                                                                                                                                            | 30-day Follow-up Period starting after the last dose of double-blind study drug for subjects who did not enter the Long-term open-label extension (LTOLE)                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                      | Duration of Extension phase:                                                                                                                                                                                | Duration of Extension phase:                                                                                                                                                                                | Optional LToLE (all eligible subjects receive open-label apixaban) intended to start if the study continued to its protocol-described, event-driven conclusion or if the study was stopped early due to the superior efficacy of apixaban.                                                                                                                                                    |
| Hypothesis                                                                                                                                                                                                  | Apixaban is superior to ASA for the primary efficacy endpoint                                                                                                                                               | Apixaban is superior to ASA for the primary efficacy endpoint                                                                                                                                               | Apixaban is superior to ASA for the primary efficacy endpoint                                                                                                                                                                                                                                                                                                                                 |
| Treatments groups                                                                                                                                                                                           | Apixaban                                                                                                                                                                                                    | Apixaban                                                                                                                                                                                                    | Apixaban (or matching apixaban-placebo) 5.0 mg BID or 2.5 mg BID for subjects deemed to be at increased risk of bleeding. Subjects randomlzed to the 2.5 mg BID dose of apixaban (or matching placebo) continued on thls dose throughout the study. Scheduled study visits occurred at Month 1, Month 3 and each 3 months thereafter until completion of the double-blind phase of the study. |
| Treatments groups                                                                                                                                                                                           | ASA                                                                                                                                                                                                         | ASA                                                                                                                                                                                                         | ASA (or matching ASA-placebo) was dosed QD (81, 162, 243, or 324 mg at the discretion of the investigator).                                                                                                                                                                                                                                                                                   |
| Endpoints and definitions                                                                                                                                                                                   | Primary endpoint                                                                                                                                                                                            | Primary endpoint                                                                                                                                                                                            | Time from randomization to first occurrence of unrefuted stroke (any type including ischemic, hemorrhagic, or of uncertain type) or SE durlng the Intended Treatment Perlod                                                                                                                                                                                                                   |
| Endpoints and definitions                                                                                                                                                                                   | Secondary endpolnt                                                                                                                                                                                          | Key Secondary endpoint                                                                                                                                                                                      | Time from randomization to first occurrence of unrefuted stroke (any type including ischemic, hemorrhagic, or of uncertain type). SE, MI, or vascular death during the Intended Treatment Period (Major vascular events)                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                   | Other endpoints                                                                                                                                                                                             | Other Efficacy Endpoints                                                                                                                                                                                    | Tlme to flrst occurrence of the Individual efficacy endpoints, including the components of the prlmary efflcacy endpoint (ischemlc stroke, stroke of unspecified type, hemorrhagic stroke, SE) and MI, during the Intended Treatment Period.                                                                                                                                                  |
| Database lock                                                                                                                                                                                               | 08-Dec-2010                                                                                                                                                                                                 | 08-Dec-2010                                                                                                                                                                                                 | 08-Dec-2010                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| ResultsandAnalysis                             | ResultsandAnalysis                                                                                                                                                             | ResultsandAnalysis                                                                                                                                                             | ResultsandAnalysis                                                                                                                                                             | ResultsandAnalysis                                                                                                                                                             | ResultsandAnalysis                                                                                                                                                             |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                           | Primary Analysis                                                                                                                                                               | Primary Analysis                                                                                                                                                               | Primary Analysis                                                                                                                                                               | Primary Analysis                                                                                                                                                               | Primary Analysis                                                                                                                                                               |
| Analysis population and time point description | Primary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period.           | Primary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period.           | Primary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period.           | Primary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period.           | Primary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period.           |
| Descriptive statistics                         | Treatment group                                                                                                                                                                | Apixaban                                                                                                                                                                       | ASA                                                                                                                                                                            | ASA                                                                                                                                                                            |                                                                                                                                                                                |
| Descriptive statistics                         | Number of subjects                                                                                                                                                             | 2807                                                                                                                                                                           | 2791                                                                                                                                                                           | 2791                                                                                                                                                                           |                                                                                                                                                                                |
| Descriptive statistics                         | Primary endpoint (rate)                                                                                                                                                        | 1.62                                                                                                                                                                           | 3.63                                                                                                                                                                           | 3.63                                                                                                                                                                           |                                                                                                                                                                                |
| Effect estimate per comparison                 | Primary endpoint                                                                                                                                                               | Comparison groups                                                                                                                                                              | Comparison groups                                                                                                                                                              | Apixaban vs. ASA                                                                                                                                                               | Apixaban vs. ASA                                                                                                                                                               |
| Effect estimate per comparison                 | Primary endpoint                                                                                                                                                               | Hazard Ratio                                                                                                                                                                   | Hazard Ratio                                                                                                                                                                   | 0.45                                                                                                                                                                           | 0.45                                                                                                                                                                           |
| Effect estimate per comparison                 | Primary endpoint                                                                                                                                                               | 95% CI                                                                                                                                                                         | 95% CI                                                                                                                                                                         | (0.32, 0.62)                                                                                                                                                                   | (0.32, 0.62)                                                                                                                                                                   |
| Effect estimate per comparison                 | Primary endpoint                                                                                                                                                               | P-value*                                                                                                                                                                       | P-value*                                                                                                                                                                       | <0.00001                                                                                                                                                                       | <0.00001                                                                                                                                                                       |
| Notes                                          | * denotes two-sided p-value for superiority                                                                                                                                    | * denotes two-sided p-value for superiority                                                                                                                                    | * denotes two-sided p-value for superiority                                                                                                                                    | * denotes two-sided p-value for superiority                                                                                                                                    | * denotes two-sided p-value for superiority                                                                                                                                    |
| Analysis description                           | Major Vascular Events                                                                                                                                                          | Major Vascular Events                                                                                                                                                          | Major Vascular Events                                                                                                                                                          | Major Vascular Events                                                                                                                                                          | Major Vascular Events                                                                                                                                                          |
| Analysis population and time point description | The key secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. |
| Descriptive statistics                         | Treatment group                                                                                                                                                                | Apixaban                                                                                                                                                                       | ASA                                                                                                                                                                            |                                                                                                                                                                                |                                                                                                                                                                                |
| Descriptive statistics                         | Number of subjects                                                                                                                                                             | 2807                                                                                                                                                                           | 2791                                                                                                                                                                           |                                                                                                                                                                                |                                                                                                                                                                                |
| Descriptive statistics                         | Major VTE (rate)                                                                                                                                                               | 4.21                                                                                                                                                                           | 6.35                                                                                                                                                                           |                                                                                                                                                                                |                                                                                                                                                                                |
| Effect estimate per comparison                 | Major Vascular Events                                                                                                                                                          | Comparison groups                                                                                                                                                              | Comparison groups                                                                                                                                                              | Apixaban vs. ASA                                                                                                                                                               | Apixaban vs. ASA                                                                                                                                                               |
| Effect estimate per comparison                 | Major Vascular Events                                                                                                                                                          | Hazard Ratio                                                                                                                                                                   | Hazard Ratio                                                                                                                                                                   | 0.66                                                                                                                                                                           | 0.66                                                                                                                                                                           |
| Effect estimate per comparison                 | Major Vascular Events                                                                                                                                                          | 95% CI                                                                                                                                                                         | 95% CI                                                                                                                                                                         | (0.53, 0.83)                                                                                                                                                                   | (0.53, 0.83)                                                                                                                                                                   |
| Effect estimate per comparison                 | Major Vascular Events                                                                                                                                                          | P-value                                                                                                                                                                        | P-value                                                                                                                                                                        | 0.00026                                                                                                                                                                        | 0.00026                                                                                                                                                                        |
| Analysisdescription                            | All-causeDeath                                                                                                                                                                 | All-causeDeath                                                                                                                                                                 | All-causeDeath                                                                                                                                                                 | All-causeDeath                                                                                                                                                                 | All-causeDeath                                                                                                                                                                 |
| Analysispopulation and time point description  | The key secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. |
| Descriptive statistics                         | Treatment group                                                                                                                                                                | Apixaban                                                                                                                                                                       | ASA                                                                                                                                                                            |                                                                                                                                                                                |                                                                                                                                                                                |
| Descriptive statistics                         | Number of subjects                                                                                                                                                             | 2807                                                                                                                                                                           | 2791                                                                                                                                                                           |                                                                                                                                                                                |                                                                                                                                                                                |
| Descriptive statistics                         | All-cause death (rate)                                                                                                                                                         | 3.51                                                                                                                                                                           | 4.42                                                                                                                                                                           |                                                                                                                                                                                |                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Effect estimate per comparison                 | All-cause death                                                                                                                                                                  | Comparison groups                                                                                                                                                                | Apixaban vs. ASA                                                                                                                                                                 |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effect estimate per comparison                 | All-cause death                                                                                                                                                                  | Hazard Ratio                                                                                                                                                                     | 0.79                                                                                                                                                                             |
| Effect estimate per comparison                 | All-cause death                                                                                                                                                                  | 95% CI                                                                                                                                                                           | (0.62, 1.02)                                                                                                                                                                     |
| Effect estimate per comparison                 | All-cause death                                                                                                                                                                  | P-value                                                                                                                                                                          | 0.06782                                                                                                                                                                          |
| Analysis description                           | IschemicorUnspecifiedStroke                                                                                                                                                      | IschemicorUnspecifiedStroke                                                                                                                                                      | IschemicorUnspecifiedStroke                                                                                                                                                      |
| Analysis population and time point description | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. |
| Descriptive statistics                         | Treatment group                                                                                                                                                                  | Apixaban                                                                                                                                                                         | ASA                                                                                                                                                                              |
| Descriptive statistics                         | Number of subjects                                                                                                                                                               | 2807                                                                                                                                                                             | 2791                                                                                                                                                                             |
| Descriptive statistics                         | Ischemic or Unspecified Stroke (rate)                                                                                                                                            | 1.37                                                                                                                                                                             | 3.11                                                                                                                                                                             |
| Effect estimate per comparison                 | Ischemic or Unspecified Stroke                                                                                                                                                   | Comparison groups                                                                                                                                                                | Apixaban vs. ASA                                                                                                                                                                 |
| Effect estimate per comparison                 | Ischemic or Unspecified Stroke                                                                                                                                                   | Hazard Ratio                                                                                                                                                                     | 0.44                                                                                                                                                                             |
| Effect estimate per comparison                 | Ischemic or Unspecified Stroke                                                                                                                                                   | 95% CI                                                                                                                                                                           | (0.31, 0.63)                                                                                                                                                                     |
| Effect estimate per comparison                 | Ischemic or Unspecified Stroke                                                                                                                                                   | P-value                                                                                                                                                                          | <0.00001                                                                                                                                                                         |
| Analysisdescription                            | HemorrhagicStroke                                                                                                                                                                | HemorrhagicStroke                                                                                                                                                                | HemorrhagicStroke                                                                                                                                                                |
| Analysis population and time point description | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. |
| Descriptive statistics                         | Treatment group                                                                                                                                                                  | Apixaban                                                                                                                                                                         | ASA                                                                                                                                                                              |
| Descriptive statistics                         | Number of subjects                                                                                                                                                               | 2807                                                                                                                                                                             | 2791                                                                                                                                                                             |
| Descriptive statistics                         | Ischemic or Hemorrhagic Stroke (rate)                                                                                                                                            | 0.19                                                                                                                                                                             | 0.28                                                                                                                                                                             |
| Effect estimate per comparison                 | Ischemic or Hemorrhagic Stroke                                                                                                                                                   | Comparison groups                                                                                                                                                                | Apixaban vs. ASA                                                                                                                                                                 |
| Effect estimate per comparison                 | Ischemic or Hemorrhagic Stroke                                                                                                                                                   | Hazard Ratio                                                                                                                                                                     | 0.67                                                                                                                                                                             |
| Effect estimate per comparison                 | Ischemic or Hemorrhagic Stroke                                                                                                                                                   | 95% CI                                                                                                                                                                           | (0.24, 1.88)                                                                                                                                                                     |
| Effect estimate per comparison                 | Ischemic or Hemorrhagic Stroke                                                                                                                                                   | P-value                                                                                                                                                                          | 0.44707                                                                                                                                                                          |
| Analysis description                           | Systemic Embolism                                                                                                                                                                | Systemic Embolism                                                                                                                                                                | Systemic Embolism                                                                                                                                                                |
| Analysis population and time point description | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. |
| Descriptive statistics                         | Treatment group                                                                                                                                                                  | Apixaban                                                                                                                                                                         | ASA                                                                                                                                                                              |
| Descriptive statistics                         | Number of subjects                                                                                                                                                               | 2807                                                                                                                                                                             | 2791                                                                                                                                                                             |
| Descriptive statistics                         | Systemic Embolism (rate)                                                                                                                                                         | 0.06                                                                                                                                                                             | 0.41                                                                                                                                                                             |
| Effect estimate per comparison                 | Systemic Embolism                                                                                                                                                                | Comparison groups                                                                                                                                                                | Apixaban vs. ASA                                                                                                                                                                 |
| Effect estimate per comparison                 | Systemic Embolism                                                                                                                                                                | Hazard Ratio                                                                                                                                                                     | 0.15                                                                                                                                                                             |
| Effect estimate per comparison                 | Systemic Embolism                                                                                                                                                                | 95% CI                                                                                                                                                                           | (0.03, 0.68)                                                                                                                                                                     |
| Effect estimate per comparison                 | Systemic Embolism                                                                                                                                                                | P-value                                                                                                                                                                          | 0.01390                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Analysis description                          | MI                                                                                                                                                                               | MI                                                                                                                                                                               | MI                                                                                                                                                                               |
|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysispopulation and time point description | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. | The other secondary efficacy population consisted of all randomized subjects based on unrefuted primary efficacy endpoint events occurring during the Intended Treatment Period. |
| Descriptive statistics                        | Treatment group                                                                                                                                                                  | Apixaban                                                                                                                                                                         | ASA                                                                                                                                                                              |
|                                               | Number of subjects                                                                                                                                                               | 2807                                                                                                                                                                             | 2791                                                                                                                                                                             |
|                                               | MI (rate)                                                                                                                                                                        | 0.76                                                                                                                                                                             | 0.89                                                                                                                                                                             |
| Effect estimate per comparison                | MI                                                                                                                                                                               | Comparison groups                                                                                                                                                                | Apixaban vs. ASA                                                                                                                                                                 |
| Effect estimate per comparison                | MI                                                                                                                                                                               | Hazard Ratio                                                                                                                                                                     | 0.86                                                                                                                                                                             |
| Effect estimate per comparison                | MI                                                                                                                                                                               | 95% CI                                                                                                                                                                           | (0.50, 1.48)                                                                                                                                                                     |
| Effect estimate per comparison                | MI                                                                                                                                                                               | P-value                                                                                                                                                                          | 0.58618                                                                                                                                                                          |

## Supportive study

Study CV185067 was presented in clinical safety section.

## 2.5.3. Discussion on clinical efficacy

In  the  ARISTOTLE study a total of 18,201 patients were randomized to double-blind treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [4.7%]) or warfarin (target INR range 2.0-3.0), patients were exposed to study drug for a mean of 20 months.  The mean age was 69.1 years, the mean CHADS2 score was 2.1 and 18.9 % of patients had prior stroke or TIA. In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke  (haemorrhagic  or  ischaemic)  and  systemic  embolism  compared  with  warfarin.  For  patients randomized to warfarin, the median percentage of time in therapeutic range (TTR) (INR 2-3) was 66%. Apixaban  showed  a  reduction  of  stroke  and  systemic  embolism  compared  to  warfarin  across  the different levels of center TTR; within the highest quartile of TTR according to center, the hazard ratio for apixaban vs warfarin was 0.73 (95% CI, 0.38, 1.40). Key secondary endpoints of major bleeding and all cause death were tested in a pre-specified hierarchical testing strategy to control the overall type  1  error  in  the  trial.  Statistically  significant  superiority  was  also  achieved  in  the  key  secondary endpoints of both major bleeding and all-cause death. With improving monitoring of INR the observed benefits of apixaban compared to warfarin regarding all cause death diminished. The efficacy results for prespecified subgroups, including CHADS2 score, age, body weight, gender, status of renal function, prior  stroke  or  TIA  and  diabetes  were  consistent  with  the  primary  efficacy  results  for  the  overall population studied in the trial.

In  the  AVERROES  study  a  total  of  5,598  patients  considered  to  be  unsuitable  for  VKA  by  the investigators were randomized to treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [6.4%]) or ASA. ASA was given at a once daily dose of 81 mg (64%), 162 (26.9%), 243 (2.1%), or 324 mg (6.6%) at the discretion of the investigator. Patients were exposed to study drug for a mean of 14 months. The mean age was 69.9 years, the mean CHADS2 score was 2.0 and 13.6% of patients had prior stroke or TIA. Common reasons for unsuitability for VKA therapy in the AVERROES  study  included  unable/unlikely  to  obtain  INRs  at  requested  intervals  (42.6%),  patient refused  treatment  with  VKA  (37.4%),  CHADS2  score = 1  and  physician  did  not  recommend  VKA (21.3%),  patient  could  not  be  relied  on  to  adhere  to  VKA  medication  instruction  (15.0%),  and difficulty/expected difficulty in contacting patient in case of urgent dose change (11.7%). AVERROES was stopped early based on a recommendation by the independent Data Monitoring Committee due to

<div style=\"page-break-after: always\"></div>

clear evidence of reduction of stroke and systemic embolism with an acceptable safety profile. In this study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic, ischaemic or unspecified) or systemic embolism compared to ASA.

Both  phase  3  studies  CV185030  and  CV185048  show  that  apixaban  5  mg  (2.5  mg  for  restricted patients)  is  associated  with  significantly  lower  incidence  of  stroke  and  SE  than  VKA  or  ASA, respectively.  Also  the  secondary  endpoint  of  all  cause  death  is  significantly  less  frequent  in  the apixaban arm compared to VKA arm. Benefits were weaker in subgroups with better INR control, but this was still an acceptable result considering that apixaban offers other advantages over VKA, like a more favourable interaction  profile  and  no  need  for  routine  monitoring.  The  use  of  apixaban  as  an alternative to patients unsuitable to VKA was not supported by the CHMP, as the criteria defining this unsuitability  were  too  subjective.  Actual  representation  of  patients  who  discontinued  VKA  due  to bleeding was very limited. Superiority of apixaban over ASA was acknowledged with the caveat that ASA may not have been the most suitable active comparator for the whole cohort as clopidogrel is sometimes  added  according  to  the ESC  Clinical  practice  guideline  for  the  management  of  atrial fibrillation 2010 . The main study results were included in section 5.1 of the SmPC.

## 2.5.4. Conclusions on the clinical efficacy

In conclusion, apixaban has shown to be a beneficial anti-thrombotic for the prevention of stroke/SE in AF patients, with no extra burden in the bleeding risk compared to VKA.

## 2.6. Clinical safety

This  section  presents  safety  information  from  the  two  completed  Phase  3  studies  (CV185030  and CV185048).  Relevant  data  will  be  presented  pooled  or  separately  for  each  of  the  studies.  Safety information  is  also  presented  for  218  treated  subjects  with  AF  from  a  completed  Phase  2  study (CV185067) conducted in Japan. Reference will also be made in certain sections to the available safety data from apixaban investigated in other indications.

## Patient exposure

The total number of subjects who received at least 1 dose of any double-blind study drug in the Phase 2/3 AF studies was 23,936, of which 23,718 were in the phase 3 studies. Of these, 11,886 subjects received  apixaban  5  mg  BID  (or  2.5  mg  BID  for  subjects  meeting  criteria  for  dose  reduction  at randomization in the Phase 3 studies), 9052 subjects received warfarin, and 2780 subjects received ASA (Figure S1).

<div style=\"page-break-after: always\"></div>

Figure S1 Completed Apixaban Studies in the Phase 2/3 Clinical Program - Treated Subjects

<!-- image -->

## Adverse events

The overall AE profile of apixaban in the Phase 3 studies was similar to that of warfarin in CV185030, and was similar to that of ASA in CV185048 (Table S1).

Table S1 Summary of Safety During the Treatment Period - Treated Subjects, Study CV185030 and Study CV185048

| CV185030                       | Apixaban N = 9088   | Apixaban N = 9088   | Warfarin N = 9052   | Warfarin N = 9052   |
|--------------------------------|---------------------|---------------------|---------------------|---------------------|
| AE (%)                         |                     | 7406(81.5)          | 7521                | (83.1)              |
| SAE (%)                        | 3182                | 35.0)               | 3302                | 36.5)               |
| BLEEDING AE (%)                | 2288                | 25.2)               | 2961                | 32.7)               |
| DISCONTINUATIONS DUE TO AE (%) | 688                 | 7.6)                | 758                 | 8.4)                |
| DEATHS (%)                     | 429                 | 4.7)                | 468                 | 5.2)                |
| CV185048                       | Apixaban N = 2798   | Apixaban N = 2798   | ASA N = 2780        | ASA N = 2780        |
| AE (%)                         | 1833                | (65.5)              | 1925                | (69.2)              |
| SAE (%)                        | 657                 | (23.5)              |                     | 804 (28.9)          |
| BLEEDING AE (%)                | 281                 | (10.0)              | 259                 | (9.3)               |
| DISCONTINUATIONS DUE TO AE (%) | 266                 | (9.5)               | 362                 | (13.0)              |
| DEATHS (%)                     |                     | 91 ( 3.3)           |                     | 115 ( 4.1)          |

In  Study  CV185030  the  frequency  of  AEs  was  similar  in  the  apixaban  and  warfarin  groups  for warfarin/VKA-naive and warfarin/VKA-experienced subjects. Drug-related AEs were reported for 27.8% of subjects in the apixaban group and 34.2% in the warfarin group. The most common drug-related AEs were related to bleeding. For the reported events, the frequency of bleeding with apixaban was generally  less  than  that  reported  with  VKA:  epistaxis  (apixaban  5.0%;  warfarin  6.1%),  haematuria (apixaban  2.6%;  warfarin  3.2%),  contusion  (apixaban  1.7%;  warfarin  3.2%),  hematoma  (apixaban 1.4%; warfarin 3.5%), gingival bleeding (apixaban 1.0%; warfarin 2.1%), and ecchymosis (apixaban 0.9%;  warfarin  2.0%).  In  CV185048,  the  frequency  of  drug-related  AEs  was  similar  in  the  two treatment groups (apixaban 16.6%, ASA 16.7%). No drug-related AEs (preferred terms) were reported in ≥ 2% of subjects in either group. During the Follow-up Period, there were no clinically meaningful differences  between  the  apixaban  and  comparator  groups  for  the  frequency  for  AEs  in  either  study (3.3% in the apixaban group and 3.4% in the warfarin group in CV185030; apixaban 7.2%, ASA 7.8% in CV185048).

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

In  study  CV185030,  the  incidence  of  death  was  shown  to  be  lower  in  the  apixaban  group  (4.7%) compared to VKA (5.2%) during the treatment period. Also, in study CV185048, serious AEs SAEs with outcome  of  death  were  reported  slightly  more  frequently  in  the  ASA  group  (4.1%)  compared  to apixaban (3.3%).

For SAEs, overall frequency was similar in  the  apixaban group compared with the warfarin group in CV185030. In CV185048, the overall frequency of SAEs with onset during the treatment period was 23.5% in the apixaban group vs. 28.9% in the ASA group (table S1). The most common SAEs were Cardiac Disorders in both studies. No new safety signals were detected in these studies.

## Adverse events of Special Interest

1.  Bleeding .  Adjudicated major  bleeding (adapted  from  ISTH  guidelines)  was  the  primary  safety endpoint in both Phase 3 studies. According to the pre-specified sequential testing strategy in study CV185030, the superiority  of  apixaban  compared  to  warfarin  demonstrated  for  the  primary  efficacy endpoint signalled the sequential testing of ISTH major bleeding. Apixaban was superior to warfarin for ISTH major bleeding, major or CRNM bleeding (clinically relevant non-major) and all bleeding (table S2 and figure S2).

Table  S2  Summary  of  Adjudicated  Bleeding  Endpoint  (ISTH  and  All  Bleeding)  during treatment period - treated subjects (CV185030)

|                                                                                                        | Apixaban N= 9088                             | Warfarin N = 9052   |
|--------------------------------------------------------------------------------------------------------|----------------------------------------------|---------------------|
| ISTH CRITERIA                                                                                          |                                              |                     |
| MAJOR, n (%)                                                                                           | 327 (3.60) 2.13                              | 462 (5.10) 3.09     |
| EVENT RATE (&/YR) HAZARD RATIO (APIXABAN/WARFARIN) 95%CIFOR HAZARD RATIO P-VALUE MAJOR OR CRNM, n (%)  | 0.69 (0.60,0.80) <.0001 613(6.75) 4.07       | 877 (9.69) 6.01     |
| EVENT RATE  (%/YR) HAZARD RATIO (APIXABAN/WARFARIN) 95%CIFORHAZARD RATIO P-VALUE                       | 0.68 (0.61, 0.75) <.0001 2356 ( 25.92) 18.08 | 3060 ( 33.80)       |
| ALL BLEEDING, n (%) EVENT RATE (%/YR) HAZARD RATIO (APIXABAN/WARFARIN) 95% CI FOR HAZARD RATIO P-VALUE | 0.71 (0.68,0.75) <.0001                      | 25.82               |

<div style=\"page-break-after: always\"></div>

Figure S2 Kaplan-Meier Plot for ISTH Major Bleeding During the Treatment Period - Treated Subjects - CV185030

<!-- image -->

Bleeding  classified  by  INR. Consistent  with  the  primary  safety  results,  apixaban  demonstrated  a reduction  in  ISTH  major  bleeding  compared  to  warfarin  for  study  sites  with  INR  control  below  and above the median TTR as well as in each of the 4 quartile intervals (table S3). Similar results were observed when these analyses were performed by using the TTR value when warfarin interruptions were included in the calculation.

Table S3 Summary of ISTH Major Bleeding During the Treatment Period (Excluding First 7 Days of the Study and Warfarin Interruptions), by Level of INR control, in QuartilesTreated Subjects (CV185030).

|                                                                                                                                       | Apixaban                               | Warfarin             |                     |
|---------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|----------------------|---------------------|
| Study Sites With INR Control < Ql*, n/N (&) EVENT RATE(&/YR) HAZARD RATIO  (APIXABAN / WARFARIN) 95% CI FOR HAZARD RATIO              | 24/1187 (2.02) 1.25 0.44 (0.27, 0.72)  |                      | 50/1174(4.26) 2.81  |
| Studly Sites With INR Control >= Ql - < Median*, n/N (%) EVENT RATE (&/YR) HAZARD RATIO (APIXABAN / WARFARIN) 95% CI FOR HAZARD RATIO | 105/3446 (3.05) 1.82 0.60 (0.47,0.76)  | 174/3471 (5.01) 3.08 |                     |
| Studly Sites With INR Control >= Median - < Q3*, n/N () EVENT RATE(&/YR) HAZARD RATIO (APIXABAN / WARFARIN) 95% CI FOR HAZARD RATIO   | 150/3346 (4.48) 2.61 0.87 (0.70, 1.08) | 174/3395 (5.13) 3.03 |                     |
| Studly Sites With INR Control >= Q3*, n/N (&) EVENT RATE (&/YR) HAZARD RATIO(APIXABAN /WARFARIN) 95% CI FOR HAZARD RATIO              | 47/1060(4.43) 2.57 0.70 (0.48,1.03)    |                      | 64/1007 (6.36) 3.61 |

<div style=\"page-break-after: always\"></div>

The frequency of the individual components of major bleeding were generally lower or similar in the apixaban group compared with the warfarin group except for intraocular bleeding (Table S4).

Table S4 Summary of Components of ISTH Major Bleeding During Treatment Period (CV185030).

|                                                                    | Apixaben N =9088   | Warfarin N = 9052   |
|--------------------------------------------------------------------|--------------------|---------------------|
| MAJOR BLEEDING, n (&) EVENT RATE (&/yr)                            | 327( 3.60) 2.13    | 462( 5.10) 3.09     |
| FATAL HEMORRHAGE, n (6) EVENT RATE (/yr)                           | 10 (0.11 0.06      | 37 (0.41) 0.24      |
| FATAL BIEED, n (6) EVENT RATE (/yr)                                | 8 (0.09) 0.05      | 11 (0.12) 0.07      |
| FATAL HEMORRHAGIC SIROKE, n (%) EVENT RATE (/yr)                   | 2(0.02) 0.01       | 26(0.29) 0.17       |
| BLEEDING INIO A CRITICAL SITE, n (%) EVENT RATE (&/yr)             | 91(1.00) 0.59      | 158 ( 1.75) 1.04    |
| INIRACRANIAL, n (%) EVENT RATE (&/yr)                              | 52(0.57) 0.33      | 122 ( 1.35) 0.80    |
| INTRAARTICULAR, n (6) EVENT RATE (&/yr)                            | 6(0.07) 0.04       | 10 ( 0.11) 0.07     |
| INTRAOCULAR, n (6) EVENT RATE (&/yr)                               | 28(0.31 ) 0.18     | 19 ( 0.21 ) 0.13    |
| FERICARDIAL, n () EVENT RATE (/yr)                                 | 0 0                | 0 0                 |
| INIRASPINAL, n (6) EVENT RATE (/yr)                                | 2(0.02) 0.01       | 2(0.02) 0.01        |
| INIRAMUSCULAR WITH COMPARIMENT SYNIROME, n (%) EVENT RATE (&/yr)   | 1 (0.01 ) <'0.01   | 1 (0.01) <0.01      |
| RETROFERITONEAL, n (%) EVENT RATE (&/yr)                           | 2(0.02 ) 0.01      | 5(0.06) 0.03        |
| IECREASE IN HEMOGIOBIN>= 2G/DL OVER 24 HRS, n (%) EVENT RATE (/yr) | 165( 1.82 ) 1.07   | 222(2.45) 1.47      |
| TRANSFUSION OF >= 2 UNITS OF FRBCs, n () EVENT RATE (&/yr)         | 70( 0.77) 0.45     | 101 ( 1.12) 0.67    |

Event  rates  for GI  bleeding (including  upper  GI,  lower  GI,  and  rectal  bleeding)  reported  by  the investigator and adjudicated as major bleeding in CV185030 were 1.30%/year in the apixaban group and 1.44%/year in the warfarin group.

Study  CV185048. The  observed  event  rate  for  adjudicated  adapted  ISTH  major  bleeding  was  45 subjects  (1.41%/year)  in  the  apixaban  group  and  29  subjects  (0.92%/year)  in  the  ASA  group [HR=1.54 (95%CI: 0.96-2.45); p=0.07] (Table S5 and Figure S3).

Table S5 Summary of Adjudicated Bleeding Endpoints During the Double-blind Treatment Period - Treated Subjects (CV185048)

Eliquis

CHMP assessment report

<div style=\"page-break-after: always\"></div>

Figure S3 Kaplan-Meier Plot for Major Bleeding during the Double-blind Treatment Period Treated Subjects

<!-- image -->

The frequencies of the components of ISTH major bleeding are displayed in Table S6.

<div style=\"page-break-after: always\"></div>

Table  S6  Summary  of  Components  of  ISTH  Major  Bleeding  During  Treatment  Period  Treated Subjects (CV185048)

|                                                                        | Apixaban N= 2798   | ASA N= 2780   |
|------------------------------------------------------------------------|--------------------|---------------|
| MAJOR BLEEDING, n (%)                                                  | 45 (1.61)          | 29(1.04)      |
| EVENT RATE (&/yr)                                                      | 1.41               | 0.92          |
| FATAL BLEED, n ()                                                      | 5(0.18)            | 5(0.18)       |
| EVENT RATE (%/yr)                                                      | 0.16               | 0.16          |
| BLEEDING INTO A CRITICAL SITE, n ($)                                   | 22(0.79)           | 12（0.43）      |
| EVENT RATE (/yr)                                                       | 0.69               | 0.38          |
| INTRACRANIAL BLEED, n (&) EVENT RATE (&/yr)                            | 11(0.39) 0.34      | 11（0.40） 0.35 |
| EVENT RATE (&/yr)                                                      |                    | 0.03          |
| INTRAARTICULAR BLEED, n (&)                                            | 2(0.07)            | 1(0.04)       |
|                                                                        | 0.06               | 0             |
| INTRAOCULAR BLEED, n (6) EVENT RATE (&/yr)                             | 6(0.21)            | 0             |
|                                                                        | 0.19               |               |
| PERICARDIAL BLEED, n ($) EVENT RATE (/yr)                              | 1(0.04) 0.03       | D 0           |
| INTRAMUSCULAR WITH COMPARIMENT SYNDROME BLEED, 1 (&) EVENT RATE (&/yr) | 1(0.04) 0.03       | 0             |
| RETROPERITONEAL BLEED, n (&)                                           | 1(0.04)            | 0             |
|                                                                        |                    | 0             |
| EVENT RATE (&/yr)                                                      | 0.03               | 0             |
| DECREASE IN HEMOGLOBIN >= 2G/DL OVER 24 HOURS, n ($) EVENT RATE (&/yr) | 14（0.50）           | 12（0.43)      |
|                                                                        | 0.44               | 0.38          |
| TRANSFUSION OF >= 2 UNITS OF PRBCs, n () EVENT RATE (/yr)              | 16（0.57)           | 13（0.47） 0.41 |
|                                                                        | 0.50               |               |

Six of 2798 subjects (0.21%, 0.19%/year) in the apixaban group (0 in the ASA group) had ISTH major bleeding  for  which  the  investigator-assigned  location  was  intraocular.  Further  analysis  revealed  an extra  case  of  vitreous  haemorrhage,  originally  classified  'Other'.  Of  these  7  ISTH  major  bleeding events, 3 were vitreous haemorrhage (resolving in 10, 12, and 19 days, respectively); 2 events of eye haemorrhage  (ocular  haemorrhage  resolving  in  21  days,  and  intraocular  bleeding,  resolving  in  129 days) and one event of loss of vision (occurred approximately 3 months after eye surgery of a macular hole). Two of the 7 apixaban-treated subjects with intraocular ISTH major bleeding had diabetes. The frequency of diabetes in the overall population was 19.1% in the apixaban group and 20.0% in the ASA group.

2. Liver-related safety results. The frequency of elevations of LFTs with onset during the Treatment Period was low and similar in the apixaban and comparator groups (table S7).

<div style=\"page-break-after: always\"></div>

Table S7 Summary of LFT Elevations during the Treatment Period - Treated Subjects with Available Measurements (Pooled CV185030 and CV185048)

<!-- image -->

|                                                    |      |             |                | Camparator   | Camparator     | Camparator   |
|----------------------------------------------------|------|-------------|----------------|--------------|----------------|--------------|
| AST EIEVATION,n/N(8)                               |      |             |                |              |                |              |
| >3XULN                                             | 134/ | 11569       |                | 132/         | 11514          |              |
| >5XULN                                             |      | 11569       |                |              | 11514          |              |
| >10xULN                                            |      | 11569       |                |              | 11514          | 0.2)         |
| >20xUIN                                            |      | 11569       | <0.1)          |              | 11514          | 0.1)         |
| ALT EIEVATION,n/N(8)                               |      |             |                |              |                |              |
| >3XULN                                             | 123/ | 11569       | 1·1            | 120/         | 11512          | 0:3          |
| >5XULN                                             |      | 11569       | 0.3            | /09          | 11512          |              |
| >10xULN                                            |      | 11569       | 0.2)           |              | 11512          | 0.2)         |
| >20xULN                                            | 8/   | 11569       | <0.1)          | 14/          | 11512          | 0.1)         |
| TBILI EIEVATION,n/N(&)                             |      |             |                |              |                |              |
| >1.5XULN                                           | 383/ | 1137 ( 1:3) |                | 331/         | 11519          |              |
| >2xUIN                                             | 118/ | 11575       |                | 129/         | 11519          | 1:3          |
| BOTH AST AND AIT ETEVATION ON THE SAME DATE,n/N（&) |      |             |                |              |                |              |
| >3XULN                                             | /88  | 11569       | 0.8)           | 83/          | 11512          | 0.7)         |
| >5xUIN                                             | 36/  | 11569       | 0.3)           | 38/          | 11512          | 8.33         |
| >10xULN                                            | 13/  | 11569       | 0.1)           | 18/          | 11512          | 0.2)         |
| >20xULN                                            | 7/   | 11569       | <0.1)          | 12/          | 11512          | 6.1)         |
| AT AND TBILIEIEVATION ON THE SAME DATE,n/N()       |      |             |                |              |                |              |
| (ALT>3XUINCRAST>3XULN)AND TBILI>2XUIN              | 35/  | 11567       | 0.3)           |              | 11509          | 0.3)         |
| (ALT>3XUINCRAST>3XUIN)ANDTBILI>1.5XUIN             |      | 11567       | 0.4)           | 49/          | 11509          | 18.8         |
| （ALT>3XUINCRAST>3XUIN)AND TBILI>2XULNAND ALP<2xUIN | 20/  | 11565       | 0.2)           | 23/          | 11508          | 0.2)         |
| ALT AND TBILI EIEVATION ON THE SAME DATE,n/N（)     |      |             |                |              |                |              |
| AIT>3XUINAND TBILI>2XULN                           | 26/  | 11567       | 8:3            | 31/          | 11508          | 0.3)         |
| ALT>3XUINAND TBILI>1.5XULN                         | 32/  | 11567       |                | 41/          | 11508          | 0.4)         |
| ALT>3XULNANDTBILI>2XUINANDALP<2XULN                | 15/  | 11565       | 0.1)           | 20/          | 11507          | 0.2)         |
| ALPELEVATION,n/N(%)                                |      |             |                |              |                |              |
| >1.5xULN                                           |      |             | 282/11576(2.4) |              | 283/11520(2.5) |              |

Liver-related SAEs occurred with low and similar frequency in the apixaban and comparator groups (59 [0.5% and 55 [0.5%] subjects, respectively).  Liver-related SAEs with outcome of death were reported for a total of 13 subjects (7 subjects in the apixaban group and 6 subjects in the comparator group). Of 13 deaths, 4 (2 in each treatment group) occurred during the Follow-up Period. Most subjects with SAEs related to elevations in LFT with outcome of death had underlying disease conditions, such as hepatic  malignancy.  Liver-related  AEs  leading  to  treatment  discontinuation  occurred  in  35  (0.3%) subjects in the apixaban group and 42 (0.4%) in the comparator group. All liver-related AEs leading to discontinuation  were  reported  for  ≤0.1%  of  subjects  in  either  treatment  group.  Comparable  results were also reported during the follow-period.

Three independent hepatologists provided blinded assessments of subjects with concurrent elevations of ALT &gt;3x ULN and total bilirubin &gt;2 x ULN and/or pre-selected SAEs (jaundice, hepatitis, and hepatic failure) related to elevated LFTs across the entire Phase 2/3 clinical program for apixaban (N=57,706 treated subjects). The number of cases assessed as possible or probable relationship to the study drug by the independent, blinded, hepatologists' panel was low and balanced between the 2 groups.  Six apixaban-treated  subjects  had  on-study  concurrent  LFT  elevations  of  ALT&gt;3xULN  and  TBili&gt;2xULN assessed by as possibly or probably related to study drug. All 6 apixaban-treated subjects had AEs or SAEs of hepatitis, and 2 of these 6 subjects had SAEs of hepatitis with outcome of death assessed as possibly  related  to  study  drug.  Another  of  these  6  subjects  had  a  nonfatal  SAE  of  acute  hepatitis assessed as probably related to study drug.

<div style=\"page-break-after: always\"></div>

For  the  non-AF  studies  (22,386  subjects  apixaban  or  reference  treatments  (placebo,  enoxaparin,  or warfarin)  in  eight  completed  studies  in  non-AF  indications),  a  total  of  11  cases  were  assessed  as possibly  related  to  study  drug  (apixaban  7,  comparator  5).  Of  the  7  cases  in  apixaban-treated subjects, one subject had a liver-related SAE with fatal outcome.

## Laboratory findings

The incidence of laboratory values that met the criteria for marked abnormalities was similar in both treatment  groups.  Few  subjects  had  platelet  counts  decreased  from  baseline  to  &lt;50,000/mm3  (4 [&lt;0.1%] subjects in each treatment group. A total of 111 (1.3%) subjects in the apixaban group and 101  (1.2%)  subjects  in the warfarin group  had  platelet counts decreased  from  baseline to &lt;100,000/mm3  during  the  Treatment  Period.  Five  (&lt;0.1%)  subjects  in  the  apixaban  group  and  7 (&lt;0.1%) subjects in the warfarin group had an SAE of thrombocytopenia during the Treatment Period.

## Safety in special populations

Bleeding .  In study CV185030, the results within each subgroup were consistent with the results for the study for ISTH major, composite of ISTH major or CRNM and all bleeding (data shown in figure S4 are only for ISTH major bleeding).

<!-- image -->

| Subgroup                  |    | Apixaban n (x/yr)   | Warfarin n (x/yr)   | Hozard Ratio (95α Cl)   |
|---------------------------|----|---------------------|---------------------|-------------------------|
| PRIOR WARFARIN/VKA STATUS |    |                     |                     |                         |
| WARFARIN /VKA NAIVE       |    | 142 ( 2.17)         | 188 ( 2.96)         | 0.73 ( 0.59, 0.91)      |
| WARFARIN/VKA EXPERIENCED  |    | 185 ( 2.11)         | 274 ( 3.18)         | 0.66 ( 0.55, 0.80)      |
| APIXABAN DOSE             |    |                     |                     |                         |
| APIX/PLACEBO 2.5 MG BID   |    | 20 ( 3.29)          | 37 ( 6.71)          | 0.50 ( 0.29, 0.86)      |
| APIX/PLACEBO 5 MG BID     | +  | 307 ( 2.09)         | 425 ( 2.95)         | 0.71 ( 0.61, 0.82)      |
| GEOGRAPHIC REGION         |    |                     |                     |                         |
| NORTH AMERICA             |    | 106 ( 2.80)         | 137 ( 3.61)         | 0.77 ( 0.60, 1.00)      |
| LATIN AMERICA             |    | 60 ( 2.11)          | 94 ( 3.50)          | 0.60 ( 0.44, 0.84)      |
| EUROPE                    |    | 110 ( 1.74)         | 135 ( 2.21)         | 0.80 ( 0.62, 1.02)      |
| ASIA/PACIFIC              |    | 51 ( 2.14)          | 96 ( 4.09)          | 0.52 ( 0.37, 0.74)      |
| AGE                       |    |                     |                     |                         |
| <65 YEARS                 |    | 56 ( 1.17)          | 72 ( 1.51)          | 0.78 ( 0.55, 1.11)      |
| 65 -<75 YEARS             |    | 120 ( 1.99)         | 166 ( 2.82)         | 0.71 ( 0.56, 0.89)      |
| >= 75 YEARS               | H  | 151 ( 3.33)         | 224 ( 5.19)         | 0.64 ( 0.52, 0.79)      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Subgroup                  |                       | Apixa ban n (z/yr)   | Warfarin n (x/yr)   | Hozard Ratio (95 Cl)   |
|---------------------------|-----------------------|----------------------|---------------------|------------------------|
| GENDER                    |                       |                      |                     |                        |
| MALE                      |                       | 225 ( 2.26)          | 294 ( 2.98)         | 0.76 ( 0.64, 0.90)     |
| FEMALE                    |                       | 102 ( 1.91)          | 168 ( 3.29)         | 0.58 ( 0.45, 0.74)     |
| FEMALE AGE GROUP          |                       |                      |                     |                        |
| FEMALE <=50 YEARS         |                       | 3 ( 2.42)            | 4 ( 2.79)           | 0.80 ( 0.18, 3.58)     |
| FEMALE >50 YEARS          |                       | 99 (1.89)            | 164 ( 3.31)         | 0.57 ( 0.45, 0.74)     |
| RACE                      |                       |                      |                     |                        |
| WHITE                     | +H                    | 275 ( 2.15)          | 370 ( 2.96)         | 0.73 ( 0.62, 0.85)     |
| BLACK/AFRICAN AMERICAN    |                       | 4 ( 2.05)            | 2 ( 1.30)           | 1.57 ( 0.29, 8.64)     |
| ASIAN                     |                       | 45 ( 2.14)           | 81 ( 3.83)          | 0.56 ( 0.39, 0.80)     |
| OTHER                     |                       | 3 ( 1.39)            | 9 ( 4.75)           | 0.20 ( 0.04, 0.95)     |
| ETHNICITY                 |                       |                      |                     |                        |
| HISPANIC/LATINO           |                       | 62 ( 2.09)           | 98 (3.48)           | 0.60 ( 0.44, 0.83)     |
| NOT HISPANIC /LATINO      |                       | 265 ( 2.14)          | 364 ( 3.00)         | 0.72 ( 0.61, 0.84)     |
| WEIGHT                    |                       |                      |                     |                        |
| <= 60 KG                  |                       | 36 ( 2.33)           | 62 ( 4.28)          | 0.55 ( 0.36, 0.83)     |
| > 60 KG                   |                       | 290 ( 2.11)          | 398 ( 2.96)         | 0.72 ( 0.62, 0.83)     |
|                           | 1 2                   |                      |                     |                        |
|                           | Hazard Ratio (95x CI) |                      |                     |                        |
| Subgroup                  |                       | Apixaban n (x/yr)    | Warfarin n (x/yr)   | Hozard Ratio (95α CI)  |
| BMI                       |                       |                      |                     |                        |
| <= 28 KG/M2               |                       | 150 ( 2.22)          | 250 ( 3.72)         | 0.60 ( 0.49, 0.73)     |
| > 28 T0 33 KG/M2          |                       | 109 ( 2.21)          | 133 ( 2.90)         | 0.76 ( 0.59, 0.98)     |
| > 33 KG/M2                |                       | 67 ( 1.89)           | 76 ( 2.12)          | 0.89 ( 0.64, 1.23)     |
| LEVEL OF RENAL IMPAIRMENT |                       |                      |                     |                        |
| SEVERE OR MODERATE        |                       | 73 ( 3.21)           | 142 ( 6.44)         | 0.50 ( 0.38, 0.67)     |
| MILD                      |                       | 157 ( 2.45)          | 199 ( 3.21)         | 0.76 ( 0.62, 0.94)     |
| NORMAL                    |                       | 96 (1.46)            | 119 ( 1.84)         | 0.79 ( 0.61, 1.04)     |
| NUMBER OF RISK FACTORS    |                       |                      |                     |                        |
| <=1                       |                       | 66 ( 1.23)           | 119 ( 2.27)         | 0.54 ( 0.40, 0.73)     |
| >=2                       |                       | 261 ( 2.62)          | 343 ( 3.53)         | 0.75 ( 0.63, 0.88)     |
| CHADS-2                   |                       |                      |                     |                        |
| <=1                       |                       | 76 ( 1.38)           | 126 ( 2.34)         | 0.59 ( 0.44, 0.78)     |
| =2                        |                       | 125 ( 2.30)          | 163 ( 3.03)         | 0.76 ( 0.60, 0.96)     |
| >=3                       |                       | 126 ( 2.88)          | 173 ( 4.15)         | 0.70 ( 0.56, 0.88)     |

<div style=\"page-break-after: always\"></div>

Figure S4 Analyses for ISTH major Bleeding - Treated Subjects (CV185030)

<!-- image -->

| Subgroup            |    | Apixaban n (x/yr)   | Warfarin n (x/yr)   | Hazard Ratio (95x CI)   |
|---------------------|----|---------------------|---------------------|-------------------------|
| PRIOR STROKE OR TIA |    |                     |                     |                         |
| YES                 |    | 77 ( 2.84)          | 106 ( 3.91)         | 0.73 ( 0.54, 0.98)      |
| NO                  |    | 250 ( 1.98)         | 356 ( 2.91)         | 0.68 ( 0.58, 0.80)      |
| AGE >=75 YEARS      |    |                     |                     |                         |
| YES                 |    | 151 ( 3.33)         | 224 ( 5.19)         | 0.64 ( 0.52, 0.79)      |
| NO                  |    | 176 ( 1.63)         | 238 ( 2.24)         | 0.73 ( 0.60, 0.89)      |
| DIABETES            |    |                     |                     |                         |
| YES                 |    | 112 ( 3.01)         | 114 ( 3.13)         | 0.96 ( 0.74, 1.25)      |
| NO                  | +  | 215 ( 1.85)         | 348 ( 3.08)         | 0.60 ( 0.51, 0.71)      |
| HYPERTENSION        |    |                     |                     |                         |
| YES                 |    | 277 ( 2.07)         | 394 ( 3.00)         | 0.69 ( 0.59, 0.81)      |
| NO                  |    | 50 ( 2.60)          | 68 ( 3.73)          | 0.70 ( 0.48, 1.00)      |
| HEART FAILURE       |    |                     |                     |                         |
| YES                 |    | 87 ( 1.92)          | 137 ( 3.14)         | 0.61 ( 0.47, 0.80)      |
| NO                  |    | 240 ( 2.22)         | 325 ( 3.07)         | 0.73 ( 0.61, 0.86)      |

Results  of  a  post  hoc  analysis  of  major  bleeding  in  the  small  subset  of  subjects  with  severe  renal impairment (136 and 132 subjects in the apixaban and warfarin groups, respectively) were consistent (event  rate  of  3.8%/year  vs.  11.9%/year,  respectively).  Another  post-hoc  sub-group  analysis  was performed  in  subjects  from  countries  of  the  EU  (apixaban  2,032,  warfarin  2,026).  Event  rates  for major  bleeding  were  slightly  higher  in  the  apixaban  and  warfarin  groups  (2.29%/yr  and  2.56%yr, respectively; HR 0.90 [95% CI: 0.66, 1.22]) than were major bleeding event rates in the larger prespecified  EU  subgroup  depicted  in  figure  S4  (1.74%/yr  and  2.21%/yr  for  apixaban  and  warfarin, respectively; HR 0.80 [95% CI: 0.62, 1.02]). Hazard ratios were favourable for apixaban in each of these subgroup analyses, albeit of lesser magnitude in the smaller EU member state analysis.

Study CV185048. Overall, the results within each subgroup were consistent with the results for the study for ISTH major, composite of ISTH major or CRNM and all bleeding identified by the investigator, as shown in figure S5.

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Subgroup               | Apixaban n(∞/yr)   | ASA n(x/yr)   | Hazord Ratio （95%C1)   |
|------------------------|--------------------|---------------|------------------------|
| VKAUnsuitable          |                    |               |                        |
| Demonstrated           | 23 (1.84)          | 15 (1.21)     | 1.52(0.80,2.92)        |
| Expected               | 22 (1.13)          | 14 (0.73)     | 1.55(0.79,3.02)        |
| Reoson VKA unsuitoble  |                    |               |                        |
| Subj.refused trt w/vKA | 3 (0.61)           | 3 (0.67)      | 0.92(0.19,4.55)        |
| CHADS2 Scr=1/Phynotrec | 3 (0.93)           | 1 (0.28)      | 3.44(0.36,33.06)       |
| All other reasons      | 39 (1.64)          | 25 (1.07)     | 1.54(0.93,2.55)        |
| Apixaban Dose          |                    |               |                        |
| Apix/Pla 2.5 mg BID    | 8 (4.48)           | 3 (1.59)      | 2.82(0.75,10.62)       |
| Apix/Pla 5 mg BID      | 37 (1.23)          | 26 (0.88)     | 1.40(0.85,2.32)        |
| ASA Dose               |                    |               |                        |
| ASA/Pla 81 mg QD       | 34 (1.65)          | 15 (0.75)     | 2.20(1.20,4.04)        |
| ASA/Pla 162 mg QD      | 8 (0.98)           | 11 (1.29)     | 0.77(0.31.1.90)        |
| ASA/Pla 243 mg QD      |                    | 1 (1.44)      | <O.01( NE)             |
| ASA/Pla 324 mg QD      | 3 (1.31)           | 2 (0.92)      | 1.46(0.24,8.74)        |
| Geogrophic Region      |                    |               |                        |
| North Americo          | 9 (1.77)           | 5 (1.02)      | 1.78(0.60,5.30)        |
| Latin America          | 9 (1.38)           | 5 (0.77)      | 1.80(0.60,5.37)        |
| Europe                 | 20 (1.35)          | 10 (0.69)     | 1.95(0.91,4.17)        |
| Asia/Pacific           | 7 (1.28)           | 9 (1.61)      | 0.80(0.30,2.15)        |
| Age                    |                    |               |                        |
| <65 yrs                | 8 (0.81)           | 5 (0.49)      | 1.67(0.55,5.11)        |
| >=65 and <75 yrs       | 11 (0.90)          | 6 (0.56)      | 1.61(0.60,4.36)        |
| >=75yrs                | 26 (2.65)          | 18 (1.70)     | 1.57(0.86,2.86)        |
| Gender                 |                    |               |                        |
| Male                   | 27 (1.43)          | 19(1.03)      | 1.39(0.77,2.50)        |
| Female                 | 18 (1.38)          | 10 (0.76)     | 1.81(0.84,3.92)        |
| Race                   |                    |               |                        |
| White                  | 38 (1.46)          | 20 (0.79)     | 1.85(1.07,3.17)        |
| Black/AfricanAmerican  | O                  |               | NE                     |
| Asian                  | 7 (1.31)           | 8 (1.47)      | 0.89(0.32,2.45)        |
| Other                  | O                  | 1 (2.09)      | <0.01( NE )            |

<div style=\"page-break-after: always\"></div>

|                             | Apixoban   | ASA       | Hozard Ratio    |
|-----------------------------|------------|-----------|-----------------|
| Subgroup                    | n（x/yr)    | n（x/yr)   | （95% C1)        |
| Ethnicity                   |            |           |                 |
| Hispanic/lotino             | 8 (1.30)   | 5 (0.82)  | 1.58(0.52.4.83) |
| Not hispanic/latino         | 37 (1.46)  | 24 (0.96) | 1.53(0.91,2.55) |
| Weight                      |            |           |                 |
| Weight <= 60 kg             | 9(1.94)    | 4 (0.91)  | 2.21(0.68.7.21) |
| Weight > 60 kg              | 36 (1.32)  | 25 (0.92) | 1.44(0.86,2.40) |
| BMI                         |            |           |                 |
| BMl<=28kg/m2                | 30 (1.92)  | 14 (0.86) | 2.23（1.18,4.21) |
| BM1 >28 to 33 kg/m2         | 11(1.09)   | 10（1.05)  | 1.03(0.44.2.44) |
| BMl > 33 kg/m2              | 4 (0.65)   | 5 (0.89)  | 0.74(0.20,2.74) |
| Level of Renol Impoirment   |            |           |                 |
| Severe/Moderote             | 20 (3.54)  | 9 (1.60)  | 2.21(1.01,4.86) |
| Mi1d                        | 12 (0.98)  | 13(1.09)  | 0.90(0.41,1.98) |
| [OWJON                      | 8(0.71)    | 4(0.36)   | 2.01(0.60.6.67) |
| Number of risk foctors < =1 | 7 (0.56)   | 4(0.32)   | 1.77(0.52.6.04) |
| =2                          | 38 (1.95)  | 25 (1.31) | 1.49(0.90.2.47) |
| CHADS2 Score                |            |           |                 |
| < = 1                       | 7 (0.57)   | 4 (0.32)  | 1.79(0.52.6.11) |
| 2                           | 15 (1.26)  | 13 (1.22) | 1.03(0.49.2.17) |
|                             | 23 (2.99)  | 12 (1.43) | 2.10(1.04.4.22) |
| Prior Stroke or TIA         |            |           |                 |
| No                          | 30 (1.08)  | 24 (0.87) | 1.24(0.73.2.12) |
|                             | 15 (3.60)  | 5 (1.24)  | 2.90(1.05.7.99) |
| Age >=75 yrs                |            |           |                 |
| No                          | 19 (0.86)  | 11 (0.53) | 1.64(0.78.3.45) |
| Yes                         | 26 (2.65)  | 18 (1.70) | 1.57(0.86,2.86) |
| Diobetes Mellitus           |            |           |                 |
| No                          | 35 (1.35)  | 22 (0.87) | 1.56(0.91,2.65) |
| Yes                         | 10 (1.69)  | 7 (1.14)  | 1.49(0.57.3.92) |
| Hypertension req. Rx        |            |           |                 |
| No                          | 3 (0.67)   | 5 (1.22)  | 0.56(0.13.2.32) |
| Yes                         | 42 (1.53)  | 24 (0.87) | 1.75(1.06.2.90) |
| Heort Failure               |            |           |                 |
| No                          | 32 (1.51)  | 16 (0.75) | 2.02(1.11,3.68) |
| Yes                         | 13 (1.21)  | 13 (1.26) | 0.96(0.44.2.06) |

Figure S5 Subgroup Analyses for Major Bleeding - Treated Subjects (CV185048)

<!-- image -->

## Safety related to drug-drug interactions and other interactions

Bleeding Risk with Concomitant Use of ASA or ASA+Thienopyridine. The number of subjects receiving ASA+study drug was 3529/9088 in the apixaban group and 3431/9052 in the warfarin group The addition of ASA to study drug increased the risk of ISTH major bleeding in each treatment group (apixaban 3.42%/year vs.1.78%/year for subjects receiving vs. not receiving ASA; warfarin 4.59%/year vs. 2.70%/year for subjects receiving vs. not receiving ASA). The bleeding risk associated with  concomitant  use  of  ASA+study  drug  was  lower  for  apixaban  compared  with  warfarin  for  ISTH major bleeding and all other bleeding endpoints, including intracranial bleeding. Fatal haemorrhages were observed for 3 subjects on apixaban and 9 subjects on warfarin while receiving ASA+study drug.

The  number of  subjects  receiving ASA+thienopyridine+study  drug was  211/9088  (2.3%)  in  the apixaban group and 170/9052 (1.9%) in the warfarin group. The addition of ASA+thienopyridine to study  drug  increased  the  risk  of  bleeding  in  each  treatment  group  (apixaban  7.53%/year  vs. 2.11%/year  for  subjects  receiving  vs.  not  receiving  ASA+thienopyridine;  warfarin  20.80%/year  vs. 3.04%/year for subjects receiving vs. not receiving ASA+thienopyridine). The bleeding risk associated with concomitant use of ASA+thienopyridine+study drug was lower for apixaban than warfarin for all

<div style=\"page-break-after: always\"></div>

bleeding endpoints and intracranial bleeds (observed rate difference &lt; 0). Given the infrequent use of the triple combination in the study, the number of events observed for subjects while on triple therapy was small, and all 95% CI for rate difference included 0. There were no fatal haemorrhages observed for subjects in either treatment group while on triple therapy.

## Discontinuation due to adverse events

No marked differences between the treatment groups were observed in the frequencies of AEs leading to discontinuation in either of the Phase 3 studies. In CV185030, the frequency of AEs leading to study treatment discontinuation was similar in the apixaban and warfarin groups in the overall population (apixaban 7.6%, warfarin 8.4%) and in warfarin/VKA-naïve subjects (apixaban 7.8%, warfarin 8.8%) and warfarin/VKA-experienced subjects (apixaban 7.4%. warfarin 8.1%).

In CV185048, the frequency of AEs leading to study treatment discontinuation was 9.5% vs. 13.0% in the apixaban vs. ASA groups, respectively. Most AEs leading to discontinuation were reported for &lt;1% of subjects in either treatment group.

## Supportive Studies Study CV185067

<div style=\"page-break-after: always\"></div>

## Table S8 Overview of study CV185067

<!-- image -->

| Title: A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin). Multicenter Study to Evaluate the Safety and Efficacy in 2 Doses of Apixaban in Comparison to Warfarin,Administered for 12 Weeksin Subiects with NVAF   | Title: A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin). Multicenter Study to Evaluate the Safety and Efficacy in 2 Doses of Apixaban in Comparison to Warfarin,Administered for 12 Weeksin Subiects with NVAF   | Title: A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin). Multicenter Study to Evaluate the Safety and Efficacy in 2 Doses of Apixaban in Comparison to Warfarin,Administered for 12 Weeksin Subiects with NVAF   | Title: A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin). Multicenter Study to Evaluate the Safety and Efficacy in 2 Doses of Apixaban in Comparison to Warfarin,Administered for 12 Weeksin Subiects with NVAF   | Title: A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin). Multicenter Study to Evaluate the Safety and Efficacy in 2 Doses of Apixaban in Comparison to Warfarin,Administered for 12 Weeksin Subiects with NVAF   | Title: A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin). Multicenter Study to Evaluate the Safety and Efficacy in 2 Doses of Apixaban in Comparison to Warfarin,Administered for 12 Weeksin Subiects with NVAF   | Title: A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin). Multicenter Study to Evaluate the Safety and Efficacy in 2 Doses of Apixaban in Comparison to Warfarin,Administered for 12 Weeksin Subiects with NVAF   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                            | Study code: CV185067                                                                                                                                                                                                                                        | Study code: CV185067                                                                                                                                                                                                                                        | Study code: CV185067                                                                                                                                                                                                                                        | Study code: CV185067                                                                                                                                                                                                                                        | Study code: CV185067                                                                                                                                                                                                                                        | Study code: CV185067                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                                                      | Design: randomized, partially blind (double-blind apixaban, open-label warfarin), active-controlled (waifarin sodium), multicenter study                                                                                                                    | Design: randomized, partially blind (double-blind apixaban, open-label warfarin), active-controlled (waifarin sodium), multicenter study                                                                                                                    | Design: randomized, partially blind (double-blind apixaban, open-label warfarin), active-controlled (waifarin sodium), multicenter study                                                                                                                    | Design: randomized, partially blind (double-blind apixaban, open-label warfarin), active-controlled (waifarin sodium), multicenter study                                                                                                                    | Design: randomized, partially blind (double-blind apixaban, open-label warfarin), active-controlled (waifarin sodium), multicenter study                                                                                                                    | Design: randomized, partially blind (double-blind apixaban, open-label warfarin), active-controlled (waifarin sodium), multicenter study                                                                                                                    |
| Design                                                                                                                                                                                                                                                      | Duration of main phase:                                                                                                                                                                                                                                     | Duration of main phase:                                                                                                                                                                                                                                     | Duration of main phase:                                                                                                                                                                                                                                     | 12 weeks: Week -1 (starting day of the observation period/enrollment), Week 0 (day of transition to the treatment period/baseline), Week 1, Week 2, Week 4 and Week 8 (visits during the treatment period), and Week 12/discontinuation (last               | 12 weeks: Week -1 (starting day of the observation period/enrollment), Week 0 (day of transition to the treatment period/baseline), Week 1, Week 2, Week 4 and Week 8 (visits during the treatment period), and Week 12/discontinuation (last               | 12 weeks: Week -1 (starting day of the observation period/enrollment), Week 0 (day of transition to the treatment period/baseline), Week 1, Week 2, Week 4 and Week 8 (visits during the treatment period), and Week 12/discontinuation (last               |
| Design                                                                                                                                                                                                                                                      | Follow-up phase:                                                                                                                                                                                                                                            | Follow-up phase:                                                                                                                                                                                                                                            | Follow-up phase:                                                                                                                                                                                                                                            | visit). starting after the end of the treatment period through 30 days after the discontinuation of                                                                                                                                                         | visit). starting after the end of the treatment period through 30 days after the discontinuation of                                                                                                                                                         | visit). starting after the end of the treatment period through 30 days after the discontinuation of                                                                                                                                                         |
| Hypothesis                                                                                                                                                                                                                                                  | No formal statistical hypothesis testing was planned in this study                                                                                                                                                                                          | No formal statistical hypothesis testing was planned in this study                                                                                                                                                                                          | No formal statistical hypothesis testing was planned in this study                                                                                                                                                                                          | No formal statistical hypothesis testing was planned in this study                                                                                                                                                                                          | No formal statistical hypothesis testing was planned in this study                                                                                                                                                                                          | No formal statistical hypothesis testing was planned in this study                                                                                                                                                                                          |
| Treatments groups                                                                                                                                                                                                                                           | Apixaban                                                                                                                                                                                                                                                    | Apixaban                                                                                                                                                                                                                                                    | Apixaban                                                                                                                                                                                                                                                    | Apixaban (or matching apixaban-placebo) 5.0 mg BID or 2.5 mg BID                                                                                                                                                                                            | Apixaban (or matching apixaban-placebo) 5.0 mg BID or 2.5 mg BID                                                                                                                                                                                            | Apixaban (or matching apixaban-placebo) 5.0 mg BID or 2.5 mg BID                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                                                           | Warfarin                                                                                                                                                                                                                                                    | Warfarin                                                                                                                                                                                                                                                    | Warfarin                                                                                                                                                                                                                                                    | Warfarin sodium 2 mg tablets QD to achieve a target prothrombin time-international normalized ratio [PT-INR] range of 2.0-3.0.                                                                                                                              | Warfarin sodium 2 mg tablets QD to achieve a target prothrombin time-international normalized ratio [PT-INR] range of 2.0-3.0.                                                                                                                              | Warfarin sodium 2 mg tablets QD to achieve a target prothrombin time-international normalized ratio [PT-INR] range of 2.0-3.0.                                                                                                                              |
| Endpoints and definitions Primary objective of                                                                                                                                                                                                              | Efficacy Endpoint                                                                                                                                                                                                                                           | Efficacy Endpoint                                                                                                                                                                                                                                           | Efficacy Endpoint                                                                                                                                                                                                                                           | Composite of stroke or systemic embolism during the Intended Treatment Period.                                                                                                                                                                              | Composite of stroke or systemic embolism during the Intended Treatment Period.                                                                                                                                                                              | Composite of stroke or systemic embolism during the Intended Treatment Period.                                                                                                                                                                              |
| Endpoints and definitions Primary objective of                                                                                                                                                                                                              | Efficacy Endpoint                                                                                                                                                                                                                                           | Efficacy Endpoint                                                                                                                                                                                                                                           | Efficacy Endpoint                                                                                                                                                                                                                                           | Composite of stroke, systemic embolism, or all-cause death during the Intended Treatment Period.                                                                                                                                                            | Composite of stroke, systemic embolism, or all-cause death during the Intended Treatment Period.                                                                                                                                                            | Composite of stroke, systemic embolism, or all-cause death during the Intended Treatment Period.                                                                                                                                                            |
| the study was safety: all efficacy endpoints were secondary endpoints.                                                                                                                                                                                      | Efficacy Endpoint                                                                                                                                                                                                                                           | Efficacy Endpoint                                                                                                                                                                                                                                           | Efficacy Endpoint                                                                                                                                                                                                                                           | Composite of MI or all-cause death during the Intended Treatment Period                                                                                                                                                                                     | Composite of MI or all-cause death during the Intended Treatment Period                                                                                                                                                                                     | Composite of MI or all-cause death during the Intended Treatment Period                                                                                                                                                                                     |
| the study was safety: all efficacy endpoints were secondary endpoints.                                                                                                                                                                                      | Safety endpoints                                                                                                                                                                                                                                            | Bleeding                                                                                                                                                                                                                                                    | Bleeding                                                                                                                                                                                                                                                    | The proportion of subjects with major or CRNM bleeding during the treatment period                                                                                                                                                                          | The proportion of subjects with major or CRNM bleeding during the treatment period                                                                                                                                                                          | The proportion of subjects with major or CRNM bleeding during the treatment period                                                                                                                                                                          |
| Last Subject Last Visit                                                                                                                                                                                                                                     | 28-Sep-2009                                                                                                                                                                                                                                                 | 28-Sep-2009                                                                                                                                                                                                                                                 | 28-Sep-2009                                                                                                                                                                                                                                                 | 28-Sep-2009                                                                                                                                                                                                                                                 | 28-Sep-2009                                                                                                                                                                                                                                                 | 28-Sep-2009                                                                                                                                                                                                                                                 |
| Results and Analysis - The primary objective of the study was related to safety.                                                                                                                                                                            | Results and Analysis - The primary objective of the study was related to safety.                                                                                                                                                                            | Results and Analysis - The primary objective of the study was related to safety.                                                                                                                                                                            | Results and Analysis - The primary objective of the study was related to safety.                                                                                                                                                                            | Results and Analysis - The primary objective of the study was related to safety.                                                                                                                                                                            | Results and Analysis - The primary objective of the study was related to safety.                                                                                                                                                                            | Results and Analysis - The primary objective of the study was related to safety.                                                                                                                                                                            |
| Analysis description                                                                                                                                                                                                                                        | Composite of stroke or systemic embolism during the Intended Treatment Period.                                                                                                                                                                              | Composite of stroke or systemic embolism during the Intended Treatment Period.                                                                                                                                                                              | Composite of stroke or systemic embolism during the Intended Treatment Period.                                                                                                                                                                              | Composite of stroke or systemic embolism during the Intended Treatment Period.                                                                                                                                                                              | Composite of stroke or systemic embolism during the Intended Treatment Period.                                                                                                                                                                              | Composite of stroke or systemic embolism during the Intended Treatment Period.                                                                                                                                                                              |
| Analysis population and time point description                                                                                                                                                                                                              | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period.                                                                                                                                            | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period.                                                                                                                                            | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period.                                                                                                                                            | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period.                                                                                                                                            | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period.                                                                                                                                            | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period.                                                                                                                                            |
| Descriptive statistics                                                                                                                                                                                                                                      | Treatment group                                                                                                                                                                                                                                             | Treatment group                                                                                                                                                                                                                                             | Warfarin                                                                                                                                                                                                                                                    | Warfarin                                                                                                                                                                                                                                                    | Apix 2.5 mg                                                                                                                                                                                                                                                 | Apix 5.0 mg                                                                                                                                                                                                                                                 |
| Descriptive statistics                                                                                                                                                                                                                                      | Number of subjects                                                                                                                                                                                                                                          | Number of subjects                                                                                                                                                                                                                                          | 74                                                                                                                                                                                                                                                          | 74                                                                                                                                                                                                                                                          | 74                                                                                                                                                                                                                                                          | 74                                                                                                                                                                                                                                                          |
| Descriptive statistics                                                                                                                                                                                                                                      | Stroke/systemic embolism (rate)                                                                                                                                                                                                                             | Stroke/systemic embolism (rate)                                                                                                                                                                                                                             | 4.1                                                                                                                                                                                                                                                         | 4.1                                                                                                                                                                                                                                                         | 0                                                                                                                                                                                                                                                           | 0                                                                                                                                                                                                                                                           |
| Descriptive statistics                                                                                                                                                                                                                                      | 95% CI                                                                                                                                                                                                                                                      | 95% CI                                                                                                                                                                                                                                                      | (1.1, 10.7)                                                                                                                                                                                                                                                 | (1.1, 10.7)                                                                                                                                                                                                                                                 | (0.0,4.8)                                                                                                                                                                                                                                                   | (0.0,4.8)                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                                                                                                                                                                                                                              | Stroke/systemic                                                                                                                                                                                                                                             | Stroke/systemic                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                           | Apix 2.5 mg vs Warfarin                                                                                                                                                                                                                                     | Apix 5.0 mg vs Warfarin                                                                                                                                                                                                                                     |
| Effect estimate per comparison                                                                                                                                                                                                                              | embolism                                                                                                                                                                                                                                                    | embolism                                                                                                                                                                                                                                                    | Proportion Difference                                                                                                                                                                                                                                       | Proportion Difference                                                                                                                                                                                                                                       | -4.1                                                                                                                                                                                                                                                        | -4.1                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             | 10 9656                                                                                                                                                                                                                                                     | 10 9656                                                                                                                                                                                                                                                     | (-11.4, 1.1)                                                                                                                                                                                                                                                | (-11.4, 1.1)                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Analysis description                           | Composite of stroke, systemic embolism, or all-cause death during the Intended Treatment Period.                 | Composite of stroke, systemic embolism, or all-cause death during the Intended Treatment Period.                 | Composite of stroke, systemic embolism, or all-cause death during the Intended Treatment Period.                 | Composite of stroke, systemic embolism, or all-cause death during the Intended Treatment Period.                 |
|------------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period. |
| Descriptive statistics                         | Treatment group                                                                                                  | Warfarin                                                                                                         | Apix 2.5 mg                                                                                                      | Apix 5.0 mg                                                                                                      |
| Descriptive statistics                         | Number of subjects                                                                                               | 74                                                                                                               | 74                                                                                                               | 74                                                                                                               |
| Descriptive statistics                         | Stroke/systemic embolism/all- cause death (rate)                                                                 | 4.1                                                                                                              | 0                                                                                                                | 0                                                                                                                |
| Descriptive statistics                         | 10 9656                                                                                                          | (1.1, 10.7)                                                                                                      | (0.0, 4.8)                                                                                                       | (0.0,4.8)                                                                                                        |
| Effect estimate per comparison                 | Stroke/systemic embolism/all- cause death                                                                        | Comparison groups                                                                                                | Apix 2.5 mg vs Warfarin                                                                                          | Apix 5.0 mg vs Warfarin                                                                                          |
| Effect estimate per comparison                 | Stroke/systemic embolism/all- cause death                                                                        | Proportion Difference                                                                                            | -4.1                                                                                                             | -4.1                                                                                                             |
| Effect estimate per comparison                 | Stroke/systemic embolism/all- cause death                                                                        | 10 9656                                                                                                          | (-11.4, 1.1)                                                                                                     | (-11.4, 1.1)                                                                                                     |
| Analysis description                           | Composite of MI or all-cause death during the Intended Treatment Period                                          | Composite of MI or all-cause death during the Intended Treatment Period                                          | Composite of MI or all-cause death during the Intended Treatment Period                                          | Composite of MI or all-cause death during the Intended Treatment Period                                          |
| Analysis population and time point description | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period. | The key secondary efficacy population consisted of all randomized subjects during the Intended Treatment Period. |
| Descriptive statistics                         | Treatment group                                                                                                  | Warfarin                                                                                                         | Apix 2.5 mg                                                                                                      | Apix 5.0 mg                                                                                                      |
| Descriptive statistics                         | Number of subjects                                                                                               | 74                                                                                                               | 74                                                                                                               | 74                                                                                                               |
| Descriptive statistics                         | MI/all-cause death (rate)                                                                                        | 0                                                                                                                | 0                                                                                                                | 0                                                                                                                |
| Descriptive statistics                         | 10 9656                                                                                                          | (0.0, 4.8)                                                                                                       | (0.0, 4.8)                                                                                                       | (0.0, 4.8)                                                                                                       |
| Effect estimate per comparison                 | MI/all-cause death                                                                                               | Comparison groups                                                                                                | Apix 2.5 mg vs Warfarin                                                                                          | Apix 5.0 mg vs Warfarin                                                                                          |
| Effect estimate per comparison                 | MI/all-cause death                                                                                               | Proportion Difference                                                                                            | 0                                                                                                                | 0                                                                                                                |
| Effect estimate per comparison                 | MI/all-cause death                                                                                               | 10 9656                                                                                                          | (-4.9, 4.9)                                                                                                      | (-4.9, 4.9)                                                                                                      |

Safety  in  the  Ongoing,  Long-term,  Open-label  Extension  of  CV185048. This  phase  is  till ongoing, data presented has a cut-off date of 01-Apr-2011. A total of 2570 subjects received openlabel apixaban in the LTOLE. The mean extent of exposure was 25.8 weeks (range 0.1 to 62.6 weeks). Approximately 60% of subjects had completed at least 26 weeks of open-label apixaban at the data cutoff date. The frequencies of deaths (24 [0.9%] subjects), SAEs (7.4%), and AEs leading to openlabel  treatment  discontinuation  (1.9%)  were  well  within  the  ranges  for  the  same  AE  categories reported for apixaban-treated subjects during the Treatment Periods of these studies.

## 2.6.1. Discussion on clinical safety

The  safety  database  of  the  two  phase  3  studies  and  the  duration  of  exposure  were  considered adequate to investigate the safety of long term administration of apixaban in AF patients. In study CV195030 VKA was used as comparator.  As shown in the efficacy section, the maintenance of an INR in  the  therapeutic  range  between  2-3  is  challenging  and  can  confound  any  claims  of  superiority  of efficacy  or  safety.  The  overall  AE  profile  of  apixaban  in  the  Phase  3  studies  was  similar  to  that  of warfarin in CV185030, and was similar to that of ASA in CV185048. As could be expected, the most common drug-related AEs were related to bleeding. In line with the general results, the frequency of bleeding with apixaban was generally less than that reported with VKA, and comparable to or slightly higher than that reported with ASA.

<div style=\"page-break-after: always\"></div>

Reported  serious  events  with  outcome death were  reported  less  frequently  in  the  apixaban  arm compared to VKA or ASA, further supporting the efficacy data.  No new safety signals were detected in these studies.

Adjudicated major bleeding (adapted from ISTH guidelines) was the primary safety endpoint in both Phase 3 studies. The use of ISTH definitions of bleeding was considered acceptable by the CHMP.

In  study  CV185030,  apixaban  was  associated  with  significantly  less  risk  of  ISTH  major  bleeding composite of ISTH major or CRNM bleeding, and for all bleeds indentified by the investigator than VKA. Intracranial bleeding, including all adjudicated hemorrhagic strokes and intracranial bleeds reported by the investigator that were adjudicated as major bleeds, occurred with lower frequency in the apixaban group. These results were in line with the efficacy data showing a benefit for apixaban in reduction of haemorrhagic stroke compared to VKA. Individual components of major bleeding were also reported in lower frequencies in the apixaban group compared to the VKA group, except for intraocular bleedings.

Additional analyses of major bleeding were performed taking INR levels into consideration. Study sites with better INR control still showed numerically better safety results in the apixaban group; although as  expected  the  efficacy  is  less  than  sites  with  worse  INR  control.  Also  in  study  sites  divided  by quartiles,  sites  with  INR  control  ≥  Median-  Q3  and  study  sites  ≥  Q3,  apixaban  shows  numerically better results and acceptable HR [HR=0.87 (95% CI: 0.70-1.08) and HR=0.7 (95% CI: 0.48-1.03), respectively,  but  no  superiority  over  VKA.  Surprisingly,  this  difference  is  driven  by  difference  in bleeding  rates  reported  in  the  apixaban  in  addition  to  the  VKA  group.  The  MAH  clarified  that comparisons across the different TTR quartiles in the apixaban group are invalid as these are grouped by centre control of INR, and not based on patient's characteristics.

The frequency of bleeding events using GUSTO and TIMI criteria were in line with the other bleeding data, providing further reassurance of the safer profile of apixaban compared to VKA.

In Study CV185048 apixaban showed numerically higher bleeding rates than ASA. Analyses of major bleeding showed that the results were driven by the incidence of intraocular bleeding, in addition to a slightly higher incidence of the components of decrease in haemoglobin ≥ 2 gm/dl and transfusion ≥ 2 units. A higher bleeding risk associated with apixaban compared to ASA was not surprising, considering the known pharmacodynamic properties of both agents.

The MAH addressed the results of the subgroup of patients with Demonstrated VKA unsuitable. Data of this subgroup are considered more relevant as it represents patients with prior VKA experience. The other  60% of AVERROES are Expected VKA unsuitable comprising patients who were considered by their physician be unsuitable for VKA for different reasons, without actual prior experience with VKA. However, these 2 subgroups are shown to share the same baseline characteristics and CHADS2 score. The  investigator-identified  reasons  for  unsuitability  were  similar  for  both  treatment  groups.  These issues  support  that  patients  considered  to  be  Expected  VKA  unsuitable  reflect  the  experiences  of physicians with reasonable judgement of the suitability of these patients to VKA treatment, and that they are not actually different from patients with actual prior experience.

The  Demonstrated  VKA  unsuitable  comprises  three  subgroups  mainly:  patients  with  a  history  of bleeding on VKA, discontinued VKA due to bleeding, and combination of bleeding risks. Although not the bigger subgroup (40% of AVERROES), they actually count 2237/5598, which was considered as adequate  representation.  Results  of  both  efficacy  and  safety  of  this  subgroup  are  in  line  with  the general results (Table S9). There is consistent superiority regarding efficacy (stroke and SE); HR of different  bleeding  endpoints  is  also  in  line  with  the  main  results.  Submitted  data  support  that  the general favourable results of apixaban is consistent in VKA naïve and experienced patients.

<div style=\"page-break-after: always\"></div>

Table  S9  AVERROES  outcomes  overall,  in  expected  and  demonstrated  VKA  unsuitable subgroups and in patients with bleeding on VKA or at increased bleeding risk

|                              | Total Patients   | Total Patients   | Stroke/SystemicEmbolism   | Stroke/SystemicEmbolism   | Major Bleeding          | Major Bleeding    | All Bleeding            | All Bleeding      | DC Due to Bleeding    | DC Due to Bleeding   |
|------------------------------|------------------|------------------|---------------------------|---------------------------|-------------------------|-------------------|-------------------------|-------------------|-----------------------|----------------------|
| AVERROES                     | Apix             | ASA              | n Apix/n ASA with Event   | HR (95% CI)               | n Apix/n ASA with Event | HR (95% CI)       | n Apiv/n ASA with Event | HR (95% CI)       | n Apix/ASA with Event | HR (95% CI)          |
| Overall                      | 2807             | 2791             | 51/113                    | 0.45 (0.32, 0.62)         | 45/29                   | 1.54 (0.96, 2.45) | 325/250                 | 1.30 (1.10, 1.53) | 35/20                 | 1.72 (1.00,2.99)     |
| Expected VKA Unsuitable      | 1699             | 1684             | 34/61                     | 0.55 (0.36, 0.84)         | 22/14                   | 1.55 (0.79,3.02)  | 171/124                 | 1.38 (1.09, 1.74) | 17/10                 | 1.68 (0.77, 3.67)    |
| Demonstrated VKA Unsuitable  | 1108             | 1107             | 17/52                     | 0.33 (0.19, 0.56)         | 23/15                   | 1.52 (0.80, 2.92) | 154/126                 | 1.22 (0.97,1.55)  | 18/10                 | 1.77 (0.82,3.84)     |
| Bleeding on VKA              | 269              | 265              | 6/18                      | 0.32 (0.13, 0.81)         | 7/7                     | 0.93 (0.32, 2.64) | 59/48                   | 1.18 (0.81, 1.73) | 8/3                   | 2.44 (0.65,9.20)     |
| DC VKA due to bleeding       | 127              | 139              | 2/10                      | 0.21 (0.05, 0.95)         | 4/4                     | 1.03 (0.26, 4.11) | 23/26                   | 0.92 (0.53, 1.62) | 3/2                   | 1.51 (0.25,9.06)     |
| Combination of bleeding risk | 502              | 503              | 10/30                     | 0.32 (0.16, 0.66)         | 10/9                    | 1.06 (0.43, 2.62) | 59/47                   | 1.23 (0.84, 1.80) | 10/8                  | 1.19 (0.47,3.03)     |

Further analysis of subgroup of patients CHADS2=1 and physician not recommending VKA showing a HR=3.44 (95%CI: 0.36-33.06) is submitted (Table S10).

Table S10 Bleeding and Stroke/Systemic Embolism in CHADS2 ≤ 1 Patients (CV185048)

|                                                                         | Apixaban n/N (%/year)                                                   | ASA n/N (%/year)                                                        | HR (95% CI)                                                             |
|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|
| All CHADS: ≤ 1 (N=2142)                                                 |                                                                         |                                                                         |                                                                         |
| Bleeding                                                                |                                                                         |                                                                         |                                                                         |
| Major                                                                   | 7/1061 (0.57)                                                           | 4/1072 (0.32)                                                           | 1.79 (0.52, 6.11)                                                       |
| Major or CRNM                                                           | 38/1061 (3.13)                                                          | 37/1072 (3.01)                                                          | 1.04 (0.66, 1.64)                                                       |
| All bleeding                                                            | 103/1061 (8.86)                                                         | 102/1072 (8.64)                                                         | 1.03 (0.78, 1.35)                                                       |
| Stroke/Systemic embolism                                                | 12/1066 (1.00)                                                          | 19/1076 (1.58)                                                          | 0.63 (0.31, 1.30)                                                       |
| CHADS, = 1 and physician does not recommend VKA (only reason) (N = 612) | CHADS, = 1 and physician does not recommend VKA (only reason) (N = 612) | CHADS, = 1 and physician does not recommend VKA (only reason) (N = 612) | CHADS, = 1 and physician does not recommend VKA (only reason) (N = 612) |
| Bleeding                                                                |                                                                         |                                                                         |                                                                         |
| Major                                                                   | 3/294 (0.93)                                                            | 1/316 (0.28)                                                            | 3.44 (0.36, 33.06)                                                      |
| Major or CRNM                                                           | 9/294 (2.83)                                                            | 14/316 (3.98)                                                           | 0.70 (0.30, 1.62)                                                       |
| All bleeding                                                            | 25/294 (8.14)                                                           | 27/316 (7.88)                                                           | 1.02 (0.59, 1.76)                                                       |
| Stroke/Systemic embolism                                                | 4/294 (1.25)                                                            | 2/318 (0.57)                                                            | 2.18 (0.40, 11.91)                                                      |
| CHADS, = 1 and physician does not recommend VKA (all) (N = 1195)        | CHADS, = 1 and physician does not recommend VKA (all) (N = 1195)        | CHADS, = 1 and physician does not recommend VKA (all) (N = 1195)        | CHADS, = 1 and physician does not recommend VKA (all) (N = 1195)        |
| Bleeding                                                                |                                                                         |                                                                         |                                                                         |
| Major                                                                   | 7/589 (1.03)                                                            | 5/603 (0.72)                                                            | 1.44 (0.46, 4.54)                                                       |
| Major or CRNM                                                           | 20/589 (2.98)                                                           | 27/603 (3.94)                                                           | 0.76 (0.42, 1.35)                                                       |
| All bleeding                                                            | 59/589 (9.16)                                                           | 63/603 (9.55)                                                           | 0.96 (0.67, 1.37)                                                       |
| Stroke/Systemic embolism                                                | 9/590 (1.37)                                                            | 12/605 (1.76)                                                           | 0.77 (0.32, 1.83)                                                       |

<div style=\"page-break-after: always\"></div>

Intraocular  bleeding .  Data  from  both  studies  show  that  apixaban  was  associated  with  a  higher frequency of intraocular bleeding compared to either VKA or ASA. The frequency of different categories of  intraocular  bleeding  was  comparable  between  treatment  groups  and  does  not  show  a  special prevalence in the apixaban group. There is also a slight imbalance in the prevalence of diabetes in study CV185030 which could explain the results at least in this study (among subjects with ISTH major intraocular bleeding 14/32 (43.8%) subjects in the apixaban group and 9/22 (40.9%) subjects in the warfarin  group).  Further  analysis  showed  no  clear  relationship  between  apixaban  and  specific intraocular pathology. The fact that the overall intraocular bleeding is lower for apixaban is reassuring. The small imbalance found in major intraocular bleeding can be a chance finding. The warning already included in section 4.4 of the SmPC about higher haemorrhage risk is considered adequate to alert about possible bleeding events, including intraocular bleeding events.

The cases of intramuscular bleeding with compartment syndrome, retroperitoneal and pericardial ISTH major bleeding during the Treatment Period in ARISTOTLE and AVERROES are summarised in Table S11 and indicate no concern for the profile of apixaban.

## Table S11  Summary of Pericardial, Intramuscular and Retroperitoneal ISTH Major Bleeding During the Treatment Period - Treated Subjects (CV185030 and CV185048)

| ARISTOTLE                                               | Apixaban N=9088                                                                                     | Warfarin N=9052 -----------------------------------------------------------------------------------   |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| PERICARDIAL BLEED, n (%/yr)                             | 0                                                                                                   | 0                                                                                                     |
| INTRAMUSCULAR WITH COMPARTMENT SYNDROME BLEED, n (%/yr) | 1 (<0.01                                                                                            | ) 1 (<0.01 )                                                                                          |
| RETROPERITONEAL BLEED, n (%/yr)                         | 2 ( 0.01                                                                                            | ) 5 ( 0.03 )                                                                                          |
| AVERROES                                                | ----------------------------------------------------------------------------------- Apixaban N=2798 | Aspirin N=2780 -----------------------------------------------------------------------------------    |
| PERICARDIAL BLEED, n (%/yr)                             | 1 ( 0.03                                                                                            | ) 0                                                                                                   |
| INTRAMUSCULAR WITH COMPARTMENT SYNDROME BLEED, n (%/yr) | 1 ( 0.03                                                                                            | ) 0                                                                                                   |
| RETROPERITONEAL BLEED, n (%/yr)                         | 1 ( 0.03                                                                                            | ) 0                                                                                                   |

The comparable event rates for GI bleeding reported in study CV185030 between apixaban and VKA is  reassuring considering recent concerns with other anti-thrombotics. However, results compared to ASA are less positive with a GI bleeding risk of GI bleedings reported as AEs in 2.7% (apixaban) and 1.8% (ASA), mostly gingival and rectal.

The  results  generally  support  that  apixaban  is  associated  with  a  lesser  bleeding  risk  than  VKA, however, one major advantage of VKA is the presence of an antidote in case of overdose. In light of the recent concerns with other anti-thrombotics and the management of bleeding in clinical practice, the development of an antidote to apixaban was considered important and the timeline regarding the developments of antidote were agreed with the CHMP and included into the RMP of this product. The MAH submitted data on the value of activated charcoal to decrease absorption. The SmPC sections 4.9 and 4.5 were updated accordingly. The MAH explained that based on available clinical data, the most promising agents appear to be prothrombin complex concentrate (PCC) and factor VII. Two recently published studies already indicate these non-specific prohaemostatic agents are capable of reversing the anticoagulant effect of another anti factor X anticoagulant (rivaroxaban) in healthy volunteers.

The proposal of the MAH to conduct a targeted bleeding questionnaire that will collect information on serious bleeding events and  interventions attempted  to control the bleeding was  considered appropriate.  The  protocol  of  the  questionnaire  was  agreed  to  be  assessed  by  the  CHMP  before implementing and included with timelines in the RMP as an 'additional pharmacovigilance activity'.

<div style=\"page-break-after: always\"></div>

The kit for monitoring anti-Xa activity (Rotachrom assay) was not used in clinical decisions during the ARISTOTLE  trial,  limiting  its  applicability  in  the  clinical  settings.  The  MAH  is  not  the  owner  of  the Rotachrom assay, and can not guarantee its commercial availability. However, the company discussed alternative assays like that by STAGO. Both assays are currently marketed in all of the EU member states,  according  to  the  MAH.  The  development  of  assay  to  measure  an  anticoagulant  activity  of apixaban was included together with timelines in the RMP. Importantly, there is the Rotachrom assay, with a LMWH standard, that could be used to assess apixaban exposure (expressed in LMWH units).

Liver-related safety results. The MAH presented an adequate assessment of the liver-related safety aspects associated with apixaban use. This topic was also thoroughly discussed during the initial MAA assessment and apixaban liver profile was considered to be adequately reflected in the SmPC and RMP. The currently presented database is much wider with the addition of the whole phase 3 database in AF, which  specifically  addresses  the  AF  population.  Presented  data  do  not  indicate  a  safety  concern  for apixaban compared to VKA or ASA. The small imbalance of total bilirubin &gt;1.5xULN in the apixaban group vs. the pooled comparator group (3.3% vs. 2.9% respectively) was in the opinion of the CHMP driven by the presence of a slightly larger percentage of subjects with peak total bilirubin &gt;1.5xULN but  ≤2xULN  in  the  apixaban  group  than  in  the  comparator  group.  The  8  cases  of  cholestasis  and jaundice  of  hepatic  origin  reported  in  apixaban  group  did  not  have  a  common  cause  (underlying cancer,  cardiac  failure,  cholecystitis  and  cholelithiasis).  No  evidence  of  clinically  significant  bilirubin elevation in the apixaban group has been detected and no subgroup seems to be at an increased risk. The assessment of the reported cases of fatal outcome associated with hepatic toxicity was endorsed by the CHMP. One case reported as possibly related to apixaban was previously assessed in a FUM (CV185030-836-9443) and did not lead to any changes in the conclusions. Causality of apixaban in the case CV185048-627-23 reported as possibly related is confounded by the co-administration of other hepatotoxic  co-medications  and  co-morbidities.  The  one  case  of  fatal  outcome  reported  in  non-AF studies  was  also  assessed  in  the  original  MAA  (CV185047-201-936).  In  the  opinion  of  the  CHMP current data do not point to the need of any further action, other than vigilant monitoring for any liversafety events in post marketing data assessments. The MAH proposed and the CHMP agreed to add liver injury as a potential risk in the RMP.

The  MAH  proposed  to  delete  the  recommendation  to  measure  LFT  before  therapy.  This  was  not endorsed. LFTs should be assessed before apixaban administration as the safety profile of apixaban is based  on  specific  exclusion  criteria  in  clinical  trials.  This  is  mentioned  in  the  SmPC  ( Patients  with elevated  liver  enzymes  (ALT/AST  &gt;2  x  ULN)  or  total  bilirubin  ≥1.5  x  ULN  were  excluded  in  clinical trials ) and should be implemented in clinical practice to ensure a favourable safety profile. In addition, considering  that  AF  is  associated  with  multiple  co-morbidities,  in  particular  heart  failure  and  coadministration  of  multiple  medicinal  products  is  expected  (some  of  them  are  hepatotoxic,  e.g., amiodarone, dronedarone) as currently reported in case CV185048-627-23 the measurement of LFT at the beginning of therapy should be advised and this is included in section 4.2 of the SmPC. This would constitute a value for further reference in case LFT elevations are noted during therapy. No regular LFT are considered necessary during long term treatment.

Neurological Adverse events : In the AF Studies 2 cases of Guillain Barre syndrome (GBS) both in the warfarin arm and 1 case of amyotrophic lateral sclerosis ALS in the warfarin arm were observed. There  was  no  evidence  of  an  increased  risk  for  GBS  or  ALS  in  the  AF  population,  the  ongoing surveillance is considered acceptable. No new cases of GBS or ALS were reported.

Subgroup analysis showed that generally the results of investigated subgroups were in line with the main results. This confirms the favourable profile of apixaban over VKA even in vulnerable subgroups like  patients  above  75  years,  prior  stroke,  different  CHADS2  scores  and  renal  impairment.  However patients with diabetes had a HR=0.96 (95% CI: 0.74-1.25), slightly worse results than the general

<div style=\"page-break-after: always\"></div>

cohort.  The  MAH  addressed  this  issue  but  no  obvious  differences  in  patients  characteristics  were identified which could explain the slightly higher risk of ISTH major bleeding, except may be the lower frequency of patients with BMI ≤ 28 kg/m2 in the diabetic group (33.9% vs 45.9%). For \"all bleeding\" the results were comparable. Also the results of AVERROES are supportive that no relevant difference is found in the risk of bleeding between diabetic and non-diabetic patients.

No conclusions can be made on females ≤50 years and blacks as the numbers of events were too few. Presented data in severe renal impairment do not strongly indicate a trend of higher risk of bleeding in patients who were administered 5 mg compared to the 2.5 mg, except when counting the ISH major bleedings/CRNM  bleedings  (7.45%  vs.4.22%).  The  lower  dose  is  currently  recommended  for  this subgroup.  Analysis  of  bleeding  in  patients  with  different  degrees  of  hepatic  impairment  was  not submitted as recruited patients were mostly with normal liver functions.

Interactions . In study CV185030, there was an adequate representation of patients co-administered the study drug with ASA (around 38% in each group). The combined use of apixaban and ASA was generally accompanied with a lower bleeding risk than the co-administration of VKA+ASA. There were limited representation of patients co-administered the study drug + ASA + a thienopyridine (around 2%  in  each  group).  No  conclusions  can  be  made  on  this  triple  combination.  Current  SmPC recommendations are considered adequate to reflect the risk associated with such combinations.

Discontinuations due to AEs . In both studies discontinuation due to AES were numerically lower in the  apixaban  group  compared  to  the  VKA  or  ASA  groups.  In  study  CV185048,  more  patients discontinued in the apixaban group (n=35; 1.2%) due to bleeding compared to ASA (n=20; 0.7%). In the  subgroup  Demonstrated  VKA  unsuitable,  the  numbers  discontinued  for  bleeding  for  apixaban versus ASA were 8 versus 3 for subjects with bleeding on previous VKA, 3 versus 2 for subjects who had previously discontinued VKA due to bleeding, and 10 versus 8 for subjects who had previously received  VKA  and  were  unsuitable  for  VKA  due  to  bleeding-related  reasons.  Not  all  of  the  bleeding events  resulting  in  study  drug  discontinuation  were  considered  clinically  important  enough  to  be adjudicated  as  major  bleeding.  Whereas  there  were  numerically  more  apixaban  discontinuations  for bleeding in patients with bleeding on previous VKA (8 vs. 3), there were a similar number of major bleeding events (7 vs. 7) compared with ASA. The higher discontinuation rate in the ASA group seems to be driven by a higher number of ischemic events related to lower efficacy showed in the ASA group as compared to apixaban.

Long term data. The presented data from the LTOLE does not indicate any new safety issues. The CHMP recommend to submit the final results of this extension phase of the AVERROES to the CHMP when available.

Study CV185067 is a supportive safety study conducted in Japan. It is of little additive value due to the limited  database  (n=222).  Generally  results  are  in  line  with  what  is  already  presented  in  studies CV185030/048.

## 2.6.2. Conclusions on the clinical safety

Results  of  study  CV185030  support  that  apixaban  is  associated  with  a  significantly  better  bleeding profile  than  VKA,  but  results  are  less  robust  when  taking  different  levels  of  INR  control  into consideration.  The  bleeding  risk  on  apixaban  is  numerically  higher  than  ASA,  which  is  expected. Presented  data  from  study  CV185048  is  insufficient  to  assess  if  apixaban  is  indeed  an  eligible alternative to patients unsuitable to VKA, in particular those with a higher bleeding risk. The lack of an antidote to apixaban is still a concern, but the MAH proposed adequate measures to address this issue. Incidence of liver injury was comparable in the studies, which was reassuring considering the available

<div style=\"page-break-after: always\"></div>

database. However as this is based on patients with normal liver functions, LFT should be performed prior to treatment to exclude unsuitable patients.

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilance system

The CHMP considered that the Pharmacovigilance system as described by the MAH fulfils the legislative requirements.

## Risk Management Plan

The MAH submitted an updated risk management plan, which included a risk minimisation plan.

Based on individual case review, the MAH has identified liver injury as an important potential risk with routine PV and risk minimization activities proposed for the AF indication. At the time of the approval of the  VTE  prevention  indication  hepatic  safety  has  been  thoroughly  discussed  and  was  adequately reflected  in  the  SmPC  and  RMP.  The  MAH  now  included  liver  injury  as  a  potential  risk  from  a precautionary point of view, which will allow to fit in ongoing pharmacovigilance activities in the overall risk management strategy. Furthermore, information on the important identified risks of bleeding and the potential risk of transient elevation of liver tests for the VTE prevention indication already existed in the RMP and are now presented for both indications in the updated RMP.

For the newly introduced potential risk of liver injury, the MAH proposes and the CHMP agreed to the following pharmacovigilance activities:

- Routine PV activities
- Continue blinded external liver expert review of prespecified liver cases
- Comprehensive  pivotal  study  clinical  safety  program  for  liver  related  events  (including supplemental case report forms)
- Targeted questions for spontaneous reports of liver events
- Ad hoc follow-up contact with the CHMP for specific severe liver events as needed
- Applicant commits to keep 'hepatotoxicity' under close monitoring in the PSUR

Also for the newly introduced potential risk of liver injury with the AF indication, the MAH considered and the CHMP agreed that the routine risk minimization activities are sufficient. Consistent with the recommendation for the indication of VTEp, LFTs will be assessed before apixaban administration.

For the important identified risk of 'bleeding,' the MAH will utilize a targeted bleeding questionnaire that  will  collect  information  on  serious  bleeding  events  and  interventions  attempted  to  control  the bleeding.  The  contents  of  the  questionnaire  will  be  submitted  for  the  CHMP  assessment  before implementing.

The applicant amended the summary of the RMP as follows:

<div style=\"page-break-after: always\"></div>

Table 1. Summary of the risk management plan

| Table Summary of the Risk Management Plan   | Table Summary of the Risk Management Plan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Table Summary of the Risk Management Plan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Safety concern                              | Proposed pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Proposed risk minimisation activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Identified Risks                            | Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Bleeding                                    | Routine PV including blinded adjudication of bleeding events in pivotal clinical trials DMC oversight of all ongoing Phase 3 studies The MAH commits to use the haemorrhage SMQ for case identification to describe bleeding in the apixaban PSURs. The MAH commits to provide the final results of the open label extension phase of the AVERROES study (CV185048) to the Health Authorities when it becomes available. Additional Pharmacovigilance with implementation of a Targeted Bleeding Questionnaire for reports of excessive bleeding events received during the post marketing period. | The risk of bleeding will be communicated in the following sections of the product information (SmPC) with explicit description of measures to be taken to avoid haemorrhage and measures to be taken in the event of hemorrhagic complications: • guidance for administration of apixaban in high risk groups such as the elderly, renally impaired and subjects with hepatic impairment in section 4.2 • Dose reduction in 2 of the 3: elderly, severe renal impairment, low body weight • Contraindication for patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk in section 4.3 • Warning in section 4.4. • Use with caution in elderly patients co-administered apixaban with acetylsalicylic acid in section 4.4. • Information regarding interaction with other medicinal products affecting hemostasis in section 4.5 • Listed as ADR in section 4.8 Additional Risk Minimisation measures • Educational materials for Healthcare Professionals • Patient alert cards • Development plan for a reversal agent for apixaban • Development plan for an assay for |
| Transient elevation of liver test           | Routine PV including: DMC oversight of all ongoing Phase 3 studies Supplemental case report forms for liver events of interest as needed Enhanced monitoring and signal detection in clinical trials External blinded hepatologist panel assessment for targeted hepatic events in clinical studies Ad hoc follow up for specific cases                                                                                                                                                                                                                                                            | Communication of elevated liver tests in appropriate product literature (SmPC) • Information regarding patients with elevated liver enzymes in section 4.2 • Warning in section 4.4 • SmPC Section 4.4 Special warnings and precautions for use: Hepatic impairment: Prior to initiating ELIQUIS, liver function testing should be performed. • Listed in section 4.8 • Further information in section 5.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Table Summary of the Risk Management Plan   | Table Summary of the Risk Management Plan                                                                                                                                                                                                                                                                                                                      | Table Summary of the Risk Management Plan                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Potential Risk:                             | Potential Risk:                                                                                                                                                                                                                                                                                                                                                | Potential Risk:                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Liver Injury                                | Routine PV including: DMC oversight of all ongoing Phase 3 studies Supplemental case report forms for liver events of interest as needed Enhanced monitoring and signal detection in clinical trials External blinded hepatologist panel assessment for targeted hepatic events in clinical studies Ad hoc follow up for specific cases of severe liver events | Communication of hepatic impairment in appropriate product literature (SmPC) • Contraindications in section 4.3 • Warning in section 4.4 • SmPC Section 4.4 Special warnings and precautions for use: Hepatic impairment: Prior to initiating ELIQUIS, liver function testing should be performed. • Further information in section 4.2 and 4.2 Additional Risk Minimisation measures • Educational materials for Healthcare Professionals • Patient alert cards |
| Missing Information                         | Missing Information                                                                                                                                                                                                                                                                                                                                            | Missing Information                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Pregnancy and lactation                     | Routine PV including pregnancy outcome follow up                                                                                                                                                                                                                                                                                                               | Communication of pregnancy and lactation treatment recommendation and requirements is in product information indicating that no human data is available in section 4.6                                                                                                                                                                                                                                                                                           |
| Non-Caucasian and non-Asian ethnicity       | Routine PV                                                                                                                                                                                                                                                                                                                                                     | There is limited clinical experience of non-Caucasian and non Asian ethnic groups in the VTEp studies with apixaban. No risk minimization activity is currently required.                                                                                                                                                                                                                                                                                        |
| Paediatric population                       | Routine PV Additional information from PIP                                                                                                                                                                                                                                                                                                                     | Communication of indication in product information (SmPC) • The recommendation limiting use to adults will be described in section 4.1 • Indicating that no data below age 18 is available in section 4.2                                                                                                                                                                                                                                                        |
| Severe renal or hepatic impairment          | Routine PV                                                                                                                                                                                                                                                                                                                                                     | Communication of severe renal or hepatic impairment risks, contraindication, cautions in product information (SmPC) • Information in section 4.2 • Contraindication in patients with hepatic disease associated with coagulopathy in section 4.3 • Warning in section 4.4 • Further information in section 5.2 Additional Risk Minimisation measures • Educational materials for Healthcare Professionals • Patient alert cards                                  |

<div style=\"page-break-after: always\"></div>

| Table Summary of the Risk Management Plan                | Table Summary of the Risk Management Plan   | Table Summary of the Risk Management Plan                                                                                                                                                                                             |
|----------------------------------------------------------|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hip Fracture Surgery                                     | Routine PV                                  | Section 4.1 of SmPC for the VTEp indication states 'Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.'                                                  |
| Black/African Americans                                  | Routine PV                                  | There is limited clinical experience of Black/African American subjects in the AF studies with apixaban. All the routine risk minimization measures described for the Important Identified and Potential risks described above apply. |
| Patients with valvular disease or prosthetic heart valve | Routine PV                                  | Section 4.1 of the SmPC for the AF indication states 'Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors'                                        |
| Potential for off-label use                              | Routine PV Drug utilization study program   | Communication of target indication in product information (SmPC) • Clarifying the target patient population in section 4.1 • Warning in section 4.4                                                                                   |
| Long-term therapy > 3 years                              | Routine PV                                  | There is limited clinical experience for long-term therapy > 3 years at present. No risk minimization activity is currently required.                                                                                                 |

The  CHMP,  having  considered  the  data  submitted,  was  of  the  opinion  that  the  below  additional pharmacovigilance  activity  in  addition  to  the  use  of  routine  pharmacovigilance  and  the  previously agreed additional pharmacovigilance activities detailed in the pharmacovigilance plan of the RMP are needed to investigate further some of the safety concerns:

| Description                                                                                                                                           | Due date                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| A targeted bleeding questionnaire that will collect information on serious bleeding events and interventions attempted to control the bleeding. (MEA) | The protocol to be submitted to the CHMP prior to the implementation on 1Q2013 |
| Submission of the final results of the open label extension phase of the AVERROES study (CV185048) when it becomes available. (MEA)                   | To be submitted 1Q2018                                                         |

The following additional risk minimisation activities were required:

The MAH shall provide an educational pack, targeting all physicians who are expected to prescribe/use Eliquis, prior to the launch of the new indication for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.

The  educational  pack  is  aimed  at  increasing  awareness  about  the  potential  risk  of  bleeding  during treatment with Eliquis and providing guidance on how to manage that risk.

<div style=\"page-break-after: always\"></div>

The  MAH  must  agree  the  content  and  format  of  the  educational  material, together with a communication plan, with the national competent authority in each Member State prior to distribution of the educational pack in their territory.

The physician educational pack should contain:

- The Summary of Product Characteristics
- Prescriber Guide
- Patient Alert Cards

The Prescriber Guide should contain the following key safety messages:

- Details of populations potentially at higher risk of bleeding
- Recommendations  for  dose  adjustment  in  at  risk  populations,  including  renal  or  hepatic impairment patients
- Guidance regarding switching from or to Eliquis treatment
- Guidance regarding surgery or invasive procedure, and temporary discontinuation
- Management of overdose situations and haemorrhage
- The use of coagulation tests and their interpretation
- That all patients should be provided with a Patient alert card and be counselled about:
- o Signs or symptoms of bleeding and when to seek attention from a health care provider.
- o Importance of treatment compliance
- o Necessity to carry the Patient alert card with them at all times
- o The need to inform Health Care Professionals that they are taking Eliquis if they need to have any surgery or invasive procedure.

The Patient alert card should contain the following key safety messages:

- Signs or symptoms of bleeding and when to seek attention from a health care provider.
- Importance of treatment compliance
- Necessity to carry the Patient alert card with them at all times
- The need to inform Health Care Professionals that they are taking Eliquis if they need to have any surgery or invasive procedure.
-  Development plan for a reversal agent for apixaban
-  Development plan for an assay for apixaban

## 2.8. User consultation

A full user test was performed on the Package Leaflet (PL) for Eliquis 2.5mg in March and April 2010 during initial marketing authorisation application. A bridging study for PL of Eliquis 2.5mg and 5 mg was performed in October and November 2011 to test the new information regarding the additional indication. The original and newly proposed PLs have a common design and layout. The bridging study successfully tested the key messages relating to the new indication. Key similarities in PL layout and house style have been described. It is therefore agreed that the results of the user consultation with target  patient  groups  on  the  package  leaflet  submitted  by  the  MAH  show  that  the  package  leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

Apixaban is  a  direct  reversible  inhibitor  of  the  coagulation  factor  Xa.  Apixaban  (2.5  mg  film-coated tablets) has been approved for the venous thromboembolic events prophylaxis in patients undergoing total hip or knee replacement surgeries in May 2011. Current application contains grouped variation and  a  line  extension  and  was  submitted  for  the  addition  of  apixaban  5  mg  film-coated  tablets  to support a new proposed indication of prevention of stroke and systemic embolism in adult patients with AF including those unsuitable for VKA with a recommended dose of 5 mg twice daily. The grouped variation contained a type II variation to add the newly proposed indication and a type IB variation to add a pack size of 168 tablets for Eliquis 2.5 mg film-coated tablets. The initial MAA for the 2.5 tablets already included sufficient pharmacokinetic data to support the marketing authorisation of the 5 mg tablet, as the pharmacokinetics of both tablets were sufficiently investigated in the submitted phase IIII studies for Eliquis 2.5 mg. All studies in this application were relevant for both strengths, and the 2.5  and  5  mg  tablets  showed  linear  dose  proportionality  in  pharmacokinetics.  To  support  the  new indication the MAH submitted two new phase 3 studies.

## Benefits

## Beneficial effects

Both  clinical  studies  (CV185030  and  CV185048)  investigate  the  primary  endpoints  of  stroke  and systemic  thromboembolism  which  are  relevant  endpoints  in  the  proposed  indication  and  have  been accepted in similar studies.

In  study  CV185030 (ARISTOTLE), non-inferiority of apixaban 5 mg BID versus warfarin (INR target range 2.0-3.0) for the primary efficacy endpoint, was demonstrated for AF patients and at least one additional risk factor for stroke. Superiority of apixaban was then assessed and demonstrated: annual event  rates  1.27%  versus  1.60%;  HR=0.79  [95%  CI=0.66;  0.95;  two-sided  p-value=  0.0114]. Sensitivity analysis confirmed the results. Analysis of stroke showed a lower incidence of hemorrhagic stroke in the apixaban group (0.42%) compared to VKA group (0.84%) and a lesser effect on ischemic stroke (1.74% vs 1.91% respectively), with comparable effect on SE (0.16% vs 0.18% respectively). Apixaban also showed a reduction in all-cause death, a secondary endpoint in the hierarchical testing strategy,  HR=0.89  [95%CI=  0.80;  1.00,  two-sided  p-value=0.0465].  Both  cardiovascular  deaths [HR=0.89; 95%CI =0.76- 1.04] and non-cardiovascular deaths [HR=0.93; 95%CI=0.77- 1.13] were numerically lower in the apixaban group.

Efficacy  results  presented  in  different  subgroups  were  generally  consistent with  the  primary  efficacy results for the study. In the subgroup of patients receiving the reduced dose of apixaban (2.5 mg BID), event rates favoured apixaban over VKA (1.43%/yr vs 7.23%/yr respectively, HR=0.19, 95% CI: 0.04, 0.91).

In  study  CV185048 (AVERROES) apixaban (1.62%/yr) was superior to ASA (3.63 %/yr) [HR=0.45; 95%CI= 0.32- 0.62; two-sided p-value &lt;0.00001] for the prevention of stroke or SE in subjects with AF and at least one additional risk factor for stroke and who were considered not suitable for VKA by the investigators. The majority of the primary outcome events were ischemic or unspecified strokes with 43 (1.53%) events in the apixaban group, versus 95 (3.4%) events in the ASA group  [HR = 0.44; 95% CI =0.31, 0.63]. Apixaban [n=2 (0.07%)] was also associated with lower numbers in SE relative to ASA [n=11 (0.39%)].

Results within most subgroups were consistent with the primary efficacy endpoint. Results of patients with demonstrated VKA intolerance (apixaban: 1.73% vs ASA: 4.2%; HR=0.33; 95% CI: 0.19-0.56)

<div style=\"page-break-after: always\"></div>

were comparable to those expected to be intolerant (apixaban: 1.79% vs ASA: 3.25%; HR=0.55; 95% CI: 0.36-0.84).

## Uncertainty in the knowledge about the beneficial effects

In Study CV185030 (ARISTOTLE) the all cause death was investigated as a secondary endpoint with borderline  significance  [HR=0.89;  95%CI=  0.80;  1.00,  two-sided  p-value=0.0465].  Superiority  of apixaban was less convincing in situations where INR control was well controlled. In the highest TTRc quartile (&gt; 72.2%) benefit was shown for VKA over apixaban; HR =1.04 (95%CI: 0.82-1.33). Also no superiority was shown for apixaban over VKA in either components of all cause death (cardiovascular and non-cardiovascular deaths).

The  general  benefit  of  apixaban  in  reduction  of  risk  of  stroke/SE  over  VKA  varied  according  to  the control of INR: benefit was observed in study sites with INR below the median quartile of INR control (HR=0.78; 95% CI: 0.62-0.98) but lost with INR ≥ median INR (HR=0.81; 95% CI: 0.61-1.08). Using TTRc, apixaban showed favourable results, with HR consistently below 1 (0.77-0.81) but no superiority compared to VKA; 95% CI varying from 0.57-1.07 to 0.52-1.26.

Subgroups . In patients &lt; 65 years, the primary efficacy endpoint was slightly higher in the apixaban group than VKA group (HR=1.16; 95% CI: 0.77- 1.73). The MAH explored three parameters which could have led to worse results in patients &lt;65 years, mainly: patients characteristics, VKA control and apixaban  exposure  in  the  ARISTOTLE  study.  Submitted  analyses  showed  that  none  of  these parameters could have significantly affected the results. This is  further  supported  by  data  from  the AVERROES study. It can be concluded that the trend for worse efficacy results in patients &lt;65 years is probably  a  chance  finding.  Reduced  efficacy  was  showed  in  patients  randomized  in  the  EU:  HR  for stroke/SE= 0.92; (95% CI = 0.56; 1.52) and HR for all cause death= 0.89 (95% CI = 0.68; 1.18). In patients  with  severe  renal  impairment  generally  lower  events  rates  were  reported  in  the  apixaban group compared to the warfarin group, with more favourable results in patients administered 2.5 mg BID (n=89) (1.43%/yr vs 7.23%/yr, HR=0.19, 95% CI: 0.04-0.91), than patients administered 5 mg BID (n=48) (HR and upper bound of the associated 95% CI were ≥ 1; 95% CI was wide (0.43-34.72).

The incidence of SE (0.2% and &lt; 0.1%, respectively) and MI (0.3% and 0.2%, respectively) leading to study discontinuation in the apixaban group are slightly higher than the VKA group, and not in line with the efficacy data. This discrepancy occurs as one calculation is based on the investigator's assessment, the other is based on the blinded adjudication by an independent committee. When the same events are  assessed  by  the  latter  committee,  the  results  of  both  apixaban  and  warfarin  were  comparable. During the period from the end of Intended Treatment Period up to 30 days after the last dose of study medication, a total of 27 stroke/SE events in the apixaban group versus only 10 events occurred in the warfarin group. Further analyses showed that the highest risk of stroke/SE was seen in patients not used to VKA (either VKA naïve, or on apixaban) switching to VKA. Most of the events in these switchers occurred 2 weeks after the switch. These findings support the view that this higher incidence of events is probably due to the difficulties associated with establishing an adequate INR in VKA naïve patients. The late onset of events precludes a rebound hypercoagulability problem. These conclusions can also explain  the  slight  imbalance  of  mortality  (apixaban=53;  VKA=48)  following  discontinuation  of  these anticoagulants.

In study CV185048 (AVERROES) the definitions used to define VKA unsuitability were quite subjective, and depend on the perception of both the investigator and the patient, making it difficult to ascertain their true unsuitability for VKA treatment. Only 40% of the patients had prior VKA experience. In this subgroup, the actual representation of patients who discontinued VKA due to bleeding was very small (11.9%) and even the majority of these patients reported mainly minor bleedings. The most common

<div style=\"page-break-after: always\"></div>

reasons  provided  for  discontinuation  of  VKA  were  physician's  decision  (20.4%),  patient's  decision (19.7%), and difficulty to control INR (19.1%). Further exploration of the recruited subgroups showed that the investigator gave 'CHADS2 score = 1 and physician does not recommend VKA' as a reason for VKA  unsuitability  for  1195  subjects.  Of  this  group,  612  patients  included  'physician  does  not recommend'  as  the  only  reason  given  for  VKA  unsuitability.  In  AVERROES,  the  decision  that  VKA therapy was unsuitable was made for all 2142 patients with a CHADS2 score of ≤1, whether or not the investigator indicated that a low CHADS2 score was the reason for VKA unsuitability, either as one of multiple reasons or as the sole reason.

The choice of ASA as a valid comparator for all VKA unsuitable patients was not fully supported by the CHMP.  According  to  the  Clinical  Practice  Guidelines  of  the  European  Society  of  Cardiology  for  the management of patients with AF, ASA could be chosen as an alternative to VKA in patients with  a higher risk of bleeding. For the rest of the patients, a combination of ASA and clopidogrel could now be considered, however this combination was not approved at the time the study was initiated.

Discontinuation of double-blind study drug due to bleeding was infrequent for both apixaban (1.2%) and for ASA (0.7%) treatment arms and similar for Expected VKA unsuitable and Demonstrated VKA unsuitable  cohorts.  The  subgroup  of  patients  with  CHADS2  =1  and  investigator  did  not  recommend VKA was the only subgroup with conflicting results (HR= 2.18; 95% CI; 0.040- 11.91).

## Risks

## Unfavourable effects

The safety database of the two phase 3 studies consisted of 11,886 patients administered apixaban (5 mg BID or 2.5 mg BID) with a mean double-blind exposure of 1.7 years (ARISTOTLE) and 1.1 years (AVERROES). The overall AE profile of apixaban in the Phase 3 studies was similar to that of warfarin in CV185030 (ARISTOTLE), and to that of ASA in CV185048 (AVERROES). The event rates for bleedingrelated AEs were lower for apixaban vs. warfarin (25.2% and 32.7%, respectively). The frequency of bleeding-related AEs for apixaban vs. ASA was similar (10.0% and 9.3%), respectively. The overall frequency of drug-related AEs with onset during the Treatment Period was similar in the apixaban and comparator  groups. In  CV185030,  drug-related  AEs  were  reported  for  27.8%  of  subjects  in  the apixaban group and 34.2% in the warfarin group. Drug-related AEs reported for ≥ 2% of subjects in either  group  included  epistaxis  (apixaban  5.0%;  warfarin  6.1%),  haematoma  (apixaban  1.4%; warfarin  3.5%),  contusion  (apixaban  1.7%;  warfarin  3.2%),  haematuria  (apixaban  2.6%;  warfarin 3.2%), gingival bleeding (apixaban 1.0%; warfarin 2.1%), and ecchymosis (apixaban 0.9%; warfarin 2.0%). In  CV185048,  the  frequency  of  drug-related  AEs  was  similar  in  the  two  treatment  groups (apixaban 16.6%, ASA 16.7%). No drug-related AEs were reported in ≥ 2% of subjects in either group. During the Follow-up Period, there were no clinically meaningful differences between the apixaban and comparator groups for the frequency of AEs in either study (3.3% in the apixaban group and 3.4% in the warfarin group in CV185030; apixaban 7.2%, ASA 7.8% in CV185048).

In study CV185030 (ARISTOTLE), SAEs with outcome of death were reported in 4.7% and 5.2% in the apixaban and VKA groups respectively. The lower incidence of death in the apixaban was also shown compared to either VKA naïve/experienced patients (apixaban 5.7% vs VKA naïve 6%; and apixaban 4% vs VKA experienced 4.5%). During the treatment period in this study the frequency of SAEs was similar in the overall apixaban (35.0%) and warfarin (36.5%) groups, in warfarin/VKA-naïve subjects (34.5% and 36.0%  respectively) and warfarin/VKA-experienced subjects (35.4% and  36.9% respectively).  In  study  CV185048  (AVERROES)  SAEs  with  outcome  of  death  were  reported  slightly more frequently in the ASA group (4.1%) compared to apixaban (3.3%). The overall frequency of SAEs

<div style=\"page-break-after: always\"></div>

with onset during the treatment period was 23.5% in the apixaban group vs. 28.9% in the ASA group. The most common SAEs were cardiac disorders in both studies.

Adjudicated major bleeding (adapted from ISTH guidelines) was the primary safety endpoint in both Phase 3 studies. In study CV18030 (ARISTOTLE), apixaban was superior to warfarin for ISTH major bleeding  [HR=0.69;  (95%  CI=  0.60;  0.80);  two-sided  p&lt;0.0001  (pre-specified  sequential  testing strategy). A similar effect was observed for the composite of ISTH major or CRNM bleeding, and for all bleeds  indentified  by  the  Investigator  [HR=0.68;  95%  CI=0.61;  0.75);  two-sided  p&lt;0.0001,  for major/CRNM; HR=0.71; [(95% CI= 0.68; 0.75); two-sided p&lt;0.0001 for all bleeds)].  The frequency of the individual components of major bleeding was generally lower or similar in the apixaban group compared with the warfarin group except intraocular bleeding. In study CV185048 (AVERROES), the observed event rate for adjudicated adapted ISTH major bleeding was 45 subjects (1.41%/year) in the apixaban  group  and  29  subjects  (0.92%/year)  in  the  ASA  group  [HR=1.54  (95%CI:  0.96-2.45); p=0.07]. Analyses of major bleeding showed that the results are driven by the incidence of introcular bleeding in addition to a slightly higher incidence of the components of decrease in haemoglobin ≥ 2 gm/dl  (0.44%/yr  and  0.38%/yr  respectively)  and  transfusion  ≥  2  units  (0.5%/yr  and  0.41%/yr respectively).

Event  rates  for  GI  bleeding  (including  upper  GI,  lower  GI,  and  rectal  bleeding)  reported  by  the investigator  and  adjudicated  as  major  bleeding  in  CV185030  (ARISTOTLE)  were  1.30%/year  in  the apixaban group and 1.44%/year in the warfarin group. In study CV185048 (AVERROES), GI bleedings were reported as AEs in 2.7% (apixaban) and 1.8% (ASA), mostly gingival and rectal.

Subgroup  analysis  did  not  show  relevant  differences  for  the  investigated  subgroups  from  the  main cohort of either study in the bleeding risk.

Current safety database does not indicate an increased risk for hepatotoxicity associated with apixaban use however LFTs should be assessed before apixaban administration as the safety profile of apixaban is based on specific exclusion criteria in clinical trials.

## Uncertainty in the knowledge about the unfavourable effects

In  study  CV185030  (ARISTOTLE),  bleeding  was  investigated  as  a  secondary  endpoint.  A  better bleeding profile is not consistently shown when INR control is taken into account: in study sites divided by quartiles, sites with INR control ≥ Median, Q3 and study sites ≥ Q3, apixaban showed numerically better results but not consistently superior to VKA [HR=0.87 (95% CI: 0.70-1.08) and HR=0.7 (95% CI: 0.48-1.03), respectively.

Both strengths (2.5 mg BID or 5 mg BID) were administered to patients with severe renal impairment. There was no indication of a higher risk of bleeding in patients administered 5 mg compared to the 2.5 mg, except when counting the ISH major bleedings/CRNM bleedings (7.45% vs. 4.22% respectively). Apixaban was associated with better results in patients randomised in Europe: HR 0.80 [95% CI: 0.62, 1.02] but of a lesser magnitude in the EU member states analysis HR 0.90 (95% CI: 0.66, 1.22), in line with the efficacy data. Patients with diabetes had a HR=0.96 (95% CI: 0.74-1.25), slightly worse than the general cohort. No obvious differences in patients characteristics could explain this results except may be the lower frequency of patients with BMI ≤28 kg/m2 in the diabetic group (33.9% vs. 45.9%). For \"all bleeding\" the results were comparable. Also, in the results of AVERROES no relevant difference was found in the risk of bleeding between diabetic and non-diabetic patients.

In study CV185048 (AVERROES), the \"demonstrated VKA unsuitable\" included three specific subgroups (bleeding on VKA, discontinued VKA due to bleeding, and combination of bleeding risks). In each of these  3  subgroups,  apixaban  demonstrates  a  favourable  benefit-risk  profile  compared  to  ASA.  Also

<div style=\"page-break-after: always\"></div>

results of the subgroup of patients with CHADS2=1 and physician not recommending VKA showed the highest HR =3.4 (95%CI: 0.36-33.06). However, the number of endpoints was too few to allow any conclusions. Further analysis shows that the risk in the subgroup of CHADS ≤ 1 [Major bleeding HR 1.79 (0.52, 6.11)] is in line with the general results of the study.

Data  from  both  studies  show  that  apixaban  was  associated  with  a  higher  frequency  of  intraocular bleeding  compared  to  either  VKA  or  ASA.  In  study  CV185030  (ARISTOTLE),  intraocular  bleeding adjudicated as major bleeding were reported in 32 cases with apixaban vs 22 cases reported with VKA; in  study  CV185048:  6  cases  (0.21%)  in  the  apixaban  group  vs  0  cases  in  the  ASA  group.  The frequency  of  different  categories  of  intraocular  bleeding  was  comparable  between  treatment  groups and does not show a special prevalence in the apixaban group.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

Apixaban was associated with significant reduction in the risk of stroke and SE compared to VKA. The results  are  clinically  relevant  considering  that  VKA  is  the  standard  of  therapy  in  this  population. Apixaban also compares favourably with available published data of other new anti-thrombotics, like dabigatran  and  rivaroxaban,  but  direct  comparison  is  lacking.  A  reduction  in  the  incidence  of haemorrhagic  stroke  appears  to  be  the  main  driving  endpoint  for  the  benefit,  highlighting  that apixaban  is  probably  a  safer  alternative  to  VKA,  rather  than  a  more  effective  one.  Apixaban  was associated  with  a  significant  reduction  in  all  cause  death,  but  superiority  is  lost  in  subgroups  with better  INR  control.  A  significantly  lower  incidence  of  major  bleeding  is  observed  with  apixaban compared to VKA, which further supports the favourable profile of apixaban. Again results are of lower significance when INR is well controlled. This questions an extra benefit of apixaban in patients who have well controlled INR, though still in these patients apixaban can offer other advantages like the absence of monitoring. It is reassuring that most of the investigated subgroups showed a consistent benefit  over  VKA  regarding  the  bleeding  profile,  in  particular  elderly  patients  or  patients  with  renal impairment. Importantly also there was  no increased risk of  GI bleeding compared to VKA, as was reported with dabigatran.

Considering  the  results  of  study  CV185030  (ARISTOTLE)  the  superiority  of  apixaban  over  ASA  in reducing the risk of stroke/SE shown in AVERROES was not surprising. Most of the recruited patients were not shown to have a high bleeding risk on VKA. In addition, 60% of the recruited patients did not even have prior VKA experience questioning the external validity of the study results. A non-significant higher  rate  of  bleeding  was  reported  in  the  apixaban  group  compared  to  ASA,  which  is  generally reassuring.  Further  analysis  of  the  results  showed  that  both  these  subgroups  (VKA  experienced  or naïve)  share  common  characteristics,  stroke  risk  and  more  importantly  the  benefit  risk  balance, supporting that the results of VKA experienced can be extrapolated to VKA naïve patients. However, the decision that these patients are not eligible for VKA in the first place is a subjective decision that is not clearly defined. The main reasons why these patients were considered to be intolerant to VKA was inability/unlikely to obtain regular INR (42%) or patient refusal to be administered VKA (37%). In a strictly medical sense, a label including \"patients unsuitable for VKA\" as proposed by the MAH would not  specifically  include  the  above  groups,  but  more  importantly  would  be  referring  to  patients  who have  discontinued  VKA  due  to  bleeding.  These  patients  constitute  only  266  patients  in  AVERROES. Patients who are unsuitable to VKA due to increased bleeding risk have not been specifically studied. Thus, the data in itself are not robust enough to support the inclusion of patients who are unsuitable to VKA in the indication.

<div style=\"page-break-after: always\"></div>

There is a slightly higher rate of stroke/SE and death recorded in the apixaban group compared to the VKA in the 30 days period following study drug discontinuation. Analysis showed that the highest risk of stroke/SEE is seen in patients not using VKA (either VKA naïve, or on apixaban) switching to VKA. Most  of  the  events  in  these  switchers  occurred  2  weeks  after  the  switch,  supporting  that  this  is probably due to the difficulties associated with establishing an adequate INR in VKA naïve patients. The late  onset  of  events  precludes  a  rebound  hypercoagulability  problem.  These  conclusions  can  also explain  the  slight  imbalance  of  mortality  (apixaban=53;  VKA=48)  following  discontinuation  of  these anticoagulants. The proposals in section 4.2 of the SmPC addressing the switch were considered by the CHMP acceptable.

## Benefit-risk balance

In general, the benefit risk of apixaban in patients with AF is favourable. Apixaban was associated with a significantly lesser risk of stroke/SE, all cause death and bleedings compared to VKA. The inclusion of patients defined as VKA unsuitable was however, not supported.

## Discussion on the benefit-risk balance

Apixaban has shown to be a beneficial anti-thrombotic for the prevention of stroke/SE in AF patients, with no extra burden in the bleeding risk compared to VKA. Benefits were smaller in subgroups with better  INR  control,  but  this  is  still  an  acceptable  effect  considering  that  apixaban  offers  other advantages over VKA, like a more favourable interaction profile and no need for routine monitoring. The main disadvantage of apixaban compared to VKA is still the lack of a specific antidote or a method to monitor anticoagulant activity (which can be necessary in emergency situations), disadvantages also shared with dabigatran and rivaroxaban. This can clearly constitute a major concern in clinical practice, especially with chronic use as in AF patients. The MAH has presented some data to show that apixaban absorption can be decreased by charcoal and elimination could be improved by dialysis. In addition, the MAH submitted adequate plans for the development of a specific antidote and they were included in  the  RMP  for  apixaban.  In  addition,  the  MAH  agreed  to  use  of  a  questionnaire  to  document  the management of bleeding in clinical practice. The protocol for the questionnaire will be submitted for the  assessment of the CHMP and was included as additional pharmacovigilance activity in the RMP. Regarding the monitoring of the anticoagulant activity, the MAH was requested to develop an assay, and the details of the development plans were also included in the RMP for apixaban. Importantly, the Rotachrom  assay  with  a  LMWH  standard  is  available  in  the  EU  and  that  could  be  used  to  assess apixaban exposure (expressed in LMWH units).

Results pertaining to comparisons of apixaban and VKA in all cause death and bleeding were presented in the SmPC.

The use of apixaban as an alternative to patients unsuitable to VKA was not supported, as the criteria defining  this  unsuitability  was  considered  by  the  CHMP  as  too  subjective.  Actual  representation  of patients who discontinued VKA due to bleeding was very limited. The main study results were included in the labelling.

The transition of patients on apixaban to other anti-coagulants was adequately addressed in the SmPC.

Further analysis of benefits and bleeding risks in certain subgroups which were originally shown to be of  concern  is  currently  seen  to  be  in  line  with  the  general  results.  This  concerns  patients  below  65 years old and diabetic patients. Analysis of data showed that patients with severe renal impairment should be administered the lower dose and this was included in the SmPC.

<div style=\"page-break-after: always\"></div>

Assessment of liver safety data did not indicate the need of further action. The vigilant monitoring as a potential risk was endorsed. A detailed report was submitted analyzing all available safety data with reassuring  conclusions.  However,  this  wide  database  excluded  patients  with  any  form  of  hepatic impairment. This information was included in the SmPC along the recommendation to perform the liver function tests before administration to ensure safe use.

During the assessment of this application some important GCP issues were raised in ARISTOTLE study regarding possible errors in medication dispensing, integrity of the interactive voice responses system and the discrepancies between the trial database and the data collected on the eCRF. All the concerns were  convincingly  explained  by  the  MAH  and  the  CHMP  agreed  with  the  conclusions  of  the  GCP inspection to consider ARISTOTLE study to be GCP compliant.

## 4. Recommendations

The  CHMP,  having  considered  the  application,  recommended  by  consensus  the  granting  of  an extension of the Marketing Authorisation for Eliquis concerning a new 5 mg strength.

In addition, based on the CHMP review of data on quality, safety and efficacy, the CHMP recommends by  consensus  the  variations  to  the  terms  of  the  Marketing  Authorisation,  concerning  the  following changes:

1

| Variation(s) requested   | Type                                        |    |
|--------------------------|---------------------------------------------|----|
| B.II.e.5                 | Change in pack size of the finished product | IB |

Addition of a new pack size for Eliquis 2.5mg film-coated tablets of 168 film coated tablets (12 blisters of 14 film-coated tablets each).

2

| Variation requested   |                                                                                                                      | Type   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------|--------|
| C.I.6.a               | Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | II     |

Update of the SmPC to include a new indication for the new strength (5 mg) and for 2.5 mg strength: Prevention  of  stroke  and  systemic  embolism  in  adult  patients  with  non-valvular  atrial  fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Furthermore, the MAH took this opportunity to update information of the local representatives in the Package Leaflet.

The above CHMP recommendation is subject to the following new conditions:

## CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

The MAH shall provide an educational pack, targeting all physicians who are expected to prescribe/use Eliquis, prior to the launch of the new indication for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.

The  educational  pack  is  aimed  at  increasing  awareness  about  the  potential  risk  of  bleeding  during treatment with Eliquis and providing guidance on how to manage that risk.

<div style=\"page-break-after: always\"></div>

The  MAH  must  agree  the  content  and  format  of  the  educational  material, together with a communication plan, with the national competent authority in each Member State prior to distribution of the educational pack in their territory.

The physician educational pack should contain:

- The Summary of Product Characteristics
- Prescriber Guide
- Patient Alert Cards

The Prescriber Guide should contain the following key safety messages:

- Details of populations potentially at higher risk of bleeding
- Recommendations for dose adjustment in at risk populations, including renal or hepatic impairment patients
- Guidance regarding switching from or to Eliquis treatment
- Guidance regarding surgery or invasive procedure, and temporary discontinuation
- Management of overdose situations and haemorrhage
- The use of coagulation tests and their interpretation
- That all patients should be provided with a Patient alert card and be counseled about:
-  Signs or symptoms of bleeding and when to seek attention from a health care provider.
-  Importance of treatment compliance
-  Necessity to carry the Patient alert card with them at all times
-  The need to inform Health Care Professionals that they are taking Eliquis if they need to have any surgery or invasive procedure.

The Patient alert card should contain the following key safety messages:

- Signs or symptoms of bleeding and when to seek attention from a health care provider.
- Importance of treatment compliance
- Necessity to carry the Patient alert card with them at all times
- The need to inform Health Care Professionals that they are taking Eliquis if they need to have any surgery or invasive procedure.

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

Not applicable.